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Horizontal gene transfer (HGT) is one of the man driving forces of evolution in prokaryotes, 
and can also promote within-strain variation of bacterial species. The genomes of three 
previously sequenced Bacteroides fragilis strains, NCTC9343, 638R and YCH46 displayed 
evidence of extensive HGT, demonstrated by the presence of 28 divergent capsular 
polysaccharide-associated biosynthesis loci. The genomes of a further four B. fragilis 
strains, LS66, GNAB92, RD48 and BE1 were sequenced and analysed. Genomic comparisons 
of BE1 and GNAB92 with NCTC9343, 638R and YCH46 identified ten new divergent 
polysaccharide biosynthesis loci. There is consequently, the potential to express 38 
different polysaccharides amongst these five strains. Such a high level of variation in 
capsular polysaccharides, in so few strains has not been previously observed. HGT has 
occurred in B. fragilis despite the presence of diverse Restriction-Modification systems.  
The genome sequences of NCTC9343 and 638R contained a gene, ubb, the product of 
which, BfUbb, has 63% identity to human ubiquitin. The closest DNA sequence homology is 
to a migratory grasshopper entomopox virus, suggesting acquisition of this gene was via 
inter-kingdom HGT. The ubb gene was also identified in the newly sequenced genomes of 
B. fragilis strains LS66 and RD48. BfUbb had a predicted signal sequence; both full-length 
and processed forms were detected in whole-cell extracts by Western blot analysis. The 
inability to detect BfUbb in periplasmic extracts isolated from a B. fragilis strain containing 
an ubb signal sequence deletion construct, supported the periplasmic location of the 
processed form of the protein and the requirement for the signal peptide for transport 
from the cytoplasm. BfUbb was also detected in concentrated supernatants containing 
outer membrane vesicles, suggesting a mechanism by which the protein may be delivered 
to the host. This is the first example of ubiquitin being produced by a prokaryote. 
Transduction by bacteriophages is one mechanism by which horizontal gene transfer can 
occur and can also be a useful tool for genetic manipulation. Fifteen potentially new B. 
fragilis-specific bacteriophages were isolated from filtered sewage and characterised by 
phage titres and restriction endonuclease cleavage profiles. Of the fifteen, seven phages 
appeared to be different to the previously identified phage ФED01. None of the 
bacteriophages were capable of transduction.  
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B. fragilis is a predominant member of the gastrointestinal microbiota. To survive within 
this specific niche, bacteria must successfully compete with other organisms for nutrients 
and space, and withstand attacks from bacteriophages. HGT may aid in the survival of B. 





















Horizontal gene transfer (HGT) is a method by which pieces of DNA can be exchanged 
between bacteria. These pieces of DNA can contain genes which are advantageous to an 
organism, for example, antibiotic resistance genes which can aid in survival. HGT is the 
major driving force of bacterial evolution and can lead to variation between strains of the 
same species.  
Bacteroides fragilis is a bacterium found in the human gut and is a member of the 
commensal microbiota, or ‘good’ bacteria, which have a positive impact on human health. 
Three previously analysed strains of Bacteroides fragilis, NCTC9343, YCH46 and 638R 
displayed an extensive amount of HGT, shown by a high variation of polysaccharides. The 
three strains have the potential to produce 28 different polysaccharides. The DNA sequence 
of four further B. fragilis strains, BE1, GNAB92, RD48 and LS66, were determined and 
analysed. Comparisons were made between strains BE1 and GNAB92 and the three 
previously analysed strains. Ten new different polysaccharides were identified within BE1 
and GNAB92. There is consequently, the potential to produce 38 different polysaccharides 
amongst these five strains. Such a high level of variation in polysaccharides, in so few 
strains has not been previously observed.  
A further occurrence of HGT in B. fragilis is the presence of a gene, ubb, which produces a 
protein, BfUbb that is similar to a protein, ubiquitin, found in abundance in human cells. 
Ubiquitin is essential for a wide range of cellular functions, including the hosts’ immune 
response to bacterial infection. BfUbb is exported from the bacterial cell, potentially via 
outer membrane vesicles (OMV), which are small spherical vesicles released by the 
bacterium. The association of BfUbb with OMV suggests a way in which BfUbb may be 
delivered to the host cell and therefore potentially interfere with the host ubiquitin 
pathway and affect the normal functioning of the cell. 
B. fragilis is a main member of the human commensal microbiota. To survive in the gut, 
bacteria must compete with each other for food and space. HGT may help B. fragilis survive 





Chapter 1. Introduction 
1.1. Horizontal Gene Transfer  
Horizontal gene transfer (HGT) is one of the main driving forces of evolution in prokaryotes 
and the mechanism by which bacteria acquire new genetic material from other species, 
genera or kingdoms. Some horizontally acquired genes will have a detrimental effect on the 
bacterial recipient, therefore these bacteria will be lost from the population over time. 
However, horizontally acquired DNA which provides a selective advantage to the organism, 
such as antibiotic resistance, can spread rapidly through the population (Thomas & Nielsen, 
2005). A genomic view of a bacterial species now suggests that bacteria have a core 
genome, which is conserved within a species, and a larger pan-genome consisting of the 
core genome and an accessory genome, which is highly variable (Tettelin et al., 2008). The 
first pan-genome analysis was carried out on eight pathogenic isolates of Streptococcus 
agalactiae, which is a leading cause of death in new-born babies. The authors determined 
that ~80% of each genome represented the core genome, which was shared by all eight 
isolates, and ~20% of genes were variable between strains (Tettelin et al., 2005). Similarly 
the core genome of Pseudomonas aeruginosa is highly conserved and accounts for ~90% of 
the overall genome, with the remaining 10% representing genes absent from some isolates 
(Kung et al., 2010). Pan-genome studies which have included a larger number of genomes 
have indicated that the core genome of some species may be much smaller. For example, 
following a comparison of 61 sequenced Escherichia coli genomes it was shown that only 
20% of genes belonged to the core genome of the organism, with the other 80% of genes 
not being found in other E. coli isolates analysed and therefore being part of the variable 
accessory genome (Lukjancenko et al., 2010). The large amount of variation between E. coli 
strains was originally suggested by a comparison of the genome sequence of the 
enterohaemorrhagic E. coli O157:H7 strain, isolated in Sakai, Japan, with that of the 
laboratory strain K-12. The two strains share a conserved 4.1 Mb backbone sequence but E. 
coli O157:H7 Sakai also contains 1.3 Mb of DNA, ~24% of the total genome, which is not 





1.2. Mechanisms of HGT 
In addition to mutations and deletions within the core genome, HGT is a main contributor 
to the constituents of bacterial accessory genomes, which contain a number of mobile 
genetic elements including plasmids, genomic islands and bacteriophages (Jackson et al., 
2011). There are three mechanisms of HGT: conjugation, transduction and transformation, 
which facilitate the generation diversity in bacterial genomes.  
1.2.1. Conjugation 
The transfer of DNA by conjugation requires direct cell-cell contact between the donor and 
recipient. Transfer is mediated by the formation of a pilus, which connects the two cells 
(Figure 1.1a) (Sorensen et al., 2005). It has been well established that plasmids, which are 
transferred by conjugation, carry a number of genes which can confer a selective advantage 
to the recipient cell, such as virulence and antibiotic resistance genes (Rankin et al., 2011). 
Conjugation of plasmids can facilitate the horizontal transfer of large amounts of DNA, 
which can result in an evolutionary ‘jump’ in the recipient organism (Jackson et al., 2011). 
Plasmids are circular, self-replicating, extra-chromosomal elements which usually consist of 
an essential ‘backbone’ of genes encoding the replicative functions and conjugative genes 
and ‘accessory’ genes which contribute adaptive traits to the host (Norman et al., 2009). 
Most conjugative plasmids encode a relaxase which nicks the double-stranded DNA at a 
specific site, known as the origin of transfer (oriT) to produce a single-stranded substrate 
for transfer to the recipient cell (Frost et al., 2005). All known conjugative plasmids from 
Gram-negative bacteria with the exception of the Bacteroides species, encode type IV 
secretion systems which are associated with the assembly of extracellular filaments, such as 
pili, which transport DNA from the donor to recipient cell (Sorensen et al., 2005). 
Conjugative plasmids tend to be larger in size than non-conjugative plasmids due to the 
extra genes encoding the conjugation machinery. They are also usually found in low copy 
numbers to reduce the metabolic burden on the host (Norman et al., 2009).  
Integrative and conjugative elements (ICEs), which are chromosome-borne mobile genetic 
elements such as conjugative transposons, are also transferred by conjugation. Under 
certain conditions ICEs are excised from the host chromosome, following which they 
circularise, are replicated, and transferred to the recipient cell via conjugation. The ICE in 
the recipient cell is integrated into the chromosome and the remaining copy of the ICE in 
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the donor cell reintegrates into the donor cell chromosome. Unlike plasmids, ICEs are 
incapable of independent replication and therefore cannot exist outside of the 
chromosome (Wozniak & Waldor, 2010). ICEs are self-transmissible mobile genetic 
elements and encode their own conjugation machinery in addition to proteins which 
control their excision from and integration into the host chromosome (Osborn & Boltner, 
2002). ICEs encode an integrase (usually designated Int) which enables their integration 
into the host chromosome and determines the site of insertion. These integrases, which are 
usually tyrosine recombinases, though serine recombinases have also been identified, 
promote site-specific recombination between the ICE and a target sequence on the host 
chromosome (Burrus & Waldor, 2004). ICEs also encode excisionases (Xis), which facilitate 
the excision of the ICE from the host genome, allowing it to circularise in preparation for 
transfer to the recipient cell.  The conjugative transfer of ICEs is believed to be similar to 
that of plasmids, with many ICEs identified in Gram-negative bacteria encoding homologues 
of type IV secretion system proteins, suggesting transfer by a secretion channel such as a 
pilus. Many identified ICEs also encode putative relaxases and oriT sequences, suggesting 
processing of the DNA for transfer is also similar to conjugative transfer of plasmids 
(Wozniak & Waldor, 2010). Initial ICEs were identified because they conferred easily 
identifiable phenotypes within an organism, such as antibiotic resistance. For example, V. 
cholera strains containing the SXT element are resistant to the antibiotics 
sulphamethoxazole, trimethoprim, chloramphenicol and streptomycin (Beaber et al., 2002). 
It has also been shown that ICEs can encode a number of other genes which give rise to a 
selective advantage within the host, such as virulence factors or pathways for the 
degradation of toxic compounds (Burrus & Waldor, 2004).  ICEs can contribute to a large 
proportion of the variable accessory genome of some bacterial species. For example, two-
thirds of the regions of diversity identified by Tettelin et al. (2008) in the genomes of eight 
S. agalactiae isolates are ICEs or genomic islands, believed to be defective ICEs which are no 
longer mobile (Brochet et al., 2008).  
1.2.2. Bacteriophages and Transduction 
The second mechanism of HGT is transduction (Figure 1.1b), which is mediated by 
bacteriophages. Phages are host-specific, genomic viruses estimated to outnumber their 
bacterial hosts ten-fold (Brüssow & Hendrix, 2002). Infection of bacterial cells by 
bacteriophages can be classed as lytic or lysogenic (temperate). Lytic infection results in the 
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multiplication of the bacteriophage and lysis of the host cell, whereas lysogenic infection 
results in the insertion of the phage genome into the host chromosome as a prophage 
which will be replicated along with the bacterial genome. The bacteriophage lifecycle 
involves a number of steps (Figure 1.2): adsorption, release of DNA from the protein coat, 
insertion and replication of phage DNA within the host chromosome, new phage assembly, 
release from the host cell and transmission (Weinbauer, 2004). The first step of 
bacteriophage infection is the adsorption of the virion to the surface of the host cell by the 
recognition of a host-specific receptor by phage receptor binding proteins (Shao & Wang, 
2008). A number of bacterial surface components have been identified as receptors for 
phage adsorption, including outer membrane proteins, flagella, LPS and capsular 
polysaccharides. LPS in particular are a common phage receptor in Gram-negative bacteria, 
for example T phage adsorb to LPS on the surface of Shigella and E. coli (Xu et al., 2013). 
Following adsorption, the host cell membrane is penetrated by the bacteriophage tail and 
phage DNA is injected into the cell. Mechanisms of penetration can vary. In the case of T7, 
proteins ejected from the phage form a channel which crosses the cell membrane allowing 
DNA to be internalised, however, the channel formed to transfer the lambda genome is 
formed by host-derived proteins  (Molineux, 2001). Following the injection of DNA, the 
bacteriophage genome is transcribed and translated in two phases, early and late. The early 
phase involves the expression of proteins to repair the bacterial cell membrane and a 
phage-specific polymerase which is required for the replication of the bacteriophage DNA. 
In the late phase structural proteins such as those involved in capsid and tail assembly are 
expressed, to enable new virions to form. This is followed by lysis of the host cell to release 
the bacteriophages which disseminate to neighbouring cells and infect (Weinbauer, 2004). 
Transduction occurs when host cell DNA is accidentally packaged into the new virions 
instead of bacteriophage DNA and later injected into a new cell (Figure 1.1b). The 
transduced DNA must then recombine with the host chromosome of the recipient cell. Due 
to this and the host-specific nature of bacteriophages, transduction usually occurs between 
bacteria of the same or closely related species (Frost et al., 2005).  
Temperate bacteriophages undergo a lysogenic lifecycle in which the phage genome is 
integrated into the host chromosome as a prophage and is replicated with the host genome 
(Figure 1.2), with the exception of bacteriophage P1, which exists as a plasmid when 
undergoing lysogeny. Temperate phage use the same unique integration site on the phage 
chromosome but do not necessarily integrate their DNA at the same site on the bacterial 
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chromosome. In E. coli for example, lambda phage normally integrates at one chromosomal 
site but bacteriophage Mu DNA integrates into the host chromosome at random (Casjens, 
2003). A stimulus, such as DNA damage can cause the prophage to be excised from the host 
chromosome. This excised can now act as a lytic phage, leading to the synthesis of new 
virions and host cell lysis (Canchaya et al., 2003a). However, not all prophage elements 
encode functional bacteriophages. These defective prophages, or cryptic prophages may 
still encode some functional genes but are unable to initiate replication of the phage 
genome, therefore cannot undergo lysis and remain within the host chromosome (Casjens, 
2003).  
Prophages can contribute to a large amount of the mobile DNA of a host genome and many 
sequenced bacterial genomes contain multiple prophages, which can represent >10% of the 
total bacterial DNA in some organisms (Brüssow & Hendrix, 2002). An example of this is the 
genome of the E. coli O157:H7 strain Sakai which contains 18 prophages accounting for 16% 
of the total genome (Ohnishi et al., 2001). Sequenced S. pyogenes strains contain between 
four and six prophage regions, which amount to 12% of the total genome content 
(Canchaya et al., 2003b). The acquisition of prophages plays a role in bacterial evolution 
through the transfer of useful genes to the host, which can increase the fitness of an 
organism (Brüssow et al., 2004). A major driving force in the emergence of pathogenic 
isolates is the horizontal transfer and acquisition of virulence factors. It has been 
demonstrated that prophages can encode virulence factors including toxins, adhesins for 
host attachment and effector proteins involved in invasion (Boyd & Brüssow, 2002). Since 
the discovery that the diphtheria toxin of Corynebacterium diphtheriae is encoded on the β-
phage genome (Freeman, 1951), phage encoded toxins have been identified in both Gram-
positive and Gram-negative bacteria, including Vibrio cholerae, Clostridium botulinum, S. 
pyogenes, Staphylococcus aureus and E. coli (Eklund et al., 1972; Weeks & Ferretti, 1984; 
Betley & Mekalanos, 1985; Huang et al., 1987). The expression of prophage-encoded 
virulence factors is usually regulated by the host chromosome rather than phage-encoded 
factors. One exception to this is the Shiga toxins (Stx1 and Stx2) of enterohaemorrhagic E. 
coli (EHEC), which are encoded by stx genes located on λ-related prophages and expression 
of which is controlled by transcriptional regulators encoded by the prophages (Wagner et 
al., 2002). Some bacterial adhesins involved in attachment to host cells have been shown to 
be prophage-encoded, for example, the toxin co-regulated pilus (TCP) of V. cholerae, which 
is important for colonisation of the host is encoded by the genome of bacteriophage VPIФ. 
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This prophage is located adjacent to the Vibrio pathogenicity island (VPI), which encodes 
the cholera toxin, in the bacterial chromosome (Karaolis et al., 1999). Bacteriophages are 
important mediators of HGT between bacterial species and the presence of prophages can 
confer inter-strain genetic variability within bacteria of the same species (Brüssow et al., 
2004).  
1.2.3. Transformation 
The third mechanism of HGT is transformation (Figure 1.1c), which is the natural uptake, 
integration and expression of extracellular DNA by a recipient cell. Unlike conjugation and 
transduction, acquisition of DNA by natural transformation is initiated by the recipient 
rather than the donor cell. Cells can be exposed to extracellular DNA that has been 
passively released by dead bacterial cells which have undergone lysis or via the active 
release of DNA by organisms such as Acinetobacter, Bacillus and Pseudomonas (Thomas & 
Nielsen, 2005). The ability of bacteria to bind and take up extracellular DNA is dependent 
on the cell being naturally competent, a state which involves the expression of specialised 
competence proteins. With the exception of Neisseria gonorrhoeae and N. meningitidis, 
which constitutively express their competence proteins, competence in naturally 
transformable bacteria is dependent on specific environmental or cellular signals (Solomon 
& Grossman, 1996).  In Streptococcus pneumoniae natural competence occurs in early 
exponential phase of growth and is induced by the binding of the secreted competence-
stimulating peptide (CSP) to its membrane-embedded receptor ComD (Johnsborg et al., 
2007). Conversely, the competence of Bacillus subtilis occurs at the beginning of stationary 
phase and involves a number of different stimuli, including cell density and nutritional 
stress (Hamoen et al., 2003). Extracellular DNA binds to the cell surface of competent 
bacteria and in most Gram-negative bacteria, transport of DNA through the outer 
membrane involves type IV pili (Chen & Dubnau, 2004). Double-stranded DNA is converted 
to single-stranded DNA during translocation across the inner membrane to the cytoplasm 
and can integrate into the host chromosome via homologous recombination. This requires 









Figure 1.1: Mechanisms of horizontal gene transfer in bacteria 
(a) Conjugation occurs by direct contact between the donor and recipient cells via a pilus. 
Plasmid or ICE DNA is exchanged which can result in acquisition of new genes by the 
recipient. (b) In transduction, the transfer of genes from donor to recipient cells is mediated 
by bacteriophages. Transferred genes can integrate into the recipient cell chromosome. (c) 
Transformation occurs when naked DNA is released following the lysis of the donor cell and 





Figure 1.2: The lytic and lysogenic lifecycles of bacteriophages 
Bacteriophages adsorb to the surface of the host cell via the recognition of host-specific surface receptors and phage DNA is injected into the cell (1). 
Lytic bacteriophages hijack the host cell machinery to synthesise and assemble new bacteriophage particles (2, 3). The host cell is lysed and the 
bacteriophages are released, these new phages disseminate to infect new cells (4). The DNA of lysogenic bacteriophages is integrated into the host 
chromosome and forms a prophage (3). The phage DNA is replicated along with the host chromosome and is present in each new daughter cell (4). An 
external stimulus can lead to the excision of the prophage from the host chromosome, at which time it enters a lytic lifecycle (5). 
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1.3. The microbiota of the human gastrointestinal tract 
The dominant members of the ‘normal’ human gastrointestinal microbiota are the 
anaerobic bacteria. These organisms outnumber aerobes and facultative anaerobes by 100-
1000 fold (Sommer & Backhed, 2013). The GI-tract is colonised by >1000 different bacterial 
species, but these represent only a few of the known bacterial phyla. The two most 
abundant of these are Bacteroidetes and Firmicutes, but members of other phyla, such as 
Proteobacteria and Actinobacteria, are also present (Backhed et al., 2005). Colonisation of 
the GI-tract begins at birth with organisms from the mother’s vagina and skin, and during 
breast feeding with organisms from milk. The composition of the intestinal microbiota 
changes with early host development but stabilises between the ages of 1-2 and begins to 
resemble the adult GI-tract (Sekirov et al., 2010). The ‘normal’ adult intestine contains 
~1014 bacterial cells, which is ten times the number of human cells in the body. Their 
combined bacterial genomes contain more than 5 million genes which provides the 
intestinal microbiota with a diverse range of gene products to facilitate their interaction 
with the host (Xu & Gordon, 2003). These commensal organisms perform several essential 
roles, including the metabolism of indigestible plant polysaccharides and the production of 
key vitamins, which are not synthesised by the host. Members of intestinal microbiota are 
also required for the development and regulation of the host immune system, to maintain 
homeostasis within the GI-tract and to provide protection against colonisation by 
opportunistic pathogens (Sommer & Backhed, 2013). In turn, the microbiota are provided 
with a protected, nutrient-rich environment to inhabit, which is maintained at a constant 
temperature (Troy & Kasper, 2010). 
1.3.1. Resistance to pathogens 
The intestinal microbiota provide protection against infection by pathogens, as 
demonstrated in germ-free mice which are more susceptible to infection than 
conventionally reared mice (Round & Mazmanian, 2009). For example, germ-free animals 
challenged with Shigella flexneri displayed decreased resistance to infection and increased 
mortality compared to conventionally reared animals (Sprinz et al., 1961). Germ-free mice 
also demonstrate a reduced clearance of the intracellular pathogen Listeria 
monocytogenes, which has been attributed to a T-cell trafficking defect which normally 
directs lymphocytes to the site of infection (Zachar & Savage, 1979; Inagaki et al., 1996). 
Finally, infection with Salmonella Typhimurium caused more acute gastroenteritis in germ-
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free mice (Round & Mazmanian, 2009). Furthermore, treatment with antibiotics, which 
disrupts the intestinal microbiota, has been associated with increased colonisation by 
pathogens in both humans and mice.  
 
A number of mechanisms by which the microbiota can inhibit colonisation by pathogens 
have been identified. The first is by direct competition for nutrients (Kamada et al., 2013). 
Several studies have shown that commensal bacteria can successfully out-compete 
pathogens for nutrients in the GI-tract. For example, E. coli out-competes EHEC for amino 
acids, organic acids and other nutrients, suggesting that commensal E. coli is better adapted 
to utilise nutrients in the gut than the pathogenic strain. E.coli can also out-compete the 
pathogen Citrobacter rodentium, which, like E. coli, uses monosaccharides as their nutrient 
source. In contrast, Bacteroides thetaiotaomicron and Bacteroides vulgatus, which utilise 
mono and polysaccharides, cannot out-compete C. rodentium, suggesting commensals are 
more successful at out-competing pathogens that are metabolically related and therefore 
utilise the same nutrient sources (Kamada et al., 2012). This was also demonstrated by the 
inability of E. coli MG1655 to out compete pathogenic E. coli strain EDL933. The two strains 
metabolise a number of the same sugars, however, EDL933 can also utilise sugars which 
MG1655 cannot. This suggests a mechanism by which pathogenic strains can gain a 
colonisation advantage in the GI-tract, by consuming sugars which are not primarily 
metabolised by the commensal microbiota (Fabich et al., 2008).  
 
Secondly, the intestinal microbiota promotes the function of the mucosal barrier, which 
prevents the attachment of pathogens to the surface of the intestinal epithelium. The 
epithelium of the colon produces mucus which covers the epithelial cells, facilitates 
gastrointestinal transport and forms a physical barrier against colonisation by both 
commensal and pathogenic organisms (Sommer & Backhed, 2013). The intestinal 
microbiota plays a role in mucus production, as shown by germ-free mice which have a 
thinner mucus layer and fewer mucus-producing goblet cells than conventionally reared 
mice. This defect can be corrected by stimulation with bacterial products such as 
lipopolysaccharide (LPS) and peptidoglycan (Petersson et al., 2011). The gut microbiota also 
induces the production of antimicrobial peptides by the epithelial cells to protect against 
invading pathogens (Kamada et al., 2013). These antimicrobial peptides can kill bacteria 
through enzymatic activity on the cell wall or by disrupting the bacterial cell inner 
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membrane of Gram-negative bacteria. Several antimicrobial peptides, such as α- and β-
defensins, are constitutively expressed by the epithelium. However, the expression of 
others is induced following the recognition of bacterial signals by the host cell pattern 
recognition receptors (Hooper & Macpherson, 2010). For example, antimicrobial peptide 
RegIIIγ, which preferentially acts upon the peptidoglycan of Gram-positive bacteria, is 
released from Paneth cells in the lumen of the GI-tract following recognition of the 
intestinal microbiota by Toll-like receptors (TLRs) (Cash et al., 2006). Germ-free mice display 
minimal levels of REGIIIγ expression and mice with REGIIIγ deficiencies have increased 
susceptibility to infection by enteric pathogens including L. monocytogenes (Brandl et al., 
2007). In mono-colonised mice, B. thetaiotaomicron can stimulate Paneth cells to produce 
the antimicrobial peptide angiogenin 4, which is bactericidal to L. monocytogenes and 
Enterococcus faecalis, but not to the commensal organisms E. coli K12 and B. 
thetaiotaomicron (Hooper et al., 2003). 
 
1.3.2. Development of the host immune system 
Germ-free mice studies revealed that the intestinal microbiota is required for the normal 
development of the host gut-associated lymphoid tissues. These play a role in antigen 
detection and presentation, lymphocyte functions and the activation of the host immune 
response (Kamada et al., 2013). Germ-free mice display a number of intestinal 
immunological defects including reduced antibody production, smaller and fewer Peyer’s 
patches and mesenteric lymph nodes, and fewer CD4+ and CD8+ T-cells, in comparison to 
conventionally reared mice (Round & Mazmanian, 2009). Additionally, the intestinal 
epithelial cells, which have a number of immunological functions including cytokine 
secretion and expression of pattern recognition receptors, display reduced cell turnover  
and reduced expression of TLRs and class II major histocompatibility complex (MHC II) 
molecules in germ-free animals (Hooper et al., 2012). Intraepithelial lymphocytes, which 
are specialised T-cells located between epithelial cells that release cytokines to kill invading 
cells, are also reduced in number and have a decreased cytotoxicity (Lee & Mazmanian, 
2010). Germ-free mice also display extra-intestinal defects in the spleen including reduced 
numbers of CD4+ T cells, reduced antibody levels and fewer and smaller germinal centres, 
which are the location of B cell differentiation and proliferation (Mazmanian et al., 2005). 
When germ-free mice are colonised with members of the intestinal microbiota, these 
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defects can be corrected, demonstrating that commensal organisms modulate the 
development of the host immune system (Reading & Kasper, 2011).   
 
1.4. Bacteroides species 
Bacteroides species are non-spore-forming, Gram-negative rods and are the predominant 
anaerobic organisms in the GI-tract, representing ~25% of the organisms identified in 
faeces (Wexler, 2007). The Bacteroides spp. have established themselves as commensal 
organisms by playing an important role in host nutrition and in the development of the host 
immune system. The impact of the intestinal microbiota, including Bacteroides spp. on 
nutrition was demonstrated in germ-free mice, which required 30% more calorific intake a 
day to maintain their body weight than conventionally reared mice (Wostmann et al., 
1983). Bacteroides spp. can degrade a wide range of ingested plant polysaccharides which 
are otherwise indigestible by the host. These polysaccharides are broken down and 
fermented into short chain fatty acids (SCFA), such as acetate, propionate and butyrate 
which can then be utilised by the host. In humans, approximately 10% of their daily 
absorbed calories are obtained from these bacterial fermentation products (Hooper et al., 
2002).  In addition to their nutritional value, SCFA have also been implicated in epithelial 
cell proliferation and differentiation and stimulating intestinal blood flow (Scheppach, 
1994). The best understood mechanism by which commensals degrade polysaccharides is 
the starch utilisation system (sus) of B. thetaiotaomicron. Starch is bound to a protein 
complex present on the bacterial cell surface where it is hydrolysed into smaller 
oligosaccharides by α-amylases. These smaller molecules are transported via a porin across 
the outer membrane and into the periplasm, where they are broken down to glucose 
monomers. The sus genes are under the control of a transcriptional activator which 
responds to the presence of larger oligosaccharides so that they are only expressed when 
the appropriate nutrients are available. This ensures that nutrient metabolism is an energy 
efficient process (Flint et al., 2008). In addition to sus, the genome of B. thetaiotaomicron 
contains 87 other polysaccharide utilisation loci (PUL) which encode proteins involved in 
sensing and degrading specific glycans in the GI-tract. This allows the organism to degrade a 
number of host derived glycans, such as mucin. The ability to utilise these glycans provides 
the organism with a readily available nutrient source, which is constantly replenished due 
to epithelial cell turnover. It also confers a selective advantage as the competition for these 
glycans will be minimal as they are not degraded by all bacterial species (Comstock, 2009).  
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1.4.1. Bacteroides fragilis Polysaccharide A 
In addition to polysaccharide metabolism, Bacteroides spp., in particular Bacteroides fragilis 
are involved in the maintenance of the host immune system. Germ-free mice display a 
number of immunological defects which can be corrected following colonisation with the 
intestinal microbiota (1.3.2), B. fragilis polysaccharide A (PSA) has been shown to play an 
important role in the development of the host immune system. PSA is a zwitterionic 
polysaccharide, a class of polysaccharides which contain both a positive and negative 
charge in each of their repeating units, and are presented on MHC class II molecules to 
antigen-presenting cells (Wexler, 2007; Reading & Kasper, 2011). B. fragilis is also able to 
prevent the pathology of experimental colitis in mice, which has been attributed to PSA. 
Oral treatment of mice with PSA can protect against symptoms of colitis including weight 
loss and pro-inflammatory cytokine expression within the gut (Mazmanian et al., 2008). It 
has been shown that colonisation of germ-free mice with wild type B. fragilis resulted in 
increased numbers of CD4+ T cells in comparison to mice colonised with B. fragilis strains 
which cannot produce PSA. Mono-colonisation of mice with wild type B. fragilis has also 
been shown to mediate the differentiation of CD4+ T cells into Foxp3+ T regulatory (Treg) 
cells. This process was defective in mice that were mono-colonised with B. fragilis strains 
that did not produce PSA. Furthermore, the defect in CD4+ T cell differentiation could be 
corrected by the administration of purified PSA alone (Mazmanian et al., 2005; Round & 
Mazmanian, 2010).  The protective effects of PSA in experimental colitis models are 
attributed to IL-10 production by Treg cells which prevents inflammation. IL-10 deficient 
Treg cells were unable to confer the protective effects of PSA.  Moreover, B. fragilis strains 
lacking PSA failed to induce IL-10 and instead had a pro-inflammatory effect on the host 
immune system, suggesting that PSA is an essential component in success of B. fragilis as a 
commensal organism (Lee & Mazmanian, 2010). PSA is also involved in splenic structural 
development. The spleens of mice mono-colonised with wild type B. fragilis display normal 
splenic development consistent with conventionally reared mice. However, mice colonised 
with a ΔPSA strain of B. fragilis showed defects similar to those observed in germ-free mice, 
including smaller and less defined follicles and depletion of lymphocyte zones (Mazmanian 
et al., 2005). Shen et al (2013) determined that B. fragilis outer membrane vesicles (OMV) 
(see section 1.6) are the delivery mechanism by which PSA interacts with the host. B. 
fragilis OMV are internalised by dendritic cells (DCs) which sense OMV-associated PSA 
17 
 
through TLR2. The authors also demonstrated that treatment of DCs with PSA containing 
OMV prevented experimental colitis.  
 
1.5. B. fragilis: An opportunistic pathogen 
B. fragilis accounts for only 1-2% of the human colonic microbiota, however, it is the most 
commonly isolated Gram-negative bacterium from clinical anaerobic infections (Patrick & 
Duerden, 2006). B. fragilis is an opportunistic pathogen; infection usually occurs when the 
wall of the gastrointestinal tract has been disrupted or perforated, usually following 
surgery, and the contents of the GI-tract can enter the sterile peritoneal cavity. Early 
colonisation is by facultative anaerobes such as E. coli, which cause the primary tissue 
damage and cause a reduction in oxygen tension. This allows obligate anaerobic bacteria to 
colonise (Wexler, 2007).  The range of B. fragilis infection includes abscess formation, intra-
abdominal sepsis, gynaecological sepsis, peritonitis, soft tissue infection and bacteraemia 
(Patrick, 2002). During peritonitis, intra-abdominal abscesses are formed, which sequester 
bacterial cells along with cellular debris and dead polymorphonuclear leukocytes within a 
fibrous membrane. If untreated, abscesses can expand and cause intestinal obstructions 
and their rupture can result in dissemination of infection and bacteraemia. B. fragilis is the 
most common cause of anaerobic bacteraemia, with a potential mortality rate of up to 
~30% (Cheng et al., 2009).  
 
1.5.1. Virulence factors 
1.5.1.1. Capsular polysaccharides 
One characteristic of B. fragilis which may play a role in its success as an opportunistic 
pathogen is the expression of within-strain variable surface polysaccharides. Three B. 
fragilis capsular types have been observed (Figure 1.3) (Patrick et al., 1986): the within-
strain variable large capsule (LC), which confers resistance to phagocytic uptake and killing 
by polymorphonuclear leukocytes in vitro (Reid & Patrick, 1984); the small capsule (SC), and 
an electron dense layer or micro capsule (MC) composed of within-strain and phase 
variable polysaccharides, which have been associated with resistance to complement 
mediated killing (Reid & Patrick, 1984) and abscess formation (Tzianabos et al., 1993). The 
genomes of three sequenced B. fragilis strains, NCTC9343, 638R and YCH46 each encode 
ten regions (PSA-J) associated with extracellular polysaccharide biosynthesis, eight of which 
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(PSA-H), have been implicated in the expression of the phase variable MC (Cerdeno-Tarraga 
et al., 2005; Patrick et al., 2010).  
Extracellular polysaccharides such as lipopolysaccharide (LPS) and capsular polysaccharides 
have diverse roles in mediating interactions between the bacterium and the environment, 
in protecting the cell from bacteriophage adsorption and the host immune response and 
can also be involved in colonisation. LPS is found on the outer membrane of most Gram-
negative bacteria. It is comprised of three regions, the lipid anchor (lipid A), a core 
oligosaccharide and the O-antigen, which is a chain of polysaccharide repeat units of 
variable length. The nature of LPS in B. fragilis has been the subject of much debate, but it 
has been hypothesised that the polysaccharides of the MC are equivalent to the O-antigen 
of enteric LPS (Patrick et al., 2009). However, unlike E. coli LPS which contains short chain 
length O-antigen polysaccharides, the B. fragilis MC is composed of high molecular mass 
polysaccharides (Lutton et al., 1991; Patrick et al., 2003). The mechanism by which the B. 
fragilis LC is synthesised is believed to be equivalent to that of E.coli group 1 and 4 capsules 
(Patrick et al., 2009).  
In E. coli, the polysaccharides required for the formation of the LPS O-antigen and group 1 
and 4 capsules are synthesised by a Wzy-dependent pathway (Figure 1.4). On the 
cytoplasmic face of the inner membrane, sugar phosphates are bound to the carrier lipid 
undecaprenyl phosphate (und-P) by a glycosyltransferase complex containing WabP (Figure 
1.4 A). The und-PP-linked repeat units are transferred across the inner membrane to the 
periplasmic face by the O-antigen flippase Wzx, and then the polymerase, Wzy assembles 
the und-PP-linked repeats into polymers (Figure 1.4 B). In the case of capsular 
polysaccharide biosynthesis, the activity of Wzy is modulated by Wzc, which also interacts 
with the export channel Wza to transport the polysaccharide to the outer membrane 
(Figure 1.4 C). In O-antigen biosynthesis, the chain length of the polymer is determined by 
the O-antigen co-polymerase, Wzz and the polysaccharide is ligated to the lipid A-core by 
WaaL (Whitfield & Paiment, 2003; Whitfield, 2006b). 
In B. fragilis NCTC9343, three genes have been implicated in LC production, a putative 
glycosyltransferase WabP homologue, a putative export protein Wza homologue and a 
putative co-polymerase Wzc homologue. This suggested that the biosynthesis of B. fragilis 
LC was similar to that of E. coli group 1 and 4 capsules (Patrick et al., 2009). The MC-
associated polysaccharide biosynthesis loci of NCTC9343, YCH46 and 638R all contain genes 
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predicted to encode Wzx and Wzy proteins, suggesting that these polysaccharides may be 
exported to the outer membrane or linked to the lipid A-core (Patrick et al., 2010). A single 
homologue of the Wzz co-polymerase has been identified in the genome of NCTC9343 and 
deletion of wzz resulted in the absence of MC, suggesting that the MC-associated 
polysaccharides may be linked to the lipid A-core. However, no homologues of WaaL have 
been identified in NCTC9343, therefore the mechanism by which polysaccharides could be 
attached to the lipid A-core is unknown (Patrick et al., 2009). 
 
 
Figure 1.3: B. fragilis capsules (taken from Patrick et al 2009) 
Three B. fragilis capsular types have been identified: A within-strain, antigenically 
variable large capsule (LC), a small capsule (SC) and a variable micro-capsule (MC). B. 
fragilis capsular polysaccharides have been associated with resistance to phagocytic 






Figure 1.4: Wzy-dependent polysaccharide biosynthesis (adapted from Whitfield, 
2006) 
E. coli O-antigen polysaccharides and group 1 and 4 capsules are synthesised via a Wzy-
dependent pathway. A) First, sugar phosphates are bound to und-PP on the cytoplasmic 
face of the inner membrane by a glycosyltransferase complex containing WbaP. B) The 
repeat units are flipped across the inner membrane by the O-antigen flippase, Wzx and 
the O-antigen polymerase, Wzy assembles the units into polymers. C) In the formation 
of capsules, polysaccharides are transported beyond the outer membrane via the 
export channel Wza. O-antigen polysaccharides are attached to the lipid A-core before 




The destruction of host cell tissues is important during B. fragilis infection as these can be 
utilised by the bacterium as a nutrient source. Several proteases have been implicated in 
tissue destruction including hyaluronidase, chondroitin sulfatase and hemolysins. These 
proteases destroy the host extracellular matrix (Wexler, 2007). Hemolysins, which have 
been identified as virulence factors in a number of Gram-positive and Gram-negative 
organisms, are cytotoxic proteins which have a haemolytic effect on host cells by causing 
damage to membranes. The lysis of neutrophils and other host cells by hemolysins can 
affect the host immune response and also provide a source of nutrients for invading 
organisms. Two hemolysins, HlyA and HlyB have been characterised in B. fragilis. These 
proteins act in conjunction and have been shown to cause the hemolysis of erythrocytes 
(Robertson et al., 2006). Bacteroides species also produce neuraminidase, encoded by the 
nanH gene, which cleaves mucin polysaccharides to produce glucose which can be utilised 
by the bacterium (Berg et al., 1983). B. fragilis strains NCTC9343, 638R and YCH46 have 
been shown to bind human fibrinogen, a major component in abscess formation. These 
strain also display fibrinogenolytic activity, which might allow B. fragilis to slow down or 
prevent abscess formation or facilitate abscess degradation, allowing infection to 
disseminate, potentially resulting in bacteraemia (Houston et al., 2010).  
1.5.1.3. Enterotoxin 
 
Enterotoxigenic B. fragilis (ETBF) strains encode a ~20 kDa zinc metalloprotease protein 
toxin termed B. fragilis enterotoxin (BFT). These strains have been associated with an acute 
form of disease, characterised by diarrhoea and loss of appetite in children, adults and 
livestock (Franco et al., 1999). Studies indicate that BFT may destroy zonula adherens tight 
junctions, which are cell-cell junctions in the intestinal epithelium linked to the actin 
cytoskeleton. BFT cleaves zonula adherens protein E-cadherin which results in the 
rearrangement of the actin cytoskeleton and loss of tight junctions. This in turn results in 
leakage in the epithelium and diarrhoea (Wu et al., 1998). The enterotoxin gene has been 
identified in strains isolated in a number of different countries, including USA, Japan and 
Italy. BFT was also detected in 18% of clinical isolates tested from the UK, Poland, France 
and Holland (Luczak et al., 2001). In one study, ETBF strains were associated with patients 
suffering from inflammatory bowel disease (Prindiville et al., 2000).  
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1.6. Bacterial outer membrane vesicles 
 
Outer membrane vesicles (OMV) are naturally secreted from Gram-negative bacteria during 
all stages of growth. OMV form when a portion of the bacterial outer membrane 
encapsulates periplasmic content and ‘blebs’ from the cell, however, the mechanism by 
which this occurs is still unknown. These vesicles are ~50-250 nm in diameter, depending 
on the strain, and act as a secretion and delivery system which can disseminate bacterial 
products and are a mechanism by which bacteria can interact with their environment and 
the host (Kulp & Kuehn, 2010).  
 
The rate of vesicle production is not consistent and can be altered by environmental factors 
and cellular stress. External conditions which upregulate the σE envelope stress response 
have been shown to increase vesiculation in E. coli and appear to play a role in cell survival 
during envelope stress. E. coli mutants that over-produce vesicles exhibit enhanced survival 
following extracellular insults in comparison to OMV under-producing and wild type strains. 
OMV allow bacterial cells to dispose of toxic products such as mis-folded proteins, 
therefore reducing membrane stress (McBroom & Kuehn, 2007).  Antibiotics can also 
influence vesicle production. Treatment of Shigella dysenteriae with mitomycin C induces 
an increase in vesicle production, an increase in OMV size and in OMV toxicity (Dutta et al., 
2004). Treatment of P. aeruginosa with gentamicin also increases vesiculation and OMV 
size, while changes in the composition of the OMV were also observed. These antibiotic 
induced vesicles contained inner membrane and cytosolic components in addition to outer 
membrane and periplasmic proteins (Kadurugamuwa & Beveridge, 1995). OMV produced 
by some organisms can confer a survival advantage by having a bactericidal effect on other 
bacteria, therefore reducing competition. This was demonstrated by protease- and toxin-
containing OMV from E.coli, Shigella and Pseudomonas which lyse other Gram-positive and 
Gram-negative bacteria  (Kuehn & Kesty, 2005). OMV may also act as a defence mechanism 
to bacteriophage infection. Manning and Kuehn (2011) demonstrated that bacteriophage 
T4 can adsorb to OMV isolated from E. coli and that T4 infectivity was reduced following 
incubation with vesicles. This suggests OMV may act as a decoy system to prevent the 




OMV play a well-established role in the delivery of bacterial products, such as toxins and 
other virulence-associated bacterial products to the host. Experimental studies have 
indicated that the interaction of OMV with host cells can occur in one of two ways. The first 
is via fusion of the OMV with the eukaryotic cell plasma membrane and delivery of their 
contents directly into the cytosol. This has been demonstrated by the detection of 
fluorescently labelled components of the outer membrane of OMV on the surface of host 
cell membrane (Galka et al., 2008). Bomberger et al (2009) proposed that OMV deliver their 
bacterial proteins by fusing with host cell lipid raft microdomains. The authors showed that 
disruption of lipid rafts with the cholesterol binding agent Filipin III eliminated the fusion of 
P. aeruginosa OMV with airway epithelial cells. A similar study by Kesty et al (2004) 
determined that Filipin III also interfered with the ability of E. coli OMV to interact with host 
cells. The second mechanism by which OMV interact with the host cells is by adherence and 
internalisation via a receptor-mediated endocytic pathway (Ellis & Kuehn, 2010). Toxins can 
act as adhesins for OMV, for example enterotoxigenic E. coli (ETEC) produces heat labile 
enterotoxin (LT) which is associated with the bacterial LPS and has been identified as a 
surface component of OMV. ETEC OMV interact with epithelial cell membranes and binding 
occurs between LT and its lipid raft-associated receptor. OMV are then internalised via 
cholesterol-mediated endocytosis. Following entry into the cell, LT is trafficked to the 
endoplasmic reticulum and the cytoplasm, resulting in enterotoxicity  (Kesty et al., 2004). 
Similarly, uptake of Helicobacter pylori OMV by gastric epithelial cells also involves 
interactions with the lipid rafts of host cells, however, cholesterol is not required for this 
process, and instead internalisation is via clathrin-mediated endocytosis. Vesicle-associated 
H. pylori vacuolating toxin (VacA) binds to a number of host cell receptors, including lipid 
rafts and has been shown to increase the uptake of OMV by epithelial cells, suggesting it 
plays a role in vesicle internalisation (Parker et al., 2010).  
 
The delivery of virulence factors to the host via OMV can play an important role in bacterial 
pathogenesis. For example, mucociliary clearance in the lung is driven by the cystic fibrosis 
transmembrane conductance regulator (CFTR) secretory chloride channels located in the 
plasma membranes of airway epithelial cells (Swiatecka-Urban et al., 2006). These channels 
are constitutively cycled in and out of the cell membrane through endosomal 
compartments. CFTR is ubiquitylated and incorporated into an early endosome, 
deubiquitylating enzyme USP10 deubiquitylates CFTR and the channel is returned to the 
membrane. However, P. aeruginosa toxin Cif, which is delivered to host cells via OMV 
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inhibits the deubiquitylating activity of USP10 which leads to the lysosomal degradation of 
CFTR. This results in a decreased number of CFTR channels in the plasma membrane, which 
in turn leads to a reduced mucociliary clearance of bacterial infection and compromises the 
immune defences of the lung (MacEachran et al., 2007; Bomberger et al., 2009; Bomberger 
et al., 2011b). 
 
As OMV contain many of the surface antigens present on bacteria, they have the potential 
to stimulate or modulate the host cell response to bacterial infection. OMV have been 
shown to activate the host inflammatory response, for example, OMV produced by 
Salmonella Typhimurium induce dendritic cell maturation, activate macrophages and 
increase the expression of MHC class II molecules, and they also stimulate pro-
inflammatory cytokine secretion and CD4+ T cell activation (Alaniz et al., 2007). A pro-
inflammatory response to OMV has also been observed for other pathogens, including H. 
pylori and P. aeruginosa, which both induce the expression of IL-8 (Ellis & Kuehn, 2010). 
Vesicles may also have an anti-inflammatory effect on the host immune system to allow the 
organism to escape detection during colonisation. Gingipain proteases on the surface of 
Porphyromonas gingivalis degrade the LPS receptor, CD14, of human macrophages. This 
could result in a reduced immune reaction in response to P. gingivalis colonisation (Duncan 
et al., 2004). Moraxella catarrhalis OMV contain the surface protein UspA1 which has been 
shown to have an inhibitory effect on the inflammatory response of epithelial cells (Schaar 
et al., 2011).  
 
B. fragilis OMV play an important role in the mutualistic relationship between the organism 
and the host because OMV-mediated delivery of B. fragilis PSA dendritic cells promotes 
host immune development and protects against experimental colitis (see section 1.4.1) 
(Shen et al., 2012). However, B. fragilis OMV have also been shown to contain degradative 
enzymes and can agglutinate erythrocytes, indicating that vesicles may also be involved in 









The main aim of this thesis was to identify instances of horizontal gene transfer within the 
genome of B. fragilis and to consider their potential contribution to the success of the 
organism as both a commensal and an opportunistic pathogen.  
 The genomes of three previously sequenced B. fragilis strains, NCTC9343, YCH46 
and 638R displayed extensive horizontal gene transfer. Whole genome sequencing 
of four further B. fragilis strains was performed and comparisons were made with 
YCH46, 638R and NCTC9343 to determine the within-strain variation of 
polysaccharide biosynthesis loci and diversity of R-M systems.  
 
 The genomes of NCTC9343 and 638R contained a gene, ubb, which had 63% 
identity to human ubiquitin. The closest DNA sequence homology was to a 
Migratory Grasshopper entomopox virus, suggesting acquisition by inter-kingdom 
HGT. The aim of this study was to determine if BfUbb was expressed by B. fragilis 
and to explore the potential of the protein to interact with the eukaryotic host. 
 
 Finally, B. fragilis-specific bacteriophages were isolated, characterised and assessed 
for their ability to mediate transduction, with the aim of identify new tools to aid in 











2. Materials and Methods 
2.1. Bacterial culture conditions 
B. fragilis strains were grown in a Don Whitley Scientific (UK) MiniMacs anaerobic work 
station at 37°C with an anaerobic gas mix (10% Hydrogen 10% Carbon dioxide and 80% 
Nitrogen), in brain heart infusion broth (BHI) (Difco, USA) supplemented with 5% cysteine, 
10% sodium bicarbonate, 50 μg/ml haemin and 0.5 μg/ml menadione or defined medium 
(DM) (Van Tassell & Wilkins, 1978). E. coli strains were grown in Luria-Bertani Broth (LB) 
(Difco, USA) shaken at 200 rpm, or on LB agar at 37 °C. Media were supplemented with 
appropriate antibiotics (Table 2.1) where stated. Strains were stored in a final 
concentration of 25% glycerol at -80°C. 
2.2. Antibiotics 
The concentration and preparation medium of antibiotics which were used in this study are 
shown in Table 2.1. 







Ampicillin 100mg ml-1 100µg ml-1 In sterile H2O 
Erythromycin 10mg ml-1 10µg ml-1 In ethanol 
Gentamicin sulphate 50mg ml-1 50µg ml-1 In sterile H2O 
Metronidazole 5mg ml-1 5µg ml-1 In sterile H2O 
Rifampicin 50mg ml-1 50µg ml-1 In methanol 










The stains used in this study and their source are shown in Table 2.2. 
Table 2.2: List of strains 
Strain Genotype Source 
DH5α 
F- φ80lacZ∆M15∆(lacZYA-argF)U169 recA1 
endA1 hsdR17(rk
-, mk
+) phoA supE44 thi-1 
gyrA96 relA1 λ- Invitrogen 
S17-1 (λpir) 
recA thi pro hsdRM+ RP4::2-Tc::mu::Km Tn 7 
λ pir  Simon et al 1983 
XL-1 Blue MRF' 
Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr 173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
 F  proAB laclqZΔM15 Tn10 (Tetr ) 
Stratagene, Aligent 
Technologies 
Δubb NCTC9343 Δubb::ermF Patrick et al 2011 
Δwzz NCTC9343 Δwzz::ermF Patrick et al 2009 
Δupcy NCTC9343 Δupcy::ermF Patrick et al 2009 
638R B. fragilis clinical isolate C.J. Smith 
3259 B. fragilis clinical isolate Sheila Patrick 
BCH1 B. fragilis clinical isolate Sheila Patrick 
BE1 B. fragilis clinical isolate Sheila Patrick 
BE3 B. fragilis clinical isolate Sheila Patrick 
GNAB4 B. fragilis clinical isolate Sheila Patrick 
GNAB92 B. fragilis clinical isolate Sheila Patrick 
JC6 B. fragilis clinical isolate Sheila Patrick 
JC15 B. fragilis clinical isolate Sheila Patrick 
JC17 B. fragilis clinical isolate Sheila Patrick 
JC19 B. fragilis clinical isolate Sheila Patrick 
LS27 B. fragilis clinical isolate Sheila Patrick 
LS54 B. fragilis clinical isolate Sheila Patrick 
LS66 B. fragilis clinical isolate Sheila Patrick 
MPRL3499VI B. fragilis clinical isolate Ian R. Poxton 
MPRL3535V B. fragilis clinical isolate Ian R. Poxton 
MPRL3536X B. fragilis clinical isolate Ian R. Poxton 
NCTC9343 B. fragilis clinical isolate Sheila Patrick 
NCTC9344 B. fragilis clinical isolate Sheila Patrick 
NCTC10584 B. fragilis clinical isolate Sheila Patrick 
RD47 B. fragilis clinical isolate Sheila Patrick 
RD48 B. fragilis clinical isolate Sheila Patrick 
VH B. fragilis clinical isolate Sheila Patrick 
WAL610 B. fragilis clinical isolate Hannah Wexler 
YCH46 B. fragilis clinical isolate Sheila Patrick 




PCR was carried out as described in 2.7.3 and the oligonucleotides used in this study are 
hown in Table 2.3 




(bp)  Sequence (5'-3') 
GyrB_full_FOR 21 TTGGTGGGATTCTGTTCTTCG 
GyrB_full_REV 21 TAGCTATAAACGTATGCAACG 
GyrB3_FOR 19 CCACACAGGAACCAAACAG 
GyrB3_REV 20 TATTGTACATGATAGCCACC 
ubb_FOR 21 CACACCTTTTTCAACAGACCC 
ubb_REV 22 CTTAGTGTTAACAGTCGACATC 
Pubb_FOR_1 36 ATTCGAGCTCGGTACCACACCTTTTTCAACAGACCC 
ubb_del-sig_FOR 27 CAAGTTTTTATAAAAAACAGATATGGC 




GFP_FOR 38 CTACTGTAAATGCAATGCGTAAAGGAGAAGAACTTTTC        
GFP_REV 42 GTTTTTTATAAAAACTTGCATTTTGTATAGTTCATCCATGCC    
ss_REV 42 GTTCTTCTCCTTTACGCATTGCATTTACAGTAGATGGCAATG                       
ubb_FOR 38 GATGAACTATACAAAATGCAAGTTTTTATAAAAAACAG     
tetQ_FOR 21 GAATTATCTCCTTAACGTACG 
tetQ_REV 21 CGGTTCAAGATTACGAAGATA 
BF3878_FOR 20 ATACGCAAATCAACAGAACG 




Phi_RecET_REV3 36 GCTTTTAAGCTTTTTGCTAAATCTTCATTTATAACC 
PrpsF_FOR2 32 GCTTTTGGTACCCAACTTTGCAAAGATAGATG 
PrpsF_REV2 27 ACTCGTTTTAATTAAATAAATAAATTA 
finB_FOR 27 GGCATATGGAGATAATAGGCTACGCTC 









The plasmids used in this study are shown in Table 2.4. 
Table 2.4: List of plasmids 
 
Plasmid Description Source 
pLYL01 Shuttle vector, AmpR Mob+ ( TetR only in Bacteroides) Li et al., 1995 
pGFPmut3.1 Shuttle vector, AmpR gfpmut3.1 Clontech 
pKJ01 pLYL01 with ubb signal sequence deletion cassette in KpnI This study 
pKJ02 pLYL01 with ubb in KpnI This study 
pKJ03 pLYL01 with gfpmut3.1-ubb fusion cassette in KpnI This study 
pKJ04 pLYL01 with Prpsf, phirecE and phirecT in KpnI/HindIII This study 
 
2.6. Bacterial techniques 
2.6.1. B. fragilis growth curves 
A single colony was used to inoculate 5 ml BHI-S broth or DM, containing antibiotics if 
appropriate and incubated overnight at 37°C anaerobically. A 1:40 dilution was made into 
fresh pre-reduced BHI-S broth or DM without antibiotic selection and incubated 
anaerobically at 37°C. Optical density readings were taken at 30 or 60 min intervals for 
strains grown in BHI-S and DM, respectively. Before readings were recorded, samples were 
diluted in the appropriate medium to ensure the OD600 reading did not exceed 1. 
Measurements were multiplied by the dilution factor to obtain the optical density. 
Readings were taken until stationary phase was reached. All growth experiments were 
performed in triplicate. 
2.6.2. Preparation of chemically competent cells  
An overnight culture of E. coli was diluted 1:100 into 100 ml, pre-warmed LB and grown 
until an OD600 of 0.4 was reached. Cells were incubated on ice for 20 min prior to 
centrifugation at 6000 x g at 4°C for 10 min. The supernatant was discarded and cells were 
re-suspended in 10 ml ice-cold 100 mM CaCl2 and incubated on ice for 2 h. Cells were 
harvested by centrifugation as previously described and re-suspended in 2 ml ice-cold 100 




2.6.3. Transformation – chemically competent cells 
For transformation, 5 – 10 μl of DNA were added to 50 μl of competent cells and incubated 
on ice for 30 min. Cells were heat shocked at 42°C for 90 seconds followed by incubation on 
ice for 5 min. 500 μl pre-warmed LB was added and cells were incubated at 37°C for 2 h, 
with the exception of transformations for which the antibiotic used for selection was 
ampicillin. These reactions required no further incubation time. Cells were spread onto LB 
plates containing the antibiotic of selection and incubated overnight at 37°C. 
2.6.4. Transformation - Electroporation 
A 1:40 dilution of B. fragilis overnight culture was made into 10 ml BHI-S and grown to an 
OD600 of 0.4. Cells were harvested by centrifugation at 4000 x g for 15 min at 4ᵒC, then 
washed (5 x 15 min) in 10 ml pre-reduced ice cold dH2O by centrifugation as previously 
described. Cells were re-suspended in 100 µl of ice cold dH2O, 40µl of cells were placed into 
a pre-chilled electroporation cuvette (Bio-Rad Gene Pulser® Cuvette 0.1cm gap electrode, 
Bio-Rad, UK), to which 0.5-1.5 μl of DNA were added. Cells were electroporated in a Bio-
Rad MicroPulser™ with a voltage of 2 kV. 1 ml pre-reduced, pre-warmed BHI-S was added 
to cells followed by anaerobic incubation for 1-3 h, depending on the antibiotic used for 
selection and 100 μl of cells were spread-plated onto BHI-S plates containing the 
appropriate antibiotics and incubated anaerobically (Patrick et al., 2009). 
2.6.5. Conjugation of E. coli S-17 with B. fragilis 
Overnight cultures of E. coli and B. fragilis were grown with the appropriate antibiotic in LB 
and BHI-S, respectively. A 1:100 dilution of E. coli was made into LB and a 1:40 dilution of B. 
fragilis was made into BHI-S without antibiotic selection. Both strains were grown to an 
OD600 of 0.6 and mixed donor to recipient in a ratio of 1:10. 200 μl were pipetted onto a 
BHI-S plate and incubated aerobically at 37°C for 2 h, followed by anaerobic incubation 
overnight. Cells were washed from the plate using 1 ml BHI-S and pelleted by centrifugation 
at 16000 x g for 5 min.  Pellets were re-suspended in 200 μl BHI-S, 100 μl aliquots were 






2.7. DNA techniques 
2.7.1. Genomic DNA extraction 
Genomic DNA was extracted from 1 ml of overnight culture using the Wizard Genomic DNA 
Purification Kit (Promega, UK) according to manufacturer’s instructions. Pellets were re-
suspended in 100 μl nuclease free water, overnight at 4°C and DNA was stored at -20°C. 
2.7.2. Plasmid DNA purification 
Plasmid DNA was extracted using the QIAprep Spin Mini prep Kit or the QIAfilter Plasmid 
Midi Kit (Qiagen, UK), according to manufacturer’s instructions. Using the Mini prep kit, 1ml 
of overnight culture was used and DNA was eluted with 30-50 μl of elution buffer (10 mM 
Tris-Cl, pH 8.5). If the Midi kit was used, 50 ml of overnight culture was used and DNA was 
eluted with 500 μl of elution buffer (10 mM Tris-Cl, pH 8.5), overnight at 4°C. DNA was 
stored at -20°C. 
2.7.3. Polymerase chain reaction (PCR) 
Oligonucleotides were synthesised by Eurofins MWG Operon (Germany) and the sequences 
are shown (Table 2.4). PCR reactions were performed in a Techne Progene Thermal Cycler 
(Bibby Scientific Limited, UK) or an Eppendorf Mastercycler gradient cycler. A standard 50 
μl reaction contained 1 μl forward primer (10 pmol/μl), 1 μl reverse primer (10 pmol/μl), 1 
μl dNTP’s (10mM), 10 μl 5x reaction buffer, 0.5 μl Phusion polymerase (NEB, UK), 1 μl ~0.1 
ng/μl template DNA and 35.5 μl dH2O. Unless otherwise stated, the thermal program was 1 
cycle at 98°C for 1 min, 30 cycles at 98°C for 10 seconds, x°C for 20 seconds, 72°C for 30 
seconds per kb, followed by a final extension of 72°C for 10 min, where x represents the 
annealing temperature of each primer pair. 
2.7.4. Agarose gel electrophoresis 
Agarose gel electrophoresis of DNA fragments was carried out in 1% (w/v) agarose gels 
(Invitrogen, USA), with 1x Tris-acetate EDTA buffer (TAE). 1 x DNA loading buffer (New 
England Biolabs, UK) was added to DNA samples before loading onto the gel alongside 
molecular weight markers, 100 bp or 1 kb DNA ladder (New England Biolabs, UK). 
Electrophoresis was carried out at 80V for 60 min. Gels were stained in 1 μg/ml ethidium 
bromide for 10 min and de-stained in dH2O for 10 min. Gels were visualised using a UVP 
VisiDoc-It Imaging system (UVP LLC, USA). 
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1xTAE buffer: 40 mM Tris, 1 mM EDTA pH8, 19 mM Glacial acetic acid 
 
2.7.5. DNA purification 
PCR products were purified using the Wizard SV Gel and PCR Clean-up System (Promega, 
UK) following manufacturer’s instructions and stored at -20°C. 
2.7.6. DNA quantification  
DNA concentration (ng/μl) was determined using a nanodrop ND-1000 spectrophotometer 
(Thermo Scientific, USA) by measuring the absorbance of the sample at a wavelength of 260 
nm or by a Qubit® 2.0 Fluorometer (Invitrogen, USA) according to manufacturer’s 
instructions. 
 
2.7.7. Gel Extraction 
Gel extraction was performed using the QIAquick gel extraction kit (Qiagen, UK) following 
manufacturer’s instructions. 
2.7.8. Restriction endonuclease digestion 
DNA was digested with restriction enzymes and their appropriate buffer as outlined in the 
manufacturer’s instructions (New England Biolabs, UK). A standard 20 μl digestion 
contained: 1 μl restriction enzyme, 2 μl 10x reaction buffer, 5 μl DNA and 12 μl dH2O. BSA 
was added where appropriate at a final concentration of 100 µg/ml. Digestions were 
incubated for 1 h at 37°C unless otherwise stated.  
2.7.9. Dephosphorylation of DNA 
Following restriction endonuclease digestion, DNA was dephosphorylated to prevent re-
ligation. To the 20 μl digestion reaction, 1 μl of Antarctic Phosphatase (NEB, UK) and 5 μl 
Antarctic Phosphatase 1x buffer were added and the sample incubated at 37°C for 15 min. 
The enzyme was heat inactivated by incubation at 65°C for 5 min and enzymes and buffers 





2.7.10. Ligation of DNA 
A standard DNA ligation was carried out in a 10 μl reaction volume containing, 1 μl 10x 
reaction buffer, 0.5 μl T4 DNA ligase (Promega, UK), Varying ratios of insert to vector were 
used (1:1, 1:2, 1:3, 2:1, 2:2 and 2:3) and dH2O. Reactions were incubated at 16°C for 2 h or 
overnight. 
2.7.11. Plasmid construction using In-fusion HD Cloning kit 
Plasmids were constructed using the In-Fusion HD Cloning kit (Clontech), in which PCR- 
generated DNA fragments were fused to linearised plasmid DNA by homologous 
recombination. In all In-Fusion reactions, PCR amplicons were inserted into the KpnI site of 
plasmid pLYL01. Oligonucleotides were designed to generate PCR products with 15 bp of 
homology to the KpnI site of pLYL01 and the plasmid backbone. DNA insert components 
were fused and amplified via crossover PCR before addition to the In-fusion cloning 
reaction.  
Plasmid DNA was digested in a 50 μl reaction containing: 2.5 μl restriction enzyme, 6 μl 10x 
reaction buffer, 30 μl DNA and 11.5 μl dH2O. Digests were incubated at 37°C, overnight. 
Plasmid DNA and PCR products were purified using the Wizard SV PCR Clean-up System 
(Promega, UK) following manufacturer’s instructions and stored at -20°C. 
PCR amplicons and linearised plasmid were fused in the In-Fusion cloning reaction. A 
standard 10 μl reaction contained: 2 μl 5X In-Fusion HD Enzyme Premix, 100 ng linearised 
vector, 100 ng insert DNA and x μl dH2O, where x was the volume of dH2O required to 
adjust the total reaction volume to 10 μl. Reactions were incubated at 50°C for 15 min, then 
placed on ice. 
Chemically competent E. coli S-17 cells (see section 2.6.2) were transformed using 2.5 μl of 
cloning reaction (see section 2.6.3). Cells were spread onto LB plates containing ampicillin 
and incubated aerobically overnight. 
2.7.12. Whole genome sequencing  
2.7.12.1. Sample preparation 
B. fragilis genomic DNA was isolated (see section 2.7.1) and the DNA pellet was rehydrated 
in 100 μl nuclease free water for 30 min at 65°C. RNA was removed by the addition of 2 μl 
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Riboshredder (Illumina, USA) for 2 h at 37°C. DNA was cleaned and purified using the 
Genomic DNA Clean and Concentrator kit (Zymo Research, USA), according to 
manufacturer’s instructions. DNA was quantified using the Qubit (see section 2.7.7) and 
diluted in ddH2O to a concentration of 0.2ng/μl.  
2.7.12.2. Library preparation 
DNA sequencing libraries were prepared using the NextERA Tagmentation Illumina 
sequencing library kit (Illumina, USA), according to manufacturer’s instructions. Illumina 
sequencing barcodes were added to each sample using PCR, 5 μl of barcode primer 1 and 5 
μl of barcode primer 2 were added to the Tagmentation product. The thermal program was 
1 cycle at 72°C for 3 min, 1 cycle at 95°C for 30 seconds, 12 cycles of 95°C for 10 seconds, 
55°C for 30 seconds, 72°C for 30 seconds followed by a final extension of 72°C for 5 min. 
Illumina Miseq whole genome sequencing was carried out by GenePool Sequencing Service 
(Edinburgh, UK).  
2.8. Protein techniques 
2.8.1. Solutions 
Tris-glycine SDS-PAGE 
4x Resolving Buffer: 1.5 M Tris-HCl, pH 8.8  
4x Stacking Buffer: 0.5 M Tris-HCl, pH 6.8 
10 x Running Buffer: 0.25 M Tris base, 1.9 M glycine 
1x Running Buffer: 1/10 dilution of 10 x Running buffer with 0.1% SDS 
5% Stacking gel: 1.5 ml 30% bis-acrylamide, 2.25 ml 4x stacking buffer, 5 ml dH2O, 90 µl 
10% SDS, 100 µl ammonium persulphate (APS), 8 µl Tetramethylethylenediamine (TEMED). 
12% Resolving gel: 4.8 ml 30% bis-acrylamide, 3 ml 4x resolving buffer, 4 ml dH2O, 120 µl 
10% SDS, 100 µl APS, 8 µl TEMED. 
Tris-tricine SDS-PAGE 
Gel Buffer: 3 M Tris-Cl, 0.3% SDS, pH 8.45 
1x running buffer: 0.1 M Tris, 0.1 M Tricine, 0.1% SDS 




Resolving gel: 4.9 ml 30% bis-acrylamide, 5 ml gel buffer, 3.5 ml dH2O, 1.6 ml glycerol, 100 
µl APS, 8 µl TEMED. 
 
1x Transfer buffer: 25 mM Tris, 192 mM Glycine 
PBS Tween (PBS-T): PBS containing 0.05% (w/v) Tween 20  
Coomassie Stain: 45% (v/v) dH2O, 45% (v/v) Methanol, 10% (v/v) Glacial acetic acid, 0.125% 
(w/v) Coomassie brilliant blue 
Coomassie de-stain: 45% (v/v) dH2O, 45% (v/v) Methanol, 10% (v/v) Glacial acetic acid 
 
2.8.2. Preparation of whole cell protein extracts 
B. fragilis strains were grown overnight in glucose defined medium. Cells were pelleted by 
centrifugation at 16 000 x g for 5 min and re-suspended in 500 µl 3x SDS Sample Buffer 
(NEB). Samples were stored at -20ᵒC. 
2.8.3. Preparation of periplasmic protein extracts 
B. fragilis strains were grown overnight in glucose defined medium. Cells were pelleted by 
centrifugation at 16 000 x g for 2 min at 4ᵒC and the pellet was washed by centrifugation as 
above in 1 ml PBS. Pellets were re-suspended in 150 µl cold 20% sucrose/10 mM Tris-Cl (pH 
7.5) and vortexed before the addition of  5µl 0.5 M EDTA (pH 8). Samples were incubated 
on ice for 10 min and centrifuged at 16 000 x g for 5 min at 4ᵒC, pellets were re-suspended 
in 100 µl ice-cold water and incubated on ice for 10 min (Quan et al., 2013). The 
supernatant containing the periplasmic fraction was removed and stored at -20ᵒC. 
2.8.4. Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved by SDS-PAGE using Tris-glycine or Tris-tricine polyacrylamide gels, 
made following the recipes shown in 2.8.1. Resolving protein gels were prepared using a 
mini protean gel casting apparatus (Bio-Rad, UK) and sealed using 250 μl isopropanol 
(Sigma-Aldrich, UK). Stacking gels were prepared and added to the polymerised resolving 
gel and a comb was inserted. Once polymerised, the protein gel was assembled in a gel tank 
and covered with 1x running buffer. Protein samples were boiled in 1x Protein sample 
buffer (New England Biolabs, UK) for 10 min at 98°C before loading onto the gel. Where 
indicated, the reducing agent dithiothreitol (DTT) (New England Biolabs, UK) was added to 
protein samples prior to boiling at a final concentration of 50 mM. ColorPlus Prestained 
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Protein Marker (New England Biolabs, UK) was loaded alongside samples which had a 
molecular weight range of 7-175 kDa. Gels were electrophoresed at 180 V for 45 min, or 
until the dye front had just run off the bottom of the resolving gel. Gels were either 
Coomassie Blue stained (see section 2.7.1 for stain and de-stain buffers) or transferred to 
PVDF membrane (Amersham Hybond™, GE Healthcare, UK) for Western blot analysis (as 
described in section 2.8.5 below).  
2.8.5. Western blot analysis 
Following SDS-PAGE separation, proteins were transferred from the gel to PVDF membrane 
at 100 V, 350 mA for 60 min with a Mini-Trans blot cell (Bio-Rad, UK) in the presence of 
transfer buffer (see section 2.8.1). After transfer, the membrane was incubated in PBS 
containing 5% (w/v) powdered milk and 0.05% (w/v) Tween 20 (Sigma-Aldrich, UK). The 
membrane was then incubated for 1 h at room temperature with primary antibody at the 
dilutions stated in each chapter. The membrane was washed 3 times with PBS-T for 5 min 
per wash, and then incubated in the corresponding secondary antibody conjugated to 
horse radish peroxidase for 1 h at room temperature. Following secondary antibody 
incubation, membranes were again washed in PBS-T (3 x 5 min) followed by a 10 min wash.  
Finally, the membrane was incubated with the enhanced chemiluminescence (ECL Plus) 
system (Amersham, GE Healthcare, UK) for 5 min and exposed to autoradiographic film 
(Amersham Hyperfilm ECL, GE Healthcare, UK) for varying periods of time. Films were 
developed using a Konica SRX-101A X-ray film processor. 
2.8.6. Bradford assay 
Protein concentration was determined according to the Bradford method. Samples were 
made up to 50 μl in dH2O and 200 μl of Bradford dye reagent (Bio-Rad, UK) was added to 
each sample to give a 1:4 ratio of sample to reagent. Samples were incubated at room 
temperature for 5 min and the absorbance measured at 595 nm. Samples were analysed in 
triplicate and compared with a standard curve constructed using serial dilutions of bovine 
serum albumin (BSA). 
2.8.7. Immunofluorescence Microscopy 
Immunoblots were prepared as previously described (Patrick et al., 2003). B. fragilis strains 
were grown overnight in BHI-S broth or DM as previously described. Cultures were diluted 
in sterile PBS to an OD600 of 0.3, and 20 μl were pipetted onto the wells of an 8-well Teflon 
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coated slide (ICN). Slides were air dried at 37°C and fixed in 100% methanol (Sigma-Aldrich, 
UK) at -20°C for 20 min. The slides were allowed to air dry and 20 μl of primary antibody 
were applied to each well. Slides were then incubated in a humidified box at 37°C for 1 h. 
Slides were washed, first by the application of sterile PBS down the centre of the slide and 
secondly in a shaking PBS bath for 20 min. The area surrounding the wells was dried using 
filter paper and 20 μl secondary antibody (IgG anti-mouse/anti-rabbit fluorescein 
isothiocyanate conjugate (FITC), Sigma-Aldrich, UK) was applied. The slides were incubated 
in a humidified box and washed as before, and then mounted in glycerol-PBS antifade 
reagent (Invitrogen). A coverslip was applied and the edges of the slide were sealed by nail 
varnish. Slides were stored in foil at -20°C. 
2.9. Bacteroides fragilis OMV 
2.9.1. Preparation of B. fragilis concentrated supernatants 
Outer membrane vesicles were prepared based on a previously described method 
(Horstman & Kuehn, 2000) with modifications for B. fragilis.  B. fragilis strains were grown 
overnight in 100 ml DM. Cells were removed by centrifugation at 6000 x g for 30 min, 
followed by centrifugation of the supernatant at 6000 x g for 15 min. The supernatant was 
filtered through a 0.45 μm PVDF filter (Millipore) to remove any remaining bacterial cells. 
Supernatants were concentrated using a 70 ml Vivaspin centrifugal concentrator (Sartorius 
Stedim Biotech, Germany) with a MWCO (molecular weight cut-off) of 100 kDa, by 
centrifugation at 1000 x g for 3 h or until a final volume of approximately 1.5 ml was 
achieved. If necessary, OMV were concentrated further by ultracentrifugation (Sorvall OTD 
ultracentrifuge, TH-641 swinging bucket rotor) at 100 000 x g for 1 h at 4°C, pellets were 
then washed twice in PBS by ultracentrifugation as previously described and re-suspended 
in 500 μl PBS. Protein concentration was determined using Bradford assay (see 2.8.6) and 
samples were stored at -20°C. All concentrates were checked to ensure there were no 
viable cells. This was done by plating 10 μl of concentrate onto two BHI-S plates, one was 
incubated anaerobically and one aerobically.  
2.9.2. DNA analysis of OMV 
DNA was isolated from B. fragilis concentrated supernatants based on previously described 
methods (Yaron et al., 2000; Renelli et al., 2004; Rumbo et al., 2011). B. fragilis 
concentrated supernatants (100 µg/ml) were treated with RQ1 RNase-Free DNase 
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(Promega, UK), at a final concentration of 50 µg/ml. A standard reaction contained 200 µl 
concentrated supernatant, 10 µl RQ1 DNase, 25 µl RNase-Free 10 x reaction buffer and 15 
µl dH2O. Reactions were incubated at 37ᵒC for 2 h before the enzyme was inactivated by 
the addition of 10 µl DNase Stop Solution and incubation at 65ᵒC for 10 min. OMVs were 
pelleted by ultracentrifugation  at 60 000 x g for 1 h at 4ᵒC. Pellets were washed three times 
in 1 ml PBS, by ultracentrifugation as previously described. Following the final wash, the 
supernatant was collected and the pellet re-suspended in 100 µl PBS, overnight at 4ᵒC. DNA 
was extracted by Mini-prep (see section 2.7.2) and PCR was carried out (see section 2.7.3) 
using oligonucleotides specific for finB, ubb and BF4298 (Table 2.4). 
 
2.9.3. Transformation of E. coli XL1-Blue MRF’ and B. fragilis Δubb with B. fragilis 
OMV 
Transformations were carried out based on a previously described method (Rumbo et al., 
2011). For E. coli, an overnight culture of E. coli XL1-Blue MRF’ grown in LB tetracycline (10 
µg/ml) was diluted 1:100 into fresh LB without antibiotic selection. Cultures were grown to 
an OD600 of 0.4 and cells were pelleted by centrifugation at 16 000 x g for 10 min. Pellets 
were re-suspended in 500 µl LB. Transformation reactions containing 800 µl LB, 100 µl E. 
coli XL1-Blue MRF’ cell suspension, 100 µg/ml concentrated supernatant isolated from B. 
fragilis NCTC9343 containing pLYL01 and 50 µg/ml DNase were incubated at 37ᵒ C for 1 h 
without shaking. Reactions were then incubated for 2 h at 37ᵒC, shaken at 200 rpm. 10 ml 
LB was added and cultures were incubated at 37ᵒC overnight. Cells were pelleted by 
centrifugation at 6 000 x g for 15 min. Pellets were re-suspended in 500 µl LB and 5 x 100 µl 
aliquots were plated onto LB ampicillin (100 µg/ml) and tetracycline (10 µg/ml) and 
incubated at 37ᵒC overnight. For B. fragilis Δubb, the method was as above with the 
following modifications: B. fragilis cells were grown in BHI-S and following transformation, 
reactions were incubated anaerobically without agitation. Samples were plated onto BHI-S 
erythromycin (10 µg/ml) and tetracycline (10 µg/ml) and incubated anaerobically overnight. 
2.9.4. Transmission Electron Microscopy 
OMV samples were diluted to 10 µg/ml and 1 µg/ml in sterile PBS, negatively stained with 




2.10. Cell culture techniques 
2.10.1. Culture and passaging of cells 
Cell culture experiments were carried out with human epithelial colorectal adenocarcinoma 
cell line, Caco-2 (Sigma Aldrich, UK). Cells were cultured in Eagle’s minimum essential 
medium with Earle’s salts (EMEM, Sigma-Aldrich, UK) supplemented with 10% foetal bovine 
serum (FBS, Sigma-Aldrich, UK), 1% non-essential amino acids (Sigma-Aldrich, UK), 5 mM L-
glutamine (Sigma-Aldrich, UK and Pen-Strep (100 U/ml penicillin, 10 μg/ml streptomycin, 
Sigma-Aldrich, UK). The cells were recovered from liquid nitrogen stocks by thawing for 1 
min at 37ᵒC before the addition of 15 ml of pre-warmed medium and centrifugation at 1000 
x g for 5 min. Cells were re-suspended in fresh medium, diluted to an appropriate dilution 
and incubated in a humid incubator at 37ᵒC with 5% CO2. The cells were checked regularly 
by microscopic examination and when monolayers reached    0% confluence, they were 
passaged by washing 3 times with 10 ml pre-warmed PBS followed by addition of 5ml 
0.05% trypsin-EDTA (Sigma-Aldrich, UK) and incubation at 37ᵒC for 5 min. 5 ml warm EMEM 
was added to cells to inactivate the trypsin, and cells were scraped off and collected by 
centrifugation at 1000 x g for 5 min. The cells were re-suspended at an appropriate 
concentration in fresh EMEM and incubated at 37ᵒC with 5% CO2. Frozen stocks were 
prepared by freezing 5x105 cells/ml in EMEM supplemented with 20% FBS and 10% DMSO 
(Sigma-Aldrich, UK). Cells were incubated at -20ᵒC for 1 h, -80ᵒC overnight and finally stored 
in liquid nitrogen.  
2.10.2. Cell counts 
Cells were counted using The Countess™ automated cell counter (Invitrogen, USA) 
following manufacturer’s instructions. 
2.10.3. Mycoplasma detection 
The LookOut™ Mycoplasma PCR Detection Kit (Sigma-Aldrich) was used to detect 
Mycoplasma infections in the Caco-2 cell line when media appeared contaminated. Cells 
were cultured in the absence of Pen-Strep until 100% confluent and 100 µl of supernatant 
was removed. The supernatant was boiled for 5 min at 95ᵒC and PCRs were prepared and 
performed following manufacturer’s instructions. The products were visualised by agarose 




2.10.4. Incubation of B. fragilis concentrated supernatants with Caco-2 cells 
Caco-2 cells were seeded onto poly-L-lysine (Sigma-Aldrich) treated glass coverslips and 
grown until 90% confluent. Cells were incubated with 100 µg/ml B. fragilis concentrated 
supernatants containing OMV for 2 h. The cells were then washed three times in PBS, fixed 
in 4% paraformaldehyde and stained by incubation with 100 μl, 300mM DAPI (Invitrogen, 
USA) for 5 min. Cells were visualised using confocal microscopy. 
 
2.10.5. Confocal Microscopy 
Confocal fluorescent images were obtained using a Leica SP5 confocal microscope with a 
x63 objective. Images were analysed by ImageJ software. 
2.11. Bacteriophage techniques 
2.11.1. Isolation of Bacteriophages 
Bacteriophages were isolated from 20L of raw sewage that was coarse filtered and fine 
filtered, then concentrated by tangential flow filtration. Ten-fold serial dilutions of sewage 
were plated onto 0.7% BHI-S top agar containing 100 µl of stationary phase B. fragilis 
culture and plates were incubated anaerobically, overnight. Individual plaques were 
extracted using a sterile glass pipette and used to inoculate 10 ml BHI-S containing 100 µl B. 
fragilis cells, cultures were incubated anaerobically overnight. Cells were then removed by 
centrifugation at 6,000 x g for 10 min and supernatants were filter sterilised through a 0.45 
µm filter (Millipore) and stored at 4ᵒC. 
2.11.2. Plaque assay for phage titre 
Ten-fold serial dilutions of bacteriophage lysates were made in phage buffer and 10 µl 
aliquots were spotted onto 0.7% (w/v) agar BHI-S top agar containing 100 µl B. fragilis cells. 
Plates were incubated anaerobically overnight and plaques were counted for each dilution. 
Plaque forming units (PFU) were calculated as follows: 
 
PFU/ml = Number of plaques                      d = dilution 
                            d x V                                     V = volume added to the plate 
 
Phage buffer: 50mM Tris-HCl pH 7.5, 150mM NaCl, 10mM MgSO4, 2mM CaCl2 
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2.11.3. Transduction by bacteriophages 
Bacteriophage lysates (100 μl) were plated onto BHI-S top agars containing 100 μl B. fragilis 
NCTC9343 ΔupcY::ermF and incubated anaerobically, overnight. The top agar was washed 
with 2 ml bacteriophage buffer, and scraped into a glass universal. This was incubated at 
room temperature for 20 min before the addition of 500 μl of chloroform and incubation 
for a further 15 min.  Samples were centrifuged at 4000 x g for 20 min and the supernatant 
filter sterilized using a 0.45 μm filter (Millipore). Neat, 1:10 and 1:100 dilutions of sterilized 
supernatants were used to inoculate 100 μl NCTC 343 or 638R, these cultures were 
incubated at 37°C for 15 min, followed by the addition of 500 μl BHI-S and incubation 
anaerobically for 30 min. Cultures were spread onto BHI-S erythromycin (10 μg/ml) plates 
and incubated anaerobically overnight. 
2.11.4. Preparing bacteriophage DNA from lysates 
2.11.4.1. PEG precipitation 
Large bacteriophage lysates were prepared in 50 ml BHI-S by inoculating 100 µl 
bacteriophage and 500 µl B. fragilis overnight culture, followed by anaerobic incubation for 
16 h. Cells were removed by centrifugation at 6 000 x g for 20 min at 4ᵒC and supernatants 
were filter sterilized through a 0.45 µm filter (Millipore). The filtered lysate was transferred 
to a 100 ml graduated cylinder and 5x PEG solution was added to a final concentration of 
1x. Tubes were inverted to mix and incubated at 4ᵒC for 48 h. The lysate was centrifuged at 
3000 x g for 10 min at 4ᵒC, the supernatant discarded and the pelleted white precipitate 
was re-suspended in 100 µl of bacteriophage buffer. The amount of KCl (Sigma-Aldrich) 
required to make a 1M solution was determined and this was added to the precipitate in 
three aliquots of approximately equal size, vortexing after each addition. The samples were 
then incubated on ice for 30 min before centrifugation at 12 000 x g for 10 min at 4ᵒC to 
pellet the PEG. The supernatant, containing the bacteriophage was decanted and stored at 
4ᵒC. 
5x PEG Solution: 20% (w/v) PEG-8000 (Sigma-Aldrich), 2.5M NaCl (Sigma-Aldrich) 
2.11.4.2. Caesium Chloride gradients 
Caesium chloride (CsCl) step gradients were used to isolate the bacteriophage particles. 
CsCl solutions were prepared in dH2O, filter sterilized and stored at 4ᵒC. Three layers of CsCl 
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were added to a centrifuge tube as follows: first layer, 3 ml CsCl solution, d = 1.7 g/ml; 
second layer, 2 ml CsCl solution, d = 1.5 g/ml; third layer, 2 ml CsCl solution, d = 1.3 g/ml. 
Layers were added slowly using a syringe to avoid mixing. 2 ml of bacteriophage lysate 
isolated from the PEG precipitation in 2.11.4.1 was carefully layered on top of the gradient 
(Figure 2.1a). Gradients were ultracentrifuged at 104 000 x g for 2 h at 4ᵒC. Following 
centrifugation, a blue band was visible in the d = 1.5 g/ml layer containing bacteriophages, 
two further bands were sometimes visible, a second blue band in the d = 1.3 g/ml layer 
containing empty phage heads and a white band above the d = 1.3 g/ml layer containing 
cell debris (Figure 2.1b). The band containing the bacteriophages was extracted using a 10 
ml syringe with a 25-G needle and stored at 4ᵒC. 
2.11.4.3. Formamide DNA extraction 
The volume of the bacteriophage band isolated in 2.11.4.2 was weighed and a 0.1 vol of 2 
M Tris-Cl (pH 8.5)/0.2 M EDTA was added. Tubes were inverted to mix. An equal volume of 
formamide (Sigma-Aldrich) was added and the sample was incubated at room temperature 
for 30 min. Two volumes, each equal to the volume of the original phage band, of room 
temperature, 100% ethanol were added, the sample was vortexed and centrifuged at 13 
000 rpm (16, 100 x g) for 2 min. The pellet was rinsed in 70 % ethanol and re-suspended in 
100 µl 1x TE (pH 8) by incubation at 37ᵒC for 30 min. DNA concentration was measured by 





Figure 2.1: Caesium chloride gradient set-up for bacteriophage isolation 
(a) Representation of the CsCl gradient prior to centrifugation, a gradient consisting of 
three densities of CsCl was added to the centrifuge tube. The phage lysate isolated from the 
PEG precipitation was layered on top. (b) Following ultracentrifugation, a blue-ish band 
containg bacteriophage was visible within the 1.5g/ml layer. A second band containing 
empty phage heads was also visible within the 1.3g/ml layer.  
 
2.11. Bioinformatics 
2.11.1. Sequencing data, assembly and annotation 
The quality of the whole genome sequencing data was assessed using FastQC (Andrews) 
and contig assemblies were performed using CLC Genomics workbench v 6.4. When the 
FASTA files containing the sequencing reads were imported, the data were identified as 
Illumina, paired-end (reverse-forward) reads under the general options section. The 
minimum and maximum read distance was set at 100 and 250 bp, respectively.  Contigs 
were assembled using the De Novo assembly tool with the following parameters:  word 
size, 45; bubble size, 98; minimum contig length, 1000bp.  
Contigs were re-ordered against the genome of NCTC9343 using the progressive Mauve 
program of the Mauve Genome Alignment Software (Darling et al., 2004; Darling et al., 
2010). Re-ordering was carried out using default settings, with the exception of the seed 
weight which was set at 11. Genomes were annotated using xbase (Altschul et al., 1997; 




et al., 2008) with B. fragilis NCTC9343 selected as the reference genome, or using the Rapid 
Annotation using Subsystem Technology (RAST) server (Aziz et al., 2008). 
2.11.2. Genome comparisons 
Genomes were viewed using the Artemis genome browser (Rutherford et al., 2000) and 
genome comparisons were carried out with the Artemis Comparison Tool (ACT), WebACT 




















Chapter 3. Inter-strain Horizontal Gene Transfer 
3.1. Introduction 
The acquisition of genes from other strains and species through HGT is a main contributor 
to bacterial evolution. The products of genes gained through HGT can confer a selective 
advantage to the organism, such as the acquisition of virulence factors. HGT can also 
mediate the rapid dissemination of antibiotic resistance determinants throughout bacterial 
species, usually via the conjugative transfer of plasmids (see section 1.2.1). The acquisition 
of antibiotic resistance genes can have a profound impact on the ability to treat bacterial 
infections; many of the bacterial pathogens associated with epidemics of disease have 
evolved into multi-drug resistant (MDR) forms (Davies & Davies, 2010).  
HGT also influences inter-strain variation, demonstrated by the presence of accessory 
genomes which are highly variable between bacteria of the same species (See section 1.1). 
Genomic comparisons of the complete genome sequences of B. fragilis strains NCTC9343, 
638R and YCH46 originally isolated in the UK, USA and Japan, respectively, revealed that 
extensive horizontal gene transfer has occurred within these strains. Patrick et al (2010) 
demonstrated that each strain contained ten divergent polysaccharide biosynthesis loci, 
none of which were similar between NCTC9343 and 638R. YCH46 had one common locus 
with 638R and one with NCTC9343, therefore a total of twenty eight divergent 
polysaccharide biosynthesis loci were identified amongst three strains. The authors also 
observed the presence of other horizontally acquired elements within the three genomes, 
such as prophages and conjugative transposons. To further examine the variation in B. 
fragilis, the genomes of seven B. fragilis clinical isolates were sequenced using the Illumina 
MiSeq sequencing platform and comparisons of four of these genomes, BE1, GNAB92, RD48 
and LS66 were made with B. fragilis strains NCTC9343, 638R and YCH46.  
3.2. Results 
3.2.1. Multi-drug resistant B. fragilis isolate, WAL610 
B. fragilis is the most frequently isolated Gram-negative pathogen from anaerobic infection 
and can cause severe intra-abdominal infections, postoperative wound infections, skin and 
soft-tissue infections and bacteraemia (see section 1.5). Metronidazole is the most effective 
antibiotic for the treatment of B. fragilis infections, however, there have been reports of 
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MDR strains. The emergence of metronidazole resistance in B. fragilis is a worrying 
development as these strains can prove difficult to treat and could result in increased 
mortality (Wareham et al., 2005). A MDR strain of B. fragilis, WAL610, was isolated from 
the leg wounds of an American soldier who sustained multiple injuries in an improvised 
explosive device blast in Afghanistan. The otherwise healthy male soldier sustained open 
fibula and tibia fractures to both legs in the explosion and the wounds were exposed to 
water contaminated with raw sewage. The wounds became infected and despite treatment 
with broad-spectrum antibiotics, wound irrigation and the removal of infected tissue, 
repeated wound cultures tested positive for B. fragilis. Upon returning to the USA, 
intravenous metronidazole was added to the antibiotic therapy, but despite this 
intervention the patient required amputation of his right leg below the knee. Subsequent 
antibiotic susceptibility testing revealed that the B. fragilis strain was resistant to penicillin, 
clindamycin, metronidazole, cefoxitin, meropenem, imipenem, piperacillin/tazobactam, 
and tigecycline (Sherwood et al., 2011).  We were contacted by Hannah Wexler from the 
West Los Angeles Veterans Medical Centre and asked to determine if resident plasmids 
were involved in this strain’s resistance to metronidazole.  
Plasmid DNA was extracted and purified from a 50ml overnight culture of B. fragilis 
WAL610, grown in BHI-S (see section 2.7.2). Two plasmids of 5.5 kb and 8.3kb were 
identified and subsequently sequenced using the Roche 454 platform. The 5.5kb plasmid 
was identical in sequence to pHAG1, isolated from a multidrug resistant strain of B. fragilis 
in the UK (Pumbwe et al., 2007), and to pBFB35, frequently isolated from B. fragilis clinical 
isolates in Hungary (Sóki et al., 2010).  The second plasmid, pWAL610 was annotated by the 
Rapid Annotation using Subsystems Technology (RAST) server (Aziz et al., 2008) and 
analysed using BLAST and Artemis. A circular plasmid map was generated using DNAplotter 
(Carver et al., 2009) (Figure 3.1). pWAL610 contained the nitromidazole resistance gene, 
nimE, which shared 100% DNA sequence identity to the nimE gene of B. fragilis plasmid 
pBF388c, from a metronidazole resistant strain of B. fragilis isolated in Kuwait (Sóki et al., 
2004). A transposase containing a putative insertion sequence was also identified, with 99% 
identity to transposase Bf6 of pBF388c. Whole genome sequencing of B. fragilis WAL610 is 





Figure 3.1: Artemis DNA plotter image of pWAL610 
 
8.3kb pWAL610 isolated and sequenced from B. fragilis WAL610.  Circular tracks from 
outside to inside: 1, DNA co-ordinates; 2, forward strand coding sequenced; 3, reverse 
strand coding sequences.  The nitromidazole resistance gene, nimE was identified, labelled 
and shown in purple, along with a transposase containing a putative insertion sequence, 
represented in pink. 
 
3.2.2. Illumina MiSeq sequencing 
The genomes of seven B. fragilis clinical isolates, BE1, RD48, GNAB92, LS66, MPRL3499VI, 
MPRL3535V and MPRL3536X were sequenced using the Illumina MiSeq platform to further 
investigate inter-strain variation present in B. fragilis. These strains were isolated from 
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patients in Edinburgh, Amsterdam and Belfast (Table 4.). Sample preparation and genome 
sequencing was carried out as described in 2.7.12.1. Bacterial chromosomal DNA was 
isolated from overnight cultures, grown in BHI-S, and any RNA was removed using 
Riboshredder. The RNase-treated DNA was purified, concentrated. A sequencing library was 
then generated using a different barcoded adaptor for each isolate. Samples were pooled 
and sequenced using the Illumina MiSeq platform, which generated 250 bp paired-end 
reads for all samples, with the exception of GNAB92, which generated 150 bp paired-end 
reads.  
3.2.2. Assembly and Annotation 
The raw data were filtered to remove barcoded adaptors and the quality of the data was 
assessed using FastQC (Andrews). The basic statistics are summarised in Table 3.1. All seven 
genomes had a GC content between 42-45%, consistent with the three previously 
sequenced strains, which have an average GC content of 43%. The estimated coverage of 
the genomes ranged from 33-fold (MPRL 3536X) to 389-fold (MPRL 3535V). 
Contig assemblies were performed on CLC Genomics Workbench v 6.4 using default 
parameters for De Novo Assembly. A minimum contig length was set at 1000 bp to 
eliminate smaller contigs, which are difficult to map. The assembly quality data are shown 
in Table 3.2. The quality of the genomes was assessed using the N50 value, the number of 
contigs, the average contig length and the overall size of the genome. N50 is a statistical 
measure of the data, in which 50% of the entire assembly is contained in contigs equal to or 
larger than this value. For example, 50% of the reads of GNAB92 were contained in contigs 
of 102122 bp or larger. A large number of contigs and a small average contig size indicate a 
poor genome assembly as it is difficult to align a high number of small fragments. The 
overall size of the genome should be similar to that of previously sequenced strains; a 
difference in size indicates there may not be complete coverage of the genome.  Based on 
these data, it was decided that three genomes, MPRL 3536X, MPRL 3499VI and MPRL 
3535V had not assembled well enough to be analysed further. The three genomes had N50 








Table 3.1: FastQC summary statistics of genomes 







GNAB92 2276671 21-150 44 65x 
BE1 898420 148-251 43 87x 
RD48 1373685 169-251 43 134x 
LS66 1094161 158-251 45 214x 
MPRL 3499VI 474823 154-251 45 49x 
MPRL 3536X 333633 155-251 44 33x 
MPRL 3535V 1335241 155-251 42 389x 
 
The contigs of the remaining four strains, GNAB92, BE1, RD48 and LS66 were aligned 
against NCTC9343 using Mauve Genome Alignment Software (Darling et al., 2004; Darling 
et al., 2010). Genomes were then annotated using xBASE (Altschul et al., 1997; Lowe & 
Eddy, 1997; Kurtz et al., 2004; Delcher et al., 2007; Lagesen et al., 2007; Chaudhuri et al., 
2008). Genomes were viewed using the Artemis genome browser (Rutherford et al., 2000), 
and comparisons were carried out with the Artemis Comparison Tool (ACT) and the online 
version, WebACT (Carver et al., 2005).  
3.2.3. Analysis of the polysaccharide biosynthesis loci 
B. fragilis NCTC9343, 638R and YCH46 each contain ten annotated regions (PSA-J) which 
have been implicated in polysaccharide production. Genetic comparisons of these loci 
revealed a high level of diversity, across the three strains, with twenty-eight different 
polysaccharide biosynthesis loci being identified (Patrick et al., 2010). Eight of the ten loci, 
A-H, were implicated in the expression of polysaccharides which form the within-strain 
variable MC. Seven of these loci are switched on and off by the site-specific inversion of 
promoter sequences, which is catalysed by the invertase, finA (Patrick et al., 2003). finA was 
identified in GNAB92 (CDS 2980), BE1 (CDS 2671), RD48 (CDS 2882) and LS66 (CDS 2768), 
each gene had 99-100% DNA sequence identity to NCTC9343, YCH46 and 638R. This 
suggested that some of the polysaccharide biosynthesis loci of BE1, RD48, GNAB92 and 









Table3.2:  Genome assembly data 
  Strains 
Feature GNAB92 BE1 RD48 LS66 MPRL 3499VI MPRL 3536X MPRL 3535V 
N75 56 843 45 651 53 326 27 602 5120 11 783 13 227 
N50 102 122 79 420 85 038 49 700 9834 22 618 24 418 
N25 183 866 144 275 143 311 84 597 17 416 38 914 39 212 
Min. contig length 1048 1070 1085 1051 1006 1006 1009 
Max. contig length 439 311 245 186 223 301 224 573 42 524  87098 94 041 
Average contig length 49 281 43 032 50 689 25 630 6183 11954 10 224 
Number of contigs 108 120 102 203 800 417 478 








944 4 946 621 4 985 020 4 022 826 
 
Transcription antitermination factors 
Although divergent, the polysaccharide biosynthesis loci A-H of NCTC9343, YCH46 and 
638R, share at least one common genetic feature. The first two genes in each of the loci 
encode UpxY and UpxZ proteins, where x represents the polysaccharide locus the proteins 
are associated with (UpaY to UphY and UpaZ to UphZ). These genes are required for 
polysaccharide synthesis because the encoded proteins act as transcription antitermination 
factors, preventing the premature termination of transcription of the associated 
polysaccharide operon (Chatzidaki-Livanis et al., 2009).  
Eight potential polysaccharide biosynthesis loci were identified in GNAB92, BE1, RD48 and 
LS66, all of which contained genes which encoded transcription antitermination proteins, 
with the exception of RD48 which did not encode homologues of upbY and upbZ.  The DNA 
sequences of the upxY and upxZ genes identified in these strains were aligned to those of 
the reference genomes using ClustalW (Larkin et al., 2007). The DNA sequence identity of 
the genes was 92-100%, the lowest being the upcZ gene of LS66 which had 92% identity to 
the upcZ genes of the other strains.  
Polysaccharides I and J 
The PSI locus in NCTC9343 has yet to be associated with a capsular type, however it has 
been identified in all three reference genomes, with 638R and YCH46 sharing the same 12 
genes in this region. NCTC9343 encodes a different set of genes suggesting the production 
of a different polysaccharide (Patrick et al., 2010). PSI appears to lack an invertible 
promoter, but does contain a transcription antitermination gene, upiY. PSJ in NCTC9343 
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contains the only homologue of the O-antigen chain length determinant protein, Wzz, 
identified in the genome of NCTC9343 (CDS 1708). Deletion of this gene resulted in the 
absence of HMMPS, which form the MC (Patrick et al., 2009). This locus is shared by YCH46 
and 638R. The composition of these loci were determined in the four new genomes. 
Alignment with the reference genomes 
Polysaccharide biosynthesis loci A - J of each of the four new genomes were compared to 
those of NCTC9343, 638R and YCH46 in a five-way ACT comparison, apart from LS66, which 
was compared to 638R and YCH46 only. The comparisons were performed to identify any 
divergent loci present in the sequenced strains. As the transcriptional regulators are highly 
conserved, the loci were aligned using these genes as a fixed point. The locations of each of 
these loci are shown in Table 3.3. 
Table 3.3: Polysaccharide associated biosynthesis loci in B. fragilis BE1, GNAB92, RD48 
and LS66. 
Locus CDSs * Capsule Association 
  BE1 GNAB92 RD48 LS66 3   
 A 1350 - 1366 1396 - 1401 1418 - 1428 1367 - 1368 MC 
 B 1739 - 1757 1922 - 1938   1951 - 1957 2 1832 - 1854 MC 
 C 1045 - 1052 1078 - 1099 1075 - 1092 1062 - 1086 MC 
 D 3752 - 3777   4006 - 4007 1 3855 - 3871 3742 - 3748 MC 
 E 2475 - 2489 2780 - 2796 2678 - 2697 2567 - 2577 MC 
 F 1448 - 1472 1551 - 1595 1597 - 1614 1521 - 1529 MC 
 G 0756 - 0777 0767 - 0796 0788 - 0811 0733 - 0746 MC 
 H 3417 - 3434 3681 - 3690 3609 - 3624 3486 - 3498 MC 
 I 2681 - 2708 2990 - 3019 2892 - 2920 2777 - 2803 Unknown 
 J 1613 - 1617 1738 - 1742 1757 - 1761 1672 - 1676 MC 
LC assembly 2673 - 2675 2982 - 2984 2884 - 2886 2770 - 2772 LC 
  
*Coding sequences 
 1 location of updY and updZ 
 2 apparent deletion, CDSs of remaining genes 








3.2.3.1 Strain RD48 
Genomic comparisons of RD48 with YCH46, 638R and NCTC9343 revealed that the strain 
shared (97-100% DNA sequence identity) nine of the polysaccharide biosynthesis loci with 
NCTC9343 (Figure 3.2). Eight of the nine common loci contained genes encoding a Wzx and 
Wzy homologue. These proteins shared 99-100% amino acid sequence identity to the Wzx 
and Wzy homologues encoded by the corresponding NCTC9343 locus. The PSB locus of 
RD48 appeared to contain a deletion of ~ 16.5 kb which included the transcriptional 
regulators upbY and upbZ, wzx, wzy and a number of glycosyltransferase genes (Figure 3.2 
PS-B). The transcription antitermination factors have been shown to be essential for 
polysaccharide production (Chatzidaki-Livanis et al., 2009). Therefore the absence of upbY 
and upbZ should render RD48 unable to express PSB. The ability of RD48 to express PSB was 
determined using IFM, with the PSB-specific monoclonal antibody, QUBf25 (see section 
2.8.7). Δwzz cells, which do not produce MC polysaccharides, were used as a negative 
control and NCTC9343 cells which have been shown to cross-react with QUBf25 (Patrick et 
al., 2009), as a positive control. 
Fluorescence was detected in a subset of RD48 cells (Figure 3.3), demonstrating that PSB 
was expressed by this strain and indicating that polysaccharide produced from this locus 
shares epitopes with PSB from NCTC9343. This suggested the deletion observed in the 
genome is likely to be an assembly associated error. MC expression is driven by invertible 
promoters, meaning that in a population there will be cells which have promoters on or off 
for multiple polysaccharide loci. This explains why only a subset of NCTC9343 cells cross-
reacted with the PSB-specific monoclonal antibody. As expected, no fluorescence was 














Figure 3.2: Comparison of RD48 polysaccharide biosynthesis loci 
Five-way ACT genome comparison of the polysaccharide biosynthesis loci of RD48 with B. 
fragilis strains NCTC9343, 638R and YCH36. Each polysaccharide is labelled and strain 
names are shown to the left of the ACT comparison.  The presence of red colour between 
sequences indicates sequence identity, no colour indicates divergent sequences and dark 
blue indicates a DNA inversion. Sequence identity was evident between RD48 and 







Figure 3.3: RD48-Immunofluorescence Microscopy with  PSB-specific antibody 
IFM using PSB-specific monoclonal antibody QUBf25 to probe cells isolated from B. fragilis 
strains NCTC 343, RD48 and Δwzz. Fluorescence was detected in a subset of NCTC9343 and 
RD48 cells, indicating PSB production. No fluorescence was detected in Δwzz cells, which do 







3.2.3.2. Strain GNAB92 
Genomic comparison of GNAB92 with NCTC9343, 638R and YCH46 (Figure 3.4) showed that 
the strain contained eight complete polysaccharide biosynthesis loci, however, there 
appeared to be a deletion in both PSA and PSD (Figure 3.3a and d). The PSA locus contained 
five of the genes found in the corresponding locus of NCTC9343 and YCH46; the 
transcription antitermination genes upaY and upaZ, along with the final three genes of the 
operon encoding two glycosyltransferases and an aminotransferase were present. The 
genes encoding Wzx and Wzy were absent, suggesting this strain is unable to produce PSA. 
However, it was observed that PSC, which had some identity to both YCH46 and 638R, 
contained eleven extra genes, two of which encoded a second predicted Wzx and Wzy. 
These genes had homology to the YCH46 PSA locus (Figure 3.5), suggesting that instead of a 
deletion in PSA, there was an error during assembly of the genome and that this locus was 
actually present. 
The PSD locus contained only updY, updZ and the final gene of the 18 gene operon, 
suggesting GNAB92 might be unable to express PSD. PSE encoded 17 genes, 8 of which had 
identity to the PSE locus of 638R. The predicted homologues of wzx and wzy however, were 
divergent therefore this locus was classified as different. 
In comparison to the three reference genomes, GNAB92 contained five divergent 
polysaccharide biosynthesis loci, PSB, PSE, PSG, PSH and PSI. GNAB92 PSA might have been 
a misassembly and therefore represent a common locus with YCH46. PSC was common 
with 638R and YCH46, PSF was similar with 638R and PSJ was conserved in all four strains 
(between 99-100% DNA sequence identities). A potential Wzx flippase and Wzy polymerase 








Figure 3.4: Comparison of GNAB92 polysaccharide biosynthesis loci  
Five-way ACT genome comparison of the polysaccharide biosynthesis loci of GNAB92 with 
B. fragilis strains NCTC9343, 638R and YCH36. Each polysaccharide is labelled and strain 
names are shown to the left of the ACT comparison. Sequence identity was evident 
between GNAB92 and 638R at locus PSF. There is sequence identity between all four strains 




Figure 3.5: ACT comparison of GNAB92 PSC and YCH46 PSA 
Two-way ACT comparison of eleven genes identified in GNAB92 PSC, which had homology 
to YCH46 PSA, including genes encoding Wzx (Similar to Bacteroides fragilis YCH46 
oligosaccharide repeat unit transporter, E-value = 0.0, 95% identity in 418aa) and Wzy 
(Similar to Bacteroides fragilis YCH46 LPS related polymerase, E-value = 0.0 99% identity in 
315aa), suggesting a misassembly in the GNAB92. 
 
3.2.3.3. Strain BE1 
An ACT comparison of BE1 with the three reference genomes indicated that the strain 
contained ten polysaccharide biosynthesis loci. In comparison to the reference genomes, 
five of these, PSA, PSB, PSD, PSE and PSG were divergent (Figure 3.6). A sixth locus, PSH 
contained 99% DNA sequence identity to 638R in eleven of the eighteen genes present in 
the operon. Due to the number of similar genes, this locus was classified as common with 
638R. There was, however, no homology between the wzx and wzy genes. 
BE1 PSF and PSI were common with YCH46 and NCTC9343 respectively, PSJ was similar to 
all three reference genomes. BE1 PSC had some homology to 638R and YCH46, 99% DNA 
sequence identity to both strains in the first seven genes of the locus, however, it appeared 
to contain a deletion in the second half of the locus. The remaining genes of the operon 
were located elsewhere in the BE1 genome, suggesting a misassembly rather than a 
deletion of this locus. This indicated that BE1 PSC was a common locus with both YCH46 
and 638R. A potential Wzx flippase was encoded in all loci, a potential Wzy polymerase was 










Figure 3.6: Comparison of BE1 polysaccharide biosynthesis loci  
Five-way ACT genome comparison of the polysaccharide biosynthesis loci of BE1 with B. 
fragilis strains NCTC9343, 638R and YCH36. Each polysaccharide is labelled and strain 
names are shown to the left of the ACT comparison.  The presence of red colour between 
sequences indicates sequence identity, no colour indicates divergent sequences and dark 
blue indicates a DNA inversion. Sequence identity was evident between BE1 and NCTC9343 
at locus PSI and with YCH46 at locus PSF. There is sequence identity between all four strains 
at locus PSJ. 
3.2.3.4. Strain LS66 
The alignment of LS66 with the reference genomes was more problematic than the other 
three strains. This was probably due to the assembly of the genome, which contained more 
contigs and had a smaller N50 value than the other genomes, which made it more difficult 
62 
 
for Mauve to rearrange them against the reference genome. Following alignment of the 
contigs against NCTC9343 a number of inverted contigs were observed; it is possible that 
some of these were aligned incorrectly.  It was particularly difficult to compare the genome 
of LS66 to NCTC9343 using the ACT comparison tool, therefore three-way comparisons 
were carried out with YCH46 and 638R (Figure 3.7). 
Five of the LS66 polysaccharide biosynthesis loci, PSA, PSD, PSE, PSF and PSH appeared to 
contain deletions. Based on the comparisons alone it could not be determined if these were 
true deletions or a result of improper genome assembly.   
3.2.3.5. Large capsule assembly 
Three genes encoding proteins have been implicated in the assembly of the within-strain 
variable LC of B. fragilis: a glycosyltransferase WbaP homologue, a polysaccharide 
export/assembly Wza homologue and a polysaccharide co-polymerase Wzc homologue 
(Patrick et al., 2010). The genes encoding these proteins were conserved in RD48, BE1, 









Figure 3.7: Comparison of LS66 polysaccharide biosynthesis loci  
Three-way ACT genome comparison of the polysaccharide biosynthesis loci of LS66 with B. 
fragilis strains 638R and YCH36. Each polysaccharide is labelled and strain names are shown 
to the left of the ACT comparison.  The presence of red colour between sequences indicates 
sequence identity, no colour indicates divergent sequences and dark blue indicates a DNA 
inversion. There was some sequence identity between the three strains at PSB. Sequence 





Figure 3.8: Comparison of the LC assembly genes  
Five-way ACT comparison of the large capsule assembly loci of GNAB92, BE1 and RD48 with 
B. fragilis NCTC9343, 638R and YCH46. Three-way comparison of LS66 with 638R and 
YCH46. All seven genomes share homology within the locus. 
3.2.3.6. Identifying Wzx and Wzy homologues 
The sixteen polysaccharide biosynthesis loci which are implicated in  MC formation in 
NCTC9343 and 638R were characterised by the presence of O-antigen flippase encoding 
genes (wzx) and polysaccharide polymerase encoding genes (wzy), which indicate that 
export of B. fragilis polysaccharides is by a Wzy-dependent pathway (Whitfield, 2006a; 
Patrick et al., 2010).  Although Wzx and Wzy proteins are found in a wide range of bacteria, 
there is very little conservation of amino acid sequences. Wzx proteins are predicted to 
contain 10-14 transmembrane helices and a loosely conserved polysaccharide biosynthesis 
protein domain (Polysacc_synt domain Protein families database of alignments and HMMs) 
(Marolda et al., 2004; Islam & Lam, 2013). Wzy proteins are predicted to contain 8-12 
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transmembrane helices and some contain the O-antigen polymerase conserved domain 
Wzy_C (Daniels et al., 1998; Samuel & Reeves, 2003).  
For the fifteen potentially new polysaccharide biosynthesis loci, all genes encoding proteins 
without an annotated function were examined to identify potential Wzx and Wzy 
homologues.  Amino acid sequence comparisons were carried out using the Basic Local 
Alignment Search Tool (BLAST). Conserved domains was identified using the Pfam protein 
families database, and transmembrane helices were predicted using the TMHMM 
(Transmembrane Hidden Markov Model) v 2.0 Server (Sonnhammer et al., 1998; Krogh et 
al., 2001). These results are summarised in Table 3.4. The Wzx and Wzy proteins of RD48 
were not included as all polysaccharide biosynthesis loci present in this strain were 
homologous to NCTC9343. 
Genes encoding potential Wzx flippases were identified in all loci present in BE1, and 
potential Wzy polymerases were identified in all loci with the exception of PSD and PSE. All 
of the putative Wzx proteins were predicted to contain 10-14 transmembrane helices, with 
seven of the nine proteins containing homology to the Polysacc_synt family. Six of these 
proteins, located in PSA, PSB, PSC, PSF, PSG and PSI had 32-100% amino acid identity to 
previously identified B. fragilis flippases. The seven potential Wzy proteins of BE1 were 
predicted to contain 8-14 transmembrane helices. This is consistent with published data in 
which identified Wzy proteins contain 8-14 transmembrane domains (Daniels et al., 1998). 
 All of the polysaccharide biosynthesis loci of GNAB92 encoded proteins with identity to 
Wzx flippases and Wzy polymerases. However, the putative polymerase of PSB (CDS 1931) 
had very low homology to any other polymerases and only contained 4 predicted 
transmembrane regions suggesting it was not a Wzy homologue. There were no other 
genes within this locus with homology to an O-antigen polymerase and the locus contained 
no genes which encoded a hypothetical protein.  
Within the five intact polysaccharide biosynthesis loci of LS66, only one potential Wzx 
protein was identified. This protein had 11 predicted transmembrane helices, and 99% 
identity to a previously characterised B. fragilis flippase in 638R. The lack of Wzx and Wzy 
homologues identified in LS66 may be due to the misassemblies present in the genome or 
















GNAB92 PSA Wzx 1097 oligosaccharide repeat unit transporter [Bacteroides fragilis YCH46] 398/418(95%) 0.0 418 12 Polysacc_synt 
GNAB92 PSA Wzy 1098 polysaccharide polymerase [Clostridium perfringens ATCC 13124] 84/336(25%) 3e-12 345 10 EspG 
GNAB92 PSB Wzx 1924 flippase [Bacteroides fragilis YCH46]  86/364(24%) 6e-16 506 14 Polysacc_synt 
GNAB92 PSB Wzy 1931 polysaccharide polymerase [Oceanicola sp. S124]  38/129(29%) 0.036 257 4 No hits 
GNAB92 PSC Wzx 1081 flippase [Bacteroides fragilis YCH46] 507/509(99%) 0.0 509 14 Polysacc_synt_3 
GNAB92 PSC Wzy 1084 polymerase [Bacteroides fragilis YCH46] 477/478(99%)   0.0 478 12 O-ag_pol_Wzy 
GNAB92 PSE Wzx 2787 O-antigen flippase [Yersinia similis]  127/368(35%) 5e-56 447 12 Polysacc_synt 
GNAB92 PSE Wzy 2782 O-antigen polymerase [Ignavibacterium album JCM 16511]  40/131(31%) 1.8 431 10 O-ag_pol_Wzy 
GNAB92 PSF Wzx 1560 putative transporter/flippase [Bacteroides fragilis 638R] 475/475(100%) 0.0 475 11 Polysacc_synt 
GNAB92 PSF Wzy 1566 polysaccharide polymerase Eps11O [Lactobacillus paraplantarum]  63/235(27%)   0.027 382 9 EspG 
GNAB92 PSG Wzx 782 O-antigen flippase [Escherichia coli] 125/439(28%)   1e-42 471 11 Polysacc_synt 
GNAB92 PSG Wzy 788 lipid A core-O-antigen ligase-like enyme [Alistipes sp. CAG:831]  69/250(28%) 4e-08   394 8 No hits 
GNAB92 PSH Wzx 3687 O-antigen flippase [Escherichia coli] 97/357(27%) 3e-27 375 8 No hits  
GNAB92 PSH Wzy 3683 O-antigen polymerase like protein  [Yersinia bercovieri]  89/334(27%) 2e-14 369 8 O-antigen_lig 
GNAB92 PSI Wzx 2991 flippase [Bacteroides fragilis YCH46]  278/512(54%) 0.0 513 12 Polysacc_synt 
GNAB92 PSI Wzy 2996 O-antigen polymerase [Bacillus megaterium WSH-002]  48/184(26%) 0.16 425 10 Wzy_C 











BE1 PSA Wzx 1360 LPS biosynthesis flippase [Bacteroides fragilis NCTC 9343] 135/426(32%) 6e-58 474 14 Polysacc_synt 
BE1 PSA Wzy 1363 Wzy [Escherichia coli] 72/253(28%) 5e-07 464 14 O-ag_pol_Wzy 
BE1 PSB Wzx 1750 capsular polysaccharide transporter [Bacteroides fragilis YCH46] 181/482(38%) 3e-93 481 11 Polysacc_synt 
BE1 PSB Wzy 1751 polysaccharide polymerase [Bacillus cereus] 48/190(25%) 0.80 428 12 O-antigen_lig 
BE1 PSC Wzx 1049 flippase [Bacteroides fragilis YCH46] 509/509(100%) 0.0 509 14 Polysacc_synt_3 
BE1 PSC Wzy 1052 Wzy [Escherichia coli] 101/402(25%)   3e-06 478 12 O-ag_pol_Wzy 
BE1 PSD Wzx 3759 O-antigen export [Clostridium botulinum H04402 065] 63/271(23%) 2e-04 480 13 Polysacc_synt 
BE1 PSE Wzx 2485 O-antigen transporter [Parabacteroides distasonis ATCC 8503] 132/394(34%) 2e-53 414 10 Polysacc_synt 
BE1 PSF Wzx 1453 hypothetical protein BF1533 [Bacteroides fragilis YCH46] 507/509(99%) 0.0 509 12 MatE 
BE1 PSF Wzy 1465 O-antigen polymerase [Paenibacillus sp. JC66] 77/293(26%)   3e-07 419 9 O-antigen_lig 
BE1 PSG Wzx 0760 capsular polysaccharide transporter [Bacteroides fragilis YCH46] 477/481(99%) 0.0 481 12 Polysacc_synt 
BE1 PSG Wzy 0766 polymerase [Clostridium thermocellum] 50/202(25%) 0.11 394 8 O-antigen_lig 
BE1 PSH Wzx 3426 O-antigen flippase [Yersinia similis] 149/432(34%) 7e-72 454 12 Polysacc_synt 
BE1 PSH Wzy 3422 O-antigen polymerase [Pectobacterium atrosepticum SCRI1043] 87/323(27%) 5e-08 369 8 No hits 
BE1 PSI Wzx 2682 hypothetical protein BF2791 [Bacteroides fragilis NCTC 9343] 514/514(100%) 0.0 514 12 MatE 
BE1 PSI Wzy 2691 Wzy [Escherichia coli] 52/203(26%) 0.12 368 8 No hits 
LS66 PSG Wzx 0741 polysaccharide transporter/flippase [Bacteroides fragilis 638R] 472/475(99%) 0.0 475 11 Polysacc_synt 




3.2.4. Whole genome comparison 
RD48, BE1, GNAB92, BE1, YCH46 and 638R were aligned to NCTC9343 using the BLAST Ring 
Image Generator (BRIG) (Figure 3.9).  The locations of the polysaccharide biosynthesis loci 
of NCTC9343 are indicated on the outer ring of the comparison. The absence of colour 
within the rings representing the genomes of RD48, BE1, GNAB2, 638R and YCH46 indicated 
regions which were divergent from NCTC9343. For example, there was an absence of colour 
in the 638R (dark blue), YCH46 (green) and GNAB92 (light blue) rings in the region which 
encoded PSI, as the equivalent polysaccharide biosynthesis locus in these three genomes 
had little sequence identity to NCTC9343. However, there was an unbroken ring of colour in 
the same region of BE1 (purple), LS66 (yellow) and RD48 (light green) as these strains had 







Figure 3.9: Whole genome comparison with NCTC9343 
The genomes of RD48, LS66, 638R, YCH46, BE1 and GNB92 were compared to NCTC9343 
using BRIG. The inner ring represents the GC content of NCTC9343, each consecutive ring 
represents an individual genome identified by the colour key. The loci of polysaccharides A-
I and the LC assembly genes are indicated in red in the inner ring and are labelled on the 
outer ring. The presence of colour indicates homology with NCTC9343, no colour indicates 
divergent sequences. 
3.2.5. DNA Restriction and Modification systems 
B. fragilis contains R-M systems, which protect the cell from incoming foreign DNA. 
NCTC9343 encodes three type I and two type III R-M systems; in comparison, 638R encodes 
two type I, one type IIS and one type III R-M systems (Cerdeño-Tárraga et al., 2005; Patrick 
et al., 2010). The genome of YCH46 encodes one type IIS and one type III R-M systems. The 
presence of R-M systems in BE1, RD48 and GNAB92 were determined and comparisons 
were made to NCTC9343, 638R and YCH46.  
71 
 
Patrick et al (2010) demonstrated that both type I R-M systems present in 638R were 
contained within a horizontally acquired island. A region, displaying little sequence identity 
between strains, was present in all five genomes and in a similar chromosomal location 
(Figure 3.10a). This region ranged in size from ~24 kb in YCH46 to ~ 74 kb in NCTC9343, and 
was flanked by bacteriophage related genes, including a gene encoding a putative phage 
integrase. Interestingly, this region encoded a type I R-M system in all strains with the 
exception of YCH46. The 638R hsdS shufflon (BF 638R 1146-1149) was located within this 
region, a similar type I shufflon was also encoded in the same location in GNAB92 (1165-
1168) (Figure 3.10b). In NCTC9343 the region also encoded one of the type III R-M systems. 
 
Figure 3.10: Restriction modification related region  
(a) Five-way ACT comparison between NCTC9343, BE1, 638R and YCH46 showing a phage-
related, divergent region present in all genomes containing R-M systems. (b) Two-way ACT 
comparison of the type I R-M shufflon present in GNAB92 and 638R. The red colour 
indicates homology. 
In addition to the type I shufflon encoded by GNAB92 there was a second type I R-M system 
(4017-4019), which was also associated with a phage related integrase encoding gene 
(4014), and a type III R-M system (1132-1133). RD48 contained the same R-M systems 
present in NCTC9343, however, the type I shufflon of RD48 appeared to contain a deletion 
of both the HsdM and HsdR subunits (Figure 3.11a), with only the specificity subunits 
remaining (RD48 1891-1893), suggesting this was a non-functional R-M system. A second 
type I system in RD48 (RD48 1510-1511), appeared to contain a deletion in the HsdS 
subunit (Figure 3.11b). A type IIS enzyme (BE1 4482), related to those encoded by 638R 
(1811) and YCH46 (3008) was identified in BE1, along with a type III R-M system. This type 
72 
 
III locus was the only R-M system common to all six of the B. fragilis genomes. This suggests 
that diversity observed in the genes encoding the other R-M systems was generated by 
horizontal gene transfer. 
 
 
Figure 3.11: Deletions in the type I R-M systems of RD48 
ACT comparisons of NCTC9343 (top) and RD48 (bottom) showing (a) a deletion of the hsdR 
and hsdM genes of the type I R-M shufflon. (b) a deletion of the hsdS gene of the type I R-M 
system equivalent to NCTC9343 1077-1079. The red colour indicates homology and the 
blue colour indicates a sequence inversion. 
3.2.6. Bacteroides fragilis toxin (BFT) 
A subset of B. fragilis strains, termed enterotoxigenic B. fragilis, contain the virulence factor 
BFT (Franco et al., 1997). The bft gene is contained within an ~ 6kb pathogenicity island, 
BfPAI, which is inserted at a specific chromosomal location in EBFT strains (Moncrief et al., 
1998). BfPAI has ~12 kb flanking regions which contains genes encoding mobilisation 
proteins and this region has been identified in approximately half of the non-
enterotoxigenic B. fragilis strains tested including NCTC9343 (Franco et al., 1999). Franco 
(2004) determined that the BfPAI flanking region of NCTC9343 is contained within a ~65 kb 
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conjugative transposon (CTn9343). A similar transposon, designated CTn86, was identified 
in the ETBF 86-5443-2-2 strain which contains BfPAI.  
The presence of BfPAI and the conjugative transposon in GNAB92, BE1, RD48, YCH46 and 
638R were determined. GNAB92 encoded the BFT pathogenicity locus (Figure 3.12), with 
98% DNA sequence identity to BfPAI isolated from ETBF VPI13784 (GenBank accession 
AF038459). GNAB92 also contained a ~ 61.5 kb region with 85% identity to CTn9343. RD48 
encoded the complete CTn9343 transposon but did not contain the BfPAI. None of the 
other genomes encoded BfPAI or the conjugative transposon. 
 
 
Figure 3.12: ACT comparison of BfPAI pathogenicity island in GNAB92 and NCTC9343 
GNAB92 encoded the BfPAI pathogenicity island which contained bft, highlighted by a black 











The genome of B. fragilis shows evidence of extensive horizontal gene transfer. The 
genomes of seven B. fragilis clinical isolates were sequenced to further examine the role of 
HGT in genetic diversity within this organism. Following sequencing, the quality of the data 
was assessed and three of the genomes were deemed unsuitable for further analysis. The 
data of the four remaining strains, RD48, LS66, BE1 and GNAB92 were assembled and 
annotated. Analysis of these genomes focused on three previously identified examples of 
HGT within B. fragilis: polysaccharide diversity, R-M systems and B. fragilis toxin.  
Patrick et al (2010) demonstrated that the genomes of B. fragilis strains NCTC9343, 638R 
and YCH46 encoded 28 divergent capsular polysaccharide-associated biosynthesis loci. 
Genomic comparisons were performed between these strains and RD48, LS66, BE1 and 
GNAB92. The genome sequences of GNAB92 and BE1 contained eleven polysaccharide 
biosynthesis loci which were divergent from those previously identified in NCTC9343, 
YCH36 and 638R. One of these loci, PSG, was a common locus. Therefore within the two 
strains, ten different polysaccharide biosynthesis loci were found. There is, consequently, 
the potential to express 38 different polysaccharides amongst these five strains. A further 
three possible divergent polysaccharides were identified in LS66. However, due to problems 
with the assembly of the genome this could not be confirmed. RD48 encoded nine 
polysaccharide biosynthesis loci identical to those previously identified in NCTC9343. The 
diversity of polysaccharides, observed in so few strains of B. fragilis is unprecedented. For 
example, in Streptococcus pneumoniae, 90 different polysaccharide loci have been 
identified, however, each single locus is associated with a single serotype (Bentley et al., 
2006). Similarly in Acinetobacter baumanii, 25 polysaccharide loci have been identified in 
27 serotypes, but each serotype contains only one locus (Hu et al., 2013).  
A number of divergent R-M systems were identified within the analysed genomes. GNAB92 
contained two type I R-M systems, one of which contained a shufflon with homology to a 
type I shufflon encoded by 638R, and a type III R-M. A type IIS and a type III R-M system 
were identified in BE1. This type III locus was the only conserved R-M system present in all 
strains analysed. The presence of only one common system suggests that the diversity of 
the R-M systems within B. fragilis strains was the result of horizontal gene transfer. 
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During analysis of the four newly sequenced genomes, a number of apparent deletions in 
polysaccharide loci were observed, one of which was a deletion of RD48 PSB. 
Immunofluorescence microscopy revealed that PSB was expressed by this strain, indicating 
the observed deletion was an artefact of the genome assembly. The other putative 
deletions should be investigated to determine whether they are true deletions. This could 
be achieved through the use of a sequencing platform which produces longer read lengths, 
which would result in fewer contigs and reduce the chance of a misassembly. 
In conclusion, four new B. fragilis genomes were sequenced.  The genomes displayed a high 


















Chapter 4. Inter-kingdom horizontal gene transfer 
4.1. Introduction 
An unusual example of HGT in Bacteroides fragilis was observed when the complete 
genome of B. fragilis NCTC9343 was sequenced and analysed. An open reading frame was 
identified which encodes a 76 amino acid protein with 63% identity to human ubiquitin. The 
protein-modifier is conserved within eukaryotes but, until now, was believed to be absent 
from prokaryotes. The closest DNA sequence homology to this ORF is found in a migratory 
grasshopper entomopox virus, which suggests the gene was acquired by inter-kingdom HGT 
(Patrick et al., 2011).  
4.1.1. Ubiquitin 
Ubiquitin is a 76 amino acid, highly conserved, eukaryotic protein-modifier. Tagging of 
target proteins with ubiquitin (ubiquitylation) is essential to a wide range of cellular 
functions, including DNA repair, endocytosis, transcription, apoptosis and immune 
response. The most studied role of ubiquitylation is in the regulation of proteolysis, in 
which a target protein is marked for degradation by the 26S proteasome. This process is 
facilitated by three enzymes, E1, E2 and E3. Ubiquitin is activated by the formation of a 
thioester bond between the C-terminal glycine residue and the cysteine active site of the 
ubiquitin-activating enzyme, E1. The bound ubiquitin is subsequently transferred to the 
cysteine residue in the active site of the ubiquitin-conjugating enzyme, E2. An isopeptide 
bond is formed between ubiquitin and a lysine residue of the target protein by the ubiquitin 
ligase, E3. Polyubiquitin chains can form on the target protein. In the case of proteolysis, 
Lys48-linked chains are recognised and the protein is degraded by the 26S proteasome 






Figure 4.1: The ubiquitylation pathway.  
The activation of ubiquitin occurs by the formation of a thioester bond between the C-
terminal glycine residue and the cysteine active site of the ubiquitin-activating enzyme. 
Ubiquitin is then transferred to the active site of the E2, conjugating enzyme before E3 
facilitates binding to the target protein. Lys48 linked polyubiquitin chains are recognised by 
the proteasome and the protein is degraded.  
4.1.2. Ubiquitin modifications 
Modifications of proteins can occur with one ubiquitin molecule (monoubiquitylation), 
multiple ubiquitin monomers attached at different lysine residues on the target protein 
(multiubiquitylation) or as a chain (polyubiquitylation) (Sadowski et al., 2012). Polyubiquitin 
chains are linked through one of the seven lysine residues; Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48 and Lys63. The formation of polyubiquitin chains can be homogeneous where all 
linkages are formed through the same lysine residue, or chains can contain a mixture of 
linkage types (Peng et al., 2003).  The type of ubiquitin modification of the target protein 
determines its fate; for example, monoubiquitylation is involved in regulating endocytosis, 
lysosomal targeting and meiosis, while polyubiquitylation is implicated in protein 




4.1.3. Ubiquitin and the immune system 
Ubiquitylation plays a major role in the regulation of the host pro-inflammatory response 
through the activation of the transcription factor, nuclear factor kappa B (NF-B), which 
occurs in response to a variety of stimuli including invading pathogens. In the absence of a 
stimulus such as cytokines, NF-B is present in the cytoplasm of the cell and is inactive, due 
to its association with inhibitor IкBα. During infection, pathogen associated molecular 
patterns (PAMPs) of extracellular pathogens are recognised by pattern recognition 
receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-like receptors, which initiates 
the NF-B signalling cascade (Oeckinghaus et al., 2011). This cascade results  in the 
ubiquitylation and subsequent degradation of IкBα, which releases NF-B, allowing it to 
translocate to the nucleus and initiate transcription of pro-inflammatory response genes 
(Schmukle & Walczak, 2012).  Traditionally Lys48 and Lys63 linked polyubiquitin chains have 
been implicated in the regulation of the pathway. Recently however, Lys11 linked chains 
have been identified as playing a role (Dynek et al., 2010; Bremm & Komander, 2011). Lys48 
linked chains mediate the essential degradation of a number of components in this 
pathway. For example, following the phosphorylation of IкBα, these proteins are 
ubiquitylated with Lys48 chains and are targeted for proteolytic destruction.  Lys63 chains 
are involved in the activation of NF-B  by modifying multiple components of the pathway 
upstream of IкBα phosphorylation, for example TRAF2 and NEMO, two proteins which are 
required for the recruitment of IKK (Chen & Chen, 2013). Homogeneous Lys11 linked chains 
are involved in the degradation of a number of cell cycle regulators, however, Lys11 
linkages present in mixed polyubiquitin chains have been identified in many other cell 
processes including the activation of NF-B via the tumor necrosis factor-α (TNF-α) 
pathway.  Receptor interacting protein 1 (RIP1) is ubiquitylated by polyubiquitin chains 
containing Lys11 linkages after stimulation of the cell by a cytokine such as TNF-α (Bremm 
& Komander, 2011; Schmukle & Walczak, 2012).  
Lys11 linkages have also been identified in the endocytosis and trafficking of 
transmembrane receptors, for example Kaposi's sarcoma associated herpesvirus produces 
two immunomodulatory proteins, K3 and K5, which can down-regulate MHC class 1 
molecules on the host cell. These molecules are responsible for presenting peptides to 
cytotoxic T-cells which alert the immune system to the presence of intracellular pathogens. 
K3 causes Lys63-linked polyubiquitylation of MCH 1, however K5 mediated endocytosis of 
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MCH I requires polyubiquitin chains consisting of both Lys63 and Lys11 linkages. K3 and K5 
act as ubiquitin E3 ligases and facilitate the polyubiquitylation of MHC 1 which targets it for 
degradation (Boname et al., 2010). 
All of the other possible lysine linkages, Lys6, Lys27, Lys29 and Lys33 have been detected in 
cells but the processes in which they are involved are less well defined (Komander & Rape, 
2012) 
4.1.4. Ubiquitin Binding Domains 
Ubiquitin acts as a signalling molecule which initiates cellular events often by forming non-
covalent interactions with proteins containing ubiquitin-binding domains (UBDs),  of which 
there are estimated to be more than 150 different types (Hurley et al., 2006; Dikic et al., 
2009). UBDs interact with different ubiquitin surface residues (Figure 4.2), the most 
common of which is the hydrophobic Ile44 patch consisting of the residues Ile44, Leu8, 
Val70 and His68. This patch binds most UBDs and is bound by the proteasome during 
degradation of substrates. Another hydrophobic patch involved in UBD interactions 
includes the residues Ile36, Leu71 and Leu73, which are recognised by deubiquitylating 
enzymes (DUBs) and HECT E3s (Komander & Rape, 2012). The Phe4 patch, consisting of 
residues Gln2, Phe4 and Thr12, is involved in cell division in yeast but is not required for 
ubiquitin conjugation or proteasome degradation (Sloper-Mould et al., 2001). The TEK-box 
of ubiquitin, which consists of the residues Thr12, Thr14, Glu34, Lys6 and Lys11, is required 
for mitotic degradation and UBE2C- and UBE2S-mediated assembly of Lys11-linked chains 
(Jin et al., 2008; Kulathu & Komander, 2012).  
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Figure 4.2: Surfaces which interact with ubiquitin binding domains  
(taken from Kommander & Rape., 2012) 
The four main binding surfaces of human ubiquitin, Ile36 patch, Ile44 patch, Phe4 patch and 
TEK-box. Each surface is colour-coded and the residues involved are shown.  
 
Since ubiquitin plays a major part in the development and function of the immune system, 
mis-regulation of the ubiquitin pathway has been implicated in a number of diseases. These 
include arthritis, cancer and type 2 diabetes (Hoeller et al., 2006; Wang & Maldonado, 
2006; Schwartz & Ciechanover, 2009; Donath & Shoelson, 2011). 
4.1.5. Pathogens and the host ubiquitylation pathway 
The role of ubiquitin in such a vast number of cellular processes has made it an ideal target 
for microbial manipulation. A number of pathogens have evolved mechanisms to subvert 
and manipulate the host immune response through the ubiquitin pathway to aid in 
pathogenesis. This is accomplished by the delivery of bacterial effector proteins to the host 
cell via Type III and Type IV secretion systems, or OMV. Once inside the host cell, effector 
proteins can act upon the ubiquitin pathway in a number of different ways (Anderson & 
Frank, 2012).   
One mechanism by which bacterial effector proteins can subvert the host ubiquitylation 
pathway is to mimic host DUB, for example Yersinia species Type III secretion effector, YopJ 
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plays a role in inhibiting the inflammatory response and inducing apoptosis in 
macrophages. YopJ interferes with the NF-B pathway by acting as a DUB for ubiquitylated 
IкBα, preventing its degradation, therefore inhibiting the translocation of  NF-B to the 
nucleus and the transcription of the pro-inflammatory response genes (Rytkönen & Holden, 
2007). 
The intracellular pathogen, Shigella flexneri injects an effector, OspG, via its Type III 
secretion system into epithelial cells which interferes with the NF-B pathway. OspG 
molecules interact with E2 ubiquitin-conjugating enzymes, specifically UbcH5 which are 
necessary for the transfer of ubiquitin to the E3 ligase involved in the degradation of IкBα. 
Blocking this interaction results in inhibition of the NF-B inflammatory response, which 
facilitates colonisation by the organism (Angot et al., 2007). S. flexneri also produces OspI 
that has deamidase activity and modifies the E2, UBC13, which prevents recognition of the 
enzyme by the TRAF6 E3 ligase, preventing polyubiquitylation and downstream activation 
of the immune response (Sanada et al., 2012).  
In addition to delivery by secretion systems, bacterial effector proteins can enter host cells 
via OMV. Pseudomonas aeruginosa uses OMV to export the protein Cif, which interferes 
with the recycling of cystic fibrosis transmembrane conductance regulator (CFTR) chloride 
channels in the lung. Mutations in these channels have been associated with cystic fibrosis 
and result in a reduced clearance of mucus in the airways, therefore a reduced clearance of 
any pathogens present. Cif stabilises a complex containing the DUB, USP10, preventing it 
from deubiquitylating CFTR and results in its degradation rather than recycling of the 
receptor back into the plasma membrane. The reduced number of CFTR channels in the 
membrane leads to reduced mucociliary clearance and compromises the immune defences 
of the lung (Bomberger et al., 2011a). 
A number of other organisms, such as Listeria monocytogenes, E. coli and Salmonella 
Typhimurium have also developed mechanisms to interfere with host signalling pathways 
to aid pathogenesis (Veiga & Cossart, 2005; Rytkönen & Holden, 2007; Patel et al., 2009). 
Although the organisms outlined above can act upon the eukaryotic ubiquitin pathway, 





4.2.1. Comparison of protein sequence of BfUbb and eukaryotic ubiquitin 
The sequencing of B. fragilis NCTC9343 identified a gene, ubb which encodes a protein with 
63% identity (48 out of 76 amino acids) to human ubiquitin (Figure 4.3a). A sequence 
comparison showed that B. fragilis ubiquitin (BfUbb) and human ubiquitin have two main 
differences. The first 28 amino acids of BfUbb represent a signal peptide, indicating 
mobilisation of the protein to the periplasm of the cell. Secondly, the two terminal glycine 
residues have been replaced with an aspartic acid and a cysteine residue in BfUbb. These 
glycine residues in ubiquitin are required for covalent interaction between ubiquitin and 
the E1 and E2 enzymes in the ubiquitylation pathway and also for the formation of 
polyubiquitin chains. 
Many of the amino acids important for the function of eukaryotic ubiquitin are conserved in 
BfUbb, including six of the seven lysine residues known to be involved in polyubiquitylation 
(Figure 4.3). Lys11 which is involved in cell cycle regulation and NF-B activation through 
RIP1 has been replaced by a tryptophan residue.  BfUbb has a seventh lysine residue at 
position 40, which replaces a glutamine present in human ubiquitin. BfUbb also contains a 
second cysteine residue at position 70. A di-sulphide bridge could potentially form between 
the C-terminal cysteine of one BfUbb molecule and Cys70 of another BfUbb molecule, 
suggesting a mechanism by which B. fragilis ubiquitin may form polyubiquitin chains. Due 




Figure 4.3: Alignment of the predicted protein sequence of BfUbb and human ubiquitin.  
The first 28 residues of BfUbb represent a signal sequence. The lysine residues necessary for 
polyubiquitin chain formation are highlighted in bold and the C-terminal residues are underlined. 
The residues involved in the surfaces which interact with UBDs are highlighted in grey. 
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The tertiary structure of BfUbb was predicted using the PHYRE2 Protein Fold Recognition 
Server (Kelley & Sternberg, 2009) (Figure 4.4), which predicted it was similar to the tertiary 
structure of human ubiquitin, however, the residues involved in binding to UBDs, are less 
well conserved (Figure 4.3).  BfUbb does not contain any of the residues required to form 
the Ile36 patch and only contains one residue, Ile44 of the Ile44 patch, which is required for 
proteosomal degradation in eukaryotic ubiquitin. All of the residues which form the Phe4 
patch and all but one residue, Lys11 of the TEK-box are conserved in BfUbb. This suggests 
that BfUbb may have evolved specificity to interact with a specific component of the 
eukaryotic ubiquitylation pathway.   
 
Figure 4.4: Tertiary structure comparison of Ubb and BfUbb 
The tertiary structure of Ubb and BfUbb, predicted using Phyre2 with 99.8% confidence. 
The predicted structures of both Ubb and BfUbb contain 5 β sheets and 3 α helices. 
4.2.2. Ubiquitin and the ubb containing region 
4.2.2.1. The presence of ubb in clinical isolates 
The ubb gene is contained within an 11kb, low GC content region of the NCTC9343 genome. 
B. fragilis 638R also contains a similar low GC region which includes ubb, however, B. 
fragilis YCH46 contains only three of the same genes in the equivalent region but does not 
contain ubb.  The presence of ubb and the composition of the ubiquitin-containing region in 
B. fragilis clinical isolates were analysed by PCR and whole genome sequence comparison. 
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To determine the prevalence of ubb, 22 B. fragilis clinical isolates, collected from patients in 
Germany, Northern Ireland, UK, Ireland and The Netherlands (Table 4.1), were analysed 
using primers specific for ubb (Figure 4.5). The identity of the B. fragilis isolates was 
confirmed by PCR using primers specific for the gene encoding DNA gyrase B. NCTC9343 
chromosomal DNA was used as a positive control and produced an amplicon of 450 bp 
(Figure 4.5, Lane NCTC9343). Chromosomal DNA isolated from LS84, which was previously 
identified as B. thetaiotaomicron, was a negative control, and no PCR product was visible 
(Lane 11). Of the 22 isolates tested, 5 produced amplicons consistent with the presence of 
ubb, LS66 (Lane 3), LS67 (Lane 13), RD48 (Lane 15), BE3 (Lane17) and GNAB4 (Lane 18).  
These samples were isolated in Northern Ireland (LS66 and LS67), Ireland (RD48), The 
Netherlands (BE3) and the UK (GNAB4). There is no apparent correlation between the 


































Table 4.1: B. fragilis clinical isolates 
Number Strain name  Place of Origin Strain isolated from 
1 NCTC 10584 Germany Pus sample 
2 3529 Unknown Clinical isolate 
3 LS66 Craigavon, Northern Ireland Pus from abdominal wound; male 
4 JC15 Northern Ireland Pus sample 
5 GNAB92 Edinburgh, UK Clinical isolate 
6 LS54 Craigavon, Northern Ireland Pus from perianal abscess 
 
7 JC15 Northern Ireland Clinical isolate 
8 NCTC9344 London, UK Septic, post-operative infection 
9 JC19 Northern Ireland Pus sample 
10 JC6 Northern Ireland Pus sample 
11 LS84* Craigavon, Northern Ireland Pus sample 
12 JC17 Northern Ireland Pus sample 
13 LS67 Craigavon, Northern Ireland Pus sample 
14 RD47 Donegal, Ireland Healthy faeces 
15 RD48 Donegal, Ireland Healthy faeces 
16 BE1 Amsterdam, The Netherlands Pus from wound 
17 BE3 Amsterdam, The Netherlands Clinical isolate 
18 GNAB4 Edinburgh, UK Pus sample 
19 BCH1 Belfast, Northern Ireland Post-operative  wound abscess 
20 VH Northern Ireland Clinical isolate, abscess 
21 MPRL3499VI Edinburgh, UK IBS: Rectal Biopsy 
22 MPRL3535V Edinburgh, UK 
Quiescent UC (extensive): Rectal 
Biopsy 
23 MPRL3536X Edinburgh, UK 
Active UC (pancolitis): Biopsy 
ascending colon 
 IBS = Irritable Bowel Syndrome 
 UC = Ulcerative colitis 





Figure 4.5: ubb in clinical isolates of B. fragilis 
Agarose gels showing detection of the ubb gene by PCR in clinical isolates of B. fragilis from 
Ireland, Northern Ireland, Germany, The Netherlands and the UK. NCTC9343 and B. 
thetaiotaomicron (Lane 11) DNA was used as a positive and negative control, respectively. 
Five clinical isolates, LS66 (3), LS67 (13), RD48 (15), BE3 (17) and GNAB4 (18), produced 
amplicons consistent with the presence of ubb. The first and last lanes of each gel contain 
DNA molecular size markers.  
4.2.2.2 Analysis of the low GC region of B. fragilis isolates by PCR 
A comparison of the three previously sequenced B. fragilis genomes, NCTC9343, 638R and 
YCH46 indicated that the ubiquitin containing region displayed variation beyond the 
presence or absence of ubb. To determine the variation in size of the low GC region in the 
22 clinical isolates, primers were designed in the DNA mismatch repair protein gene mutL, 
downstream of ubb and a hypothetical protein (BF3878 in NCTC9343) upstream of the 
ubiquitin gene (Figure 4.6a). These genes were chosen as they were conserved in 
NCTC9343, 638R and YCH46 and the four newly sequenced genomes described in Chapter 
3.  The size of the low GC region in each the sequenced genomes was: NCTC9343, 4298 bp; 
638R, 3121 bp; YCH46, 1608 bp; BE1, 2898 bp; GNAB92, 1607 bp; LS66, 3199 bp; RD48, 
3598 bp. NCTC9343 chromosomal DNA was used as a positive control to generate an 
amplicon of 4298 bp. PCR analysis of DNA from the 23 clinical isolates (Table 4.1) produced 
amplicons ranging in size from 1.4-4kb (Figure 4.5b), confirming variation in this region 
between strains.  The low GC region of ubb containing isolates, including NCTC9343, 
produced amplicons of 4 different sizes, which ranged from ~3.1 - 4 kb, LS66 (Lane 3, 3199 
bp), LS67 (Lane 13, ~3 kb), RD48 (Lane 15, 3598 bp), BE3 (Lane 17, ~3.5 kb) and GNAB4 
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(Lane 18,  ~3 kb). Those isolates which did not contain ubb produced amplicons of 5 
different sizes, which ranged from ~ 1.4- 2.9 kb, the smallest of which were B. fragilis 
strains JC15 (Lane 6) and VH (Lane 20). Strains NCTC 10584 (Lane 1), 3529 (Lane 2) and 
MPRL3535V (Lane 22), which did not encode ubb, produced amplicons of ~2.9 kb. 
 
Figure 4.6: Analysis of the low GC region of B. fragilis clinical isolates by PCR 
(a) Schematic diagram showing the low GC region of NCTC9343 flanked by mutL and 
BF3878. The two black arrows indicate the approximate location of the forward and reverse 
primers which produced an amplicon size of 4298 bp from DNA isolated from the positive 
control, NCTC9343.  (b) Agarose gels showing the variation in size of the low GC regions of 





4.2.2.3. Analysis by whole genome sequencing. 
Comparisons of the low GC region of NCTC9343, YCH46 and 638R were made with the four 
newly sequenced genomes RD48, BE1, GNAB92 and LS66 using the Artemis comparison 
tool (Figure 4.7b) to examine the variation present within this area of the genome. Two of 
the genomes, LS66 and RD48 contained ubb, which was confirmed by PCR (Figure 4.5, lanes 
3 and 15, respectively). Genome sequencing also confirmed the variations in size of the low 
GC region as shown by PCR in Figure 4.6. The region was 1607 bp in GNAB92, 3598 bp in 
RD48, 2898 bp in BE1 and 3119 bp in LS66. Although there was variation within the region, 
there were some common genes present in strains which contained ubb and similarly in 
those in which ubiquitin was absent. The low GC region between BF3878 and mutL of 
NCTC9343 contained six ORFs: BF3879 (840 bp), encoding for a transposase and IS element; 
BF3880 (168 bp), BF3881 (258 bp) and BF3882 (279 bp), each encoding a hypothetical 
protein; ubb (228 bp) encoding BfUbb and BF3884 encoding a putative membrane protein 
(231 bp) (Figure 4.7a). ubb positive strains, 638R, LS66 and RD48 all contained ORFs with 
100% DNA sequence identity to BFBF3881, BF3882, ubb and BF3884. The strains in which 
ubb was absent, YCH46, BE1 and GNAB92 all contained a gene encoding a hypothetical 
protein (288 bp) and gene encoding a protein with 88% identity to an XRE transcriptional 
family regulator. In addition, BE1 contained an ORF (1134 bp) encoding a hypothetical 
protein (BE1 3921) not present in the other sequenced genomes but which has been 
identified in a number of other Bacteroides spp.  
During analysis, it was observed that preceding the low GC region there was another area 
of variation.  An ACT alignment (Figure 4.8a) of this region from ompA to mutL shows an 
approximately 38kb insertion present in NCTC9343 and RD48 which is absent from the five 
other genomes. This insertion, shown in NCTC9343 in Figure 4.8b is flanked by a 
transposase, BF3879 and a tyrosine recombinase, BF3839 and contains 40 genes which are 
predicted to encode a number of hypothetical proteins, outer membrane proteins and a 
homologue of the ferric iron transporter FeoB.  In the genomes of YCH46, 638R, BE1, LS66 
and GNAB92, the region from ompA to mutL is approximately 25kb in size. Although there 
was some homology between strains, this region also displayed a high level of variation, 






Figure 4.7: Sequence analysis of the low GC region of B. fragilis 
 
Comparison of the low GC region of the four sequenced B. fragilis genomes with the 
reference genomes (NCTC9343, YCH46 and 638R) using ACT. (a) Alignment of genomes 
showing the 4kb region between mutL and BF3878. The transposase present in NCTC9343 is 
highlighted. (b) Schematic showing the similarities between the strains containing ubb and 





Figure 4.8: ACT comparison of the ompA to mutL region 
(a) ACT comparison of the region between ompA and mutL of the reference sequences and 
the four sequenced B. fragilis genomes highlighting the difference in size of the region in 
NCTC9343 and RD48 and the other genomes (b) Artemis view of the insert region in 








4.2.3 Growth rate of Δubb 
As YCH46, which lacks ubb has a slower growth rate and attains a lower cell density in 
stationary phase than NCTC9343 (Patrick et al., 2010), the growth rate of B. fragilis strain 
Δubb. The ubb deletion strain was generated by Dr Zubin Thacker, using the method 
described by Patrick et al (2009,) in which ubb was replaced with an erythromycin 
resistance cassette (Δubb::ermF). The growth rate of this strain was compared to that of 
NCTC9343 in both BHI-S and glucose defined medium (DM). Δubb had a similar growth rate 
to NCTC9343 (Figure 4.9), suggesting ubb is not essential for B. fragilis growth in laboratory 
medium. Growth experiments were performed in triplicate and an average was calculated. 
 
Figure 4.9: Comparison of the growth rate of NCTC9343 and Δubb 




4.2.5 Expression of BfUbb  
Following identification of the ubiquitin gene, the next step was to determine if the protein 
was expressed by the bacterium. Initial experiments were carried out using anti-bovine 
ubiquitin antibodies, which were shown to detect purified BfUbb (100 μg/ml) at a 
concentration of 5 μg/ml primary antibody (Figure 4.10). NCTC 343, 638R and Δubb were 
grown in different media, including BHI-S, DM and glucose DM, and cells were harvested 
during both stationary and exponential phases of growth. Whole cell protein extracts were 
prepared (see section 2.8.2). As BHI-S contains eukaryotic ubiquitin, all samples grown in 
this medium were extensively washed in PBS. The strains were also grown in the presence 
of polymyxin B (10 mg/ml), H2O2 (50 μM for 15 minutes) or ethanol to induce bacterial cell 
envelope stress. Whole cell extracts were analysed by SDS-PAGE using Tris-glycine 
polyacrylamide gels and Western blot. The purified 6xHis-BfUbb control (purified by the 
Dryden lab, Chemistry, University of Edinburgh) was detected using 0.4 μg/ml HRP-
conjugated anti-rabbit secondary antibody, but there was no detectable level of BfUbb 
present in any of the whole cell extracts, suggesting either the antibody avidity was not 
high enough for detection or ubiquitin was not present in any of the strains tested or the 
concentration was too low in comparison to the purified protein. 
 
Fi 
Figure 4.10: Western blot analysis of anti-bovine ubiquitin antibody specificity 
Anti-bovine ubiquitin antibodies cross-reacted with BfUbb with a different binding avidity 
to bovine ubiquitin. Blot shows reaction of antibodies with BfUbb and bovine ubiquitin at 
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Using purified 6xHis-tagged BfUbb, rabbit polyclonal antiserum was generated and the 
whole cell extracts were re-probed for the presence of BfUbb. At this point SDS-PAGE was 
carried out using Tris-tricine polyacrylamide gels as they provided a better separation of 
proteins <15 kDa. BfUbb was detected in whole cell extracts of NCTC9343 grown in both 
BHI-S and DM. As shown in Figure 4.11, Western blot analysis of whole cell extracts from 
NCTC9343 grown in glucose DM revealed three bands. BfUbb is represented as a band of     
kDa, consistent with the size of the protein following cleavage of the signal peptide, a 
second band of    12 kDa, consistent with the size of BfUbb before processing and a lower 
molecular mass band which might represent a degradation product. 
 
Figure 4.11: Detection of BfUbb in whole cell extracts of B. fragilis 
Western blot using rabbit anti-BfUbb polyclonal antiserum. Lanes: 1, purified 6xHis-BfUbb; 
2, whole cell extract of B. fragilis NCTC9343; 3, whole cell extract of B. fragilis Δubb. The 
three bands in lane two represent BfUbb before signal peptide cleavage (12kDa), BfUbb 
(8kDa) and the lowest band represents a degradation product of BfUbb 
4.2.6 BfUbb forms dimers under reducing and non-reducing conditions 
Eukaryotic ubiquitin forms polyubiquitin chains via the interaction of the C-terminal glycine 
residue of one ubiquitin molecule with one of seven lysine residues on the subsequent 
ubiquitin molecule (see section 4.1.2). BfUbb contained a C-terminal cysteine residue, 
suggesting that BfUbb molecules may form poly-BfUbb chains via a di-sulphide bridge (see 
section 4.2.1). Protein di-sulphide bonds are formed by the oxidation of thiol groups of two 
cysteine residues in a non-reducing environment (Gilbert, 1995). In prokaryotic and 
eukaryotic cells di-sulphide bonds form in extra-cytoplasmic compartments, for example, in 
E. coli, these bonds form in the periplasm of the cell (Shouldice et al., 2010). Therefore the 
periplasm of B. fragilis was a potential location for poly-BfUbb chain formation. The ability 
of BfUbb to form poly-BfUbb chains was determined. 
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Samples of 6xHis-tagged BfUbb were prepared in the presence and absence of the reducing 
agent DTT before SDS-PAGE and Western blot analysis. In both the reducing and non-
reducing sample, two bands (Figure 4.12) were detected at ~9 kDa and ~18 kDa 
corresponding to the size of a BfUbb monomer and dimer, respectively.  The difference in 
intensity of the two bands suggests BfUbb was primarily present in its monomeric form. 
The ability of BfUbb to form a dimer in the presence of DTT is unusual, although, there are 
examples of di-sulphide bond formation in reducing environments.  Proteins of the vaccinia 
virus have been shown to form di-sulphide bonds in the eukaryotic cytosol and were 
resistant to reduction by DTT, SDS, urea and β-mercaptoethanol (Locker & Griffiths, 1999). 
 
 
Figure 4.12: BfUbb in reducing and non-reducing conditions 
Western blot analysis of BfUbb under reducing and non-reducing conditions. BfUbb appears 
to form dimers under both reducing and non-reducing conditions. 
4.2.7 Generation and analysis of a ubb signal sequence deletion construct. 
The presence of a signal sequence and its apparent cleavage is consistent with BfUbb being 
transported across the inner membrane and into the periplasm of the cell. To confirm this, 
a plasmid in which the BfUbb signal sequence had been deleted was constructed (pKJ01) 
using the Clontech In-Fusion®Cloning System (2.7.11). Primers were designed to amplify 
both the ubiquitin promoter (Pubb) and ubb without the signal sequence. The two 
components were isolated and then fused via crossover PCR and amplified using the two 
outside primers. These primers contained 15bp of homology to the KpnI restriction site 
present in the multiple cloning site of the shuttle vector pLYL01 (Figure 4.13a). A plasmid 
containing ubiquitin with the signal sequence still attached was also generated (pKJ02). The 
E.coli S-17 strain was transformed with the two plasmids and then used for conjugation 
with B. fragilis Δubb.  Tetracycline resistant B. fragilis colonies were selected and plasmids 
were extracted for analysis. The presence of ubb was confirmed using PCR and Sanger 
sequencing. PCR was performed using the two outside primers (Figure 4.13b and c). The 
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PCR product of pKJ01 (Figure 4.13b lanes 3-5) was 84 bp smaller than that of the NCTC9343 
chromosomal DNA control (Figure 4.13b lane 2) which is consistent with the deletion of the 
signal sequence.  As expected, the PCR product of pKJ02 (Figure 4.13c lanes 3-5) was the 
same size as the NCTC9343 control (~500 bp) (Figure 4.13c lane 2). 
Whole cell and periplasmic extracts of B. fragilis strains Δubb, Δubb containing pKJ01 and 
Δubb containing pKJ02 grown in glucose DM were prepared (2.8.3).  Western blot analysis 
using anti-BfUbb polyclonal antiserum detected BfUbb in whole cell and periplasmic 
extracts of the Δubb strain containing pKJ02, demonstrated by the presence of an 8 kb band 
(Figure 4.13d lanes 3 and 4). In contrast, BfUbb was detected in whole cell extracts of the 
Δubb strain containing pKJ01 (lane 5) but not in the periplasmic extract (lane 6). These data 
support the periplasmic location of the processed form of BfUbb and the requirement of 
the signal peptide for transport from the cytoplasm. It should be noted however, that this is 




















Figure 4.13 : Construction and expression of a ubb signal sequence deletion plasmid 
(a) Schematic of the construction of a signal sequence deletion. The black arrows indicate 
the location of the primers. The two outside primers had homology to the KpnI restriction 
site present in the multiple cloning site of pLYL01. (b) Agarose gel showing pKJ02 in Δubb by 
PCR for ubb. Lanes: 1, I kb DNA size marker; 2, uncut pLYL01; 3,NCTC9343 chromosomal 
DNA; 4, pKJ02 clone 1 mini-prep; 5, pKJ02 clone 2 mini-prep. (c) Agarose gel showing pKJ01 
in Δubb by PCR for ubb. Lanes: 1, I kb DNA size marker; 2,NCTC9343 chromosomal DNA; 3, 
pKJ01 clone 1 mini-prep; 4, pKJ01 clone 2 mini-prep; 5, pKJ01 clone 3 mini-prep; 6, 100 bp 
DNA size marker. (d) Immunoblot using rabbit anti-BfUbb polyclonal antiserum Lanes: 1, 
Prestained protein size marker; 2, purified 6xHis-tagged BfUbb; 3, whole-cell extract Δubb 
containing pKJ02; 4, periplasmic extract Δubb containing pKJ02; 5, whole-cell extract Δubb 
containing pKJ01; 6, periplasmic extract Δubb containingpKJ01; 7, whole-cell extract Δubb; 





4.2.8 Bacteroides fragilis OMV 
Our data support the notion that BfUbb is present in the periplasm of the cell, however, to 
interact with the eukaryotic host and modulate ubiquitylation, the protein would need to 
be secreted from the bacterium. B. fragilis produces OMV which consist of outer 
membrane and periplasmic contents (see section 1.6). These vesicles have been shown to 
be phagocytosed by dendritic cells (Shen et al., 2012). Concentrated supernatants 
containing OMV were isolated and the presence of BfUbb was detected by Western blot 
analysis.  
4.2.8.1 Isolation of OMV 
B. fragilis concentrated supernatants containing OMV were isolated (see section 2.9.1). Cell 
free supernatants from overnight cultures of B. fragilis grown in DM were filter sterilised 
and concentrated with a 100 kDa cut-off membrane. OMV preparations were then pelleted 
by ultracentrifugation and washed in PBS. Aliquots were plated and incubated anaerobically 
at 37°C overnight to check for bacterial cell contamination. The protein concentrations of 
OMV samples were measured using a Bradford assay (see section 2.8.6). 
OMV were visualised using Transmission Electron Microscopy (TEM) (Figure 4.14) and the 
size distribution of OMV was measured using Dynamic Light Scattering (DLS). DLS indicated 
B. fragilis OMV range in size from 100-250nm which is consistent with the size of OMV 
produced by other Gram-negative bacteria. Negatively stained spherical structures were 
visible by TEM. Outer membrane, shown by a lighter ring surrounding the darker centre 







Figure 4.14 : B. fragilis OMV 
Transmission electron micrographs of 1% (w/v) uranyl acetate stained B. fragilis OMV 
present in concentrated supernatants. OMV represented as negatively stained spherical 
structures which ranged in size from 100-250 nm. The outer membrane was visible in some 
OMV, , encompassing a darker stained contents, presumably representing the periplasmic 
component of the vesicles 
 
To determine if BfUbb is associated with B. fragilis OMV, thereby suggesting a mechanism 
by which BfUbb may be delivered to the host cell, concentrated supernatants were 
prepared from overnight cultures of NCTC9343 and Δubb strains and analysed by Western 
blot (Figure 4.15). BfUbb was detected using rabbit anti-BfUbb polyclonal antiserum in both 
whole cell extracts and concentrated supernatants of NCTC9343, as indicated by a band at 
~ 8.5 kDa. A second band of ~ 17 kDa was also detetcted in the concentrated supernatants 
and whole cell extracts suggesting both BfUbb monomers and multimers may be associated 




Figure 4.15: Detection of BfUbb in concentrated supernatants. 
Western blot using rabbit anti-BfUbb polyclonal antiserum. BfUbb was present in whole cell 
extracts and concentrated supernatant  of NCTC 343 but not Δubb under reducing 
conditions. A band of ~17 kDa was detected in the concentrated supernatant and whole cell 
extract of NCTC9343, possibly indicating a BfUbb dimer. Some non-specific bands were also 
visible. 
 
4.2.8.2 Generation and analysis of a GFP-BfUbb fusion protein. 
As a tool to aid investigation of BfUbb within eukaryotic cells, a plasmid expressing a GFP-
BfUbb fusion protein was generated.  Green fluorescent protein (GFP) is a 23 kDa reporter 
protein isolated from the genus Aequorea (Chalfie et al., 1994). It is commonly used due to 
its autofluorescence and ability to be viewed under a range of conditions. GFP was chosen 
as it has been shown that eukaryotic ubiquitin tagged with GFP (GFP-Ub) retained the 
functionality of the untagged protein (Qian et al., 2002).  Since the formation of the final 
GFP fluorophore only occurs following correct folding of the protein, which is dependent on 
the presence of oxygen, it is usually an unsuitable reporter in anaerobes. However, it has 
been shown that GFP expressed in organisms grown under anaerobic conditions can 
flouresce after oxygen has been introduced (Cubitt et al., 1995; Scott et al., 1998; Zhang et 
al., 2005).  
The GFP-BfUbb expressing fusion plasmid, pKJ03, was generated using the Clontech In-
Fusion®Cloning System (see section 2.7.11). The gfp gene was isolated from the plasmid 
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pFU31 which encodes a derivative of GFP, GFPmut 3.1 which has a 35- fold increase in 
fluorescence compared to wild-type GFP. ubb and its promoter, Pubb were isolated from 
NCTC9343 chromosomal DNA. Primers to generate the insert used in the cloning reaction 
were designed to isolate Pubb, gfp and ubb. Primers were designed with approximately 
20bp of homology to the next component of the construct, for example, SS_REV contained 
homology to gfp. This was to facilitate the assembly of the insert by crossover PCR.  To 
ensure transport of the protein into the periplasm, gfp was inserted following the signal 
sequence.  The reverse primer to isolate gfp (GFP_REV) was designed with the stop codon 
omitted so that translation was not terminated before ubb.  The two outside primers 
(Pubb_puc19_FOR and ubb_puc19_REV) contained 15bp homology to the KpnI restriction 
site of the multiple cloning site of pLYL01.  
E.coli S17 cells were transformed with pKJ03 and ampicillin resistant colonies were selected 
and screened for the presence of the plasmid. pKJ03 was then transferred into NCTC9343 
by conjugation. Plasmid DNA was extracted from tetracycline resistant clones and the 
presence of the insert was confirmed by PCR (Figure 4.16b) and Sanger sequencing. The 
presence of the whole DNA insert confirmed using the two outside primers produced an 
amplicon of ~1.4 kb (lane 5), which was consistent with the size of the insert used for 
cloning (lane 2). Amplicons of ~250 bp (lane 3) and ~1.1 kb were generated following PCR 
with primers for ubb and gfp, respectively. 
Expression of the GFP-BfUbb fusion protein was confirmed by Western blot analysis under 
reducing conditions. Whole cell extracts and concentrated supernatants were prepared 
from NCTC9343 containing pKJ03 and NCTC9343 containing pLYL01 as the control, grown in 
DM. Blots were probed with rabbit anti-BfUbb (Figure 4.16ci) and rabbit anti-GFP polyclonal 
antisera (Figure 4.16cii) to detect the presence of BfUbb and GFP, respectively. Purified 
BfUbb (Figure 4.16ci lane 2) and samples prepared form NCTC9343 containing pLYL01 
(Figure 4.16ci lanes 3 and 4) cross reacted with anti-BfUbb antiserum, indicated by the 
presence of a band of ~8.5 kDa. Purified BfUbb and whole cell extract of NCTC9343 
containing pLYL01 also showed the presence of a second band of ~17 kDa which is the same 
size as the BfUbb dimer, shown previously to form even in the presence of DTT (Figure 
4.12).  Purified BfUbb and proteins from the whole cell extract and concentrated 
supernatant of NCTC9343 containing pLYL01 did not cross-react with anti-GFP anti-serum 
(Figure 4.16cii lanes 2-4). 
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Proteins from whole cell extracts and concentrated supernatants isolated from NCTC9343 
containing pKJ03 cross-reacted with both anti-BfUbb and anti-GFP antiserum. Bands were 
detected at the same molecular mass on both blots, indicating the two proteins, BfUbb and 
GFP were migrating to the same location on the gel. Two main bands were detected. The 
first of ~30-35 kDa corresponded to the size of a GFP-BfUbb monomer (~31kDa) confirming 
the generation and expression of a fusion protein.  The second band was ~60-75 kDa; an 
exact size was difficult to determine as there was less separation of the protein size marker 
near the top of the gel (Figure 4.16cii lanes 5 and 6). The size of a dimer of the fusion 
protein would be ~62 kDa. The higher band observed may indicate that GFP-BfUbb can 
form multimers, however, since this was a denaturing gel, the mechanism by which 

















Figure 4.16: The generation of a GFP-BfUbb fusion construct 
(a)  Schematic representation of the cloning of the fusion construct indicating where the 
primers were located. Each component was isolated separately before fusion using 
crossover PCR. (b) Agarose gel of PCR products from pKJ03 plasmid DNA extracted from B. 
fragilis NCTC 9343::pKJ03. Lanes: 1, I kb molecular size marker; 2, GFP-ubb insert control; 3, 
ubb; 4, gfp; 5, whole construct. (c) Western blot analysis of whole cell extracts and OMV, 
grown in glucose DM of NCTC9343::pLYL01 and NCTC9343::pKJ03. Lanes: 1, ColorPlus 
PreStained protein size marker; 2, BfUbb; 3, NCTC9343::pLYL01 whole cell; 4, 
NCTC9343::pLYL01 OMV; 5, NCTC9343::pKJ03 whole cell; 6, NCTC9343::pKJ03 OMV. (ci) was 






4.2.8.3 Detection of GFP-BfUbb fluorescence 
GFP fluorescence is dependent on the correct folding of the fluorophore, which only occurs 
in the presence of oxygen (see section 4.2.8.2). To determine the ability of the GFP-BfUbb 
fusion protein to fluoresce, concentrated supernatants, containing OMV, isolated from B. 
fragilis strain NCTC9343 containing pKJ03 were incubated with Caco-2 cells for 2 hours and 
fluorescence was detected using confocal microscopy (see section 2.10.5). Caco-2 cells 
were grown and maintained (see section 2.10.1) before they were seeded onto glass 
coverslips and grown until confluent. Cells were then incubated with OMV (100ug/ml 
protein concentration as measure by a Bradford assay). After 2 hours, cells were washed in 
PBS and fixed in 4% paraformaldehyde. Cells were visualised using confocal microscopy 
(Figure 4.17). It was observed that following incubation with the OMV, cells appeared to be 
undergoing cell death, characterised by rounding up, disruption of cell membranes and 
release of cytoplasmic content. Death was not observed in cells which were incubated 
without B. fragilis OMV (Figure 4.17). The experiment was carried out in triplicate, but due 
to the cell death there were very few intact cells and GFP fluorescence was only detected in 
one cell in two of the three replicates. However, detection of fluorescence indicated that 
the GFP-BfUbb fusion protein was delivered to the eukaryotic cell via OMV. It also 
demonstrated the correct folding of GFP after its introduction to an aerobic environment, 
which suggested that GFP-BfUbb could be used as a reporter to investigate the function of 





Figure 4.17: Caco-2 cells incubated with concentrated supernatants containing GFP-BfUbb 
GFP fluorescence detected in Caco-2 cells following incubation with OMV containing GFP-
BfUbb for 2 h. The bottom right-hand panel shows fluorescence within the cell, indicated by 
the red arrows. Death was observed in cells which had been incubated with OMV. This was 
not seen in cells which had been incubated in the absence of OMV (top-left panel). This 
suggests B. fragilis OMV had a toxic effect on Caco-2 cells. 
 
Cell death was also observed after the incubation of Caco-2 cells with 100 μg/ml (protein 
concentration) NCTC9343 OMV. Cells were incubated with vesicles for 2 hours before they 
were washed,  fixed in 4% paraformaldyhyde and stained with DAPI. Cells were visualised 
using confocal microscopy (Figure 4.18). In comparison to the OMV free control, cells 
incubated with OMV appeared to be rounded and undergoing cell death. In the control cells 
DAPI was confined to the nucleus, however, cells which had been incubated with OMV 
showed DAPI in the cytoplasm, which indicated the breakdown of the nucleus and 
dissemination of the nuclear material throughout the cell.  The observed cell death may be 
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due the contents of the OMV being released into the cell, however, it may also be due to B. 
fragilis LPS which is a component of the OMV.  
 
 
Figure 4.18: Colonic carcinoma cells incubated with B. fragilis OMV 
Confocal images of Caco-2 cells following incubation with NCTC9343 concentrated 
supernatants containing OMV (bottom panels). Cells were incubated with OMV for 2 hours 
prior to washing and fixation with 4% paraformaldehyde. Cellular DNA was stained with 
DAPI. Cells which were incubated with OMV underwent cell death and dissemination of the 
nuclear material into the cytoplasm. Cell death was not observed in the OMV free control 
(top panels). 
 
4.2.8.5 B. fragilis OMV contain plasmid and chromosomal DNA 
A number have studies have identified DNA as component of OMV. To date, chromosomal 
and plasmid DNA have been isolated from OMV produced by Haemophilus, Neisseria, E. 
coli, P. aeruginosa and Acinetobacter (Kahn et al., 1982; Dorward et al., 1989; Yaron et al., 
2000; Renelli et al., 2004; Rumbo et al., 2011).  To investigate the presence of DNA in B. 
fragilis OMV, vesicles were treated with DNase (see section 2.9.2) to remove exogenous 
DNA present in the supernatant. OMV were isolated from NCTC9343 which contains a 
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36.5kb plasmid, pBF9343. DNA was extracted from samples taken from the cell-free 
supernatant before any filtration or concentration, the supernatant of the final PBS wash 
and the final OMV sample. This was done to confirm that any DNA detected was isolated 
from the OMV and not simply present in the supernatant as a result of bacterial cell lysis. 
PCR assays were carried out using primers specific for the pBF9343 encoded Hin invertase 




Figure 4.19: PCR detection of DNA isolated from B. fragilis OMV 
Agarose gel showing detection of  (1) ubb (2) finB (3) 4298 by PCR in mini-preps from untreated cell-
free supernatant, supernatant of the final PBS wash post-DNase treatment and OMV post-DNase 
treatment.  
Amplicons for all three genes were detected in the cell free supernatant which had not 
undergone concentration or treatment with DNase (Figure 4.19 cell-free supernatant 1-3). 
All three genes were also detected in DNA extracted from the OMV, however, ubb was also 
detected in the final wash sample indicating it was present in the supernatant rather than 
the OMV and that DNase treatment was not sufficient to remove all DNA. finB and BF4298 
were not detected in the final wash by PCR, suggesting both plasmid and chromosomal 
DNA can be packaged into B. fragilis OMV. 
4.2.8.6 B. fragilis OMV-mediated transformation 
The packaging of DNA into OMV may be a mechanism by plasmids can be transferred 
between bacteria. Rumbo et al (2011) demonstrated that Acinetobacter bumannii can 
transfer carbapenem resistance plasmids between strains via OMV.  The ability of B. fragilis 
OMV to mediate transformation was investigated (see section 2.9.3). NCTC9343 was 
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transformed with pLYL01, which contains an ampR gene and OMV were isolated from this 
strain. The presence of the plasmid in OMV was confirmed by mini-prep and agarose gel 
electrophoresis. OMV isolated from NCTC9343 containing pLYL01 (concentrations of 200, 
100 and 50 μg/ml were used) were incubated with E. coli XL-1 Blue MRF’ cells (~105), which 
are deficient in Type I and Type IV restriction systems and tetracycline resistant, in the 
presence of 50 μg/ml DNase. Cultures were grown aerobically at 37°C, samples were taken 
at 2h, 4h and 12h and plated onto LB plates containing ampicillin and tetracycline.  The 
ability of OMV to mediate transformation between two B. fragilis strains was also 
investigated. OMV isolated from NCTC9343 containing pLYL01 (concentrations of 200. 100 
and 50 μg/ml) were incubated with B. fragilis Δubb cells (~105), which are erythromycin 
resistant, in the presence of 50 μg/ml DNase. All stages of the experiment were carried out 
anaerobically at 37°C. Samples of culture were taken at 2h, 4h, 12h and 24 h and plated 
onto BHI-S plates containing erythromycin and tetracycline. These experiments were 
carried out in triplicate and repeated three times, in all instances, no resistant colonies 
were identified. This indicated that under these conditions B. fragilis OMV were unable to 














Bacteroides fragilis encodes and expresses a unique homologue of the eukaryotic protein-
modifier, ubiquitin. This is the first example of ubiquitin being produced by a prokaryote.  
The number of Bacteroides present in the GI-tract is estimated between 109 to 1014 cells per 
gram of faeces, approximately 4-14% of which are B. fragilis (Patrick et al., 2009). This 
means that some people could have a large amount of BfUbb present in their GI-tract. 
BfUbb may interact with the host ubiquitylation pathway to aid the survival of the organism 
as a member of the resident microbiota or as an opportunistic pathogen.  
The genome of B. fragilis does not appear to encode the activating or conjugating enzymes 
of the ubiquitylation pathway, nor does it encode any components of the proteasome.   The 
changes in the amino acid sequence and the presence of a signal sequence, which 
facilitates transport of the protein into the periplasm, suggests that BfUbb has evolved to 
perform a unique role. 
The detection of BfUbb associated with OMVs suggests a mechanism by which the protein 
is packaged and exported from the bacterial cell. OMVs are secretory vesicles which have a 
well-established role in the delivery of bacterial effector proteins to host cells. B. fragilis 
OMV have been shown to be phagocytosed by dendritic cells (Shen et al., 2012), therefore 
the target for BfUbb may be the host ubiquitylation pathway in this cell type. 
The residues important for the interaction of ubiquitin with the E1 activating and E2 
conjugating enzymes have been conserved in BfUbb. It has also been shown that BfUbb can 
covalently bind to E1 and inhibit eukaryotic ubiquitylation in vitro (Patrick et al., 2011).  This 
suggests that the interaction between BfUbb and these enzymes could be important. 
However, BfUbb could also potentially be interacting with other eukaryotic proteins to 
modify their function. 
In eukaryotic ubiquitylation, the binding of ubiquitin to a target protein involves the 
formation of an isopeptide bond between the C-terminal glycine residue and a lysine 
residue of the target protein. Although BfUbb has a cysteine residue at the C-terminus it is 
possible that it could form a thiol-ester bond with other amino acids on the target protein. 
Eukaryotic ubiquitin has been shown to bind to residues other than lysine on a target 
substrate. For example, the viral E3 ligase, mK3, which targets the MHC I heavy chain for 
degradation can catalyse the binding of ubiquitin to lysine, serine and threonine residues of 
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the target protein (Wang et al., 2007). The authors demonstrated that polyubiquitylation 
still occurred after the mutation of all of the lysine residues present in the substrate. 
Vosper et al (2009) also showed that ubiquitylation of the transcription factor Neurogenin 
can occur via a cysteine residue, after the mutation of lysine residues, and the protein was 
still degraded by the proteasome.  
The identification of BfUbb dimers (Figure 4.12) suggests the protein may be able to form 
multimers via a di-sulphide bridge between C-terminal cysteine residues or Cys70 giving the 
potential for poly-BfUbb chain formation. Traditionally di-sulphide bridges cannot form in 
the reducing environment of the eukaryotic cytosol, however there is some evidence to 
suggest that intracellular organelles such as endosomes and lysosomes contain a non-
reducing environment (Austin et al., 2005; Yang et al., 2006).  As BfUbb contains six of the 
seven lysine residues involved in polyubiquitin chain formation, could BfUbb form mixed 
chains with the native ubiquitin? 
 Although the predicted tertiary structures of BfUbb and eukaryotic ubiquitin are similar, 
the residues important for interactions with UBDs are less well conserved. BfUbb is missing 
residues belonging to the two hydrophobic patches involved in the majority of UBD 
interactions. BfUbb has retained all of the residues involved in the formation of the Phe4 
patch. The change in the C-terminal residue of B. fragilis ubiquitin and the loss of binding 
surfaces which are important in the function of ubiquitin, suggests BfUbb has evolved 
specificity. Unlike eukaryotic ubiquitin which is involved in a vast array of cellular processes, 
BfUbb may interact with a specific part of the host ubiquitylation pathway.  
B. fragilis is a commensal organism, and BfUbb may aid in the organism’s ability to establish 
itself as a member of the resident microbiota of the GI-tract. A number of bacterial 
pathogens have developed mechanisms to subvert the host ubiquitin pathway to aid 
pathogenesis. The target of many of these mechanisms is the regulation of the pro-
inflammatory response, in which ubiquitin plays a major role. Commensal bacteria have 
been shown to interfere with this pathway to maintain homeostasis in the gut. Excessive 
NF-B activation in intestinal epithelial cells may lead to colitis. However, commensals can 
cause an anti-inflammatory effect by interfering with NF-B signalling (Goto & Ivanov, 
2013). Bacteroides thetaiotaomicron has an anti-inflammatory effect by enhancing the 
export of the NF-B subunit RelA from the nucleus back into the cytoplasm. This reduces 
the amount of time NF-B is active, therefore limiting the inflammatory response (Kelly et 
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al., 2004).  Could BfUbb play a role in inhibiting NF-B activation and dampening the 
inflammatory response? 
It has been established that the resident microbiota of the GI-tract have a role in the 
development of the host immune system, of which ubiquitin is also an integral component. 
Inflammatory bowel disease (IBD) is caused by a combination of genetic susceptibility and 
an abnormal mucosal immune response (Xavier & Podolsky, 2007). It has been 
demonstrated that B. fragilis has an intimate association with the mucosa of the GI-tract 
(Lee et al., 2013) and that in patients with IBD it was the predominant member of the 
mucosal biofilm, accounting for >60% of the biofilm mass (Swidsinski et al., 2005).  
Crohn’s disease, a type of IBD has been associated with dysregulation of the NOD2 
signalling pathway. Nucleotide binding and oligomerization domain 2 (NOD2) is an 
intracellular PRR which recognises a component of bacterial peptidoglycan and initiates a 
cascade which results in the activation of a number of signalling pathways, including the 
NF-B and autophagy pathways (Abbott et al., 2004).  Both activation of NF-B by NOD2 
and downregulation of this signalling involves ubiquitin, DUBs and a number of ubiquitin E3 
ligases (Tigno-Aranjuez & Abbott, 2012). Interference in this signalling pathway could 
contribute to the inflammation observed in Crohn’s disease.  
The mis-regulation of ubiquitin has been implicated in a number of diseases, including, 
neurodegenerative disorders, cancer and cardiac disease.  The causes of diseases such as 
IBD are not currently understood, however, a number of cellular pathways in which 
ubiquitin is an essential component have been implicated. Could BfUbb play a role in the 
















Chapter 5. Bacteriophages as mediators of horizontal gene transfer 
5.1. Introduction 
Transduction by bacteriophages is one mechanism by which horizontal gene transfer can 
occur and might contribute to the high level of variation observed between the B. fragilis 
genomes (see section 1.2.2 and chapter 3). Bacteriophage transduction is also a useful tool 
for bacterial genetic manipulation, for example, cloning using P1 transduction in E. coli. 
Genetic manipulation of B. fragilis is difficult, probably in part due to the presence of 
variable R-M systems (see section 3.2.5). Transduction by bacteriophages may be a 
mechanism by which the host R-M systems could be subverted to improve genetic 
manipulation of B. fragilis. The non-transducing, B. fragilis-specific bacteriophage ФED01 
was previously isolated from sewage collected in the Edinburgh area, its host-range was 
identified and its genome sequenced (G.W Blakely, personal communication). The aim of 
this chapter was to identify further B. fragilis-specific phages, different to ФED01 and 
determine their transducing capability.  
5.2. Results 
5.2.1. Isolation and identification of B. fragilis-specific bacteriophage 
20L of raw sewage from the Edinburgh area (Veolia Seafield sewage treatment plant) were 
coarse filtered, fine filtered and then concentrated by tangential flow filtration. Samples of 
treated sewage were plated onto soft agar overlays containing B. fragilis 638R and 
NCTC9343. Plaques were extracted and amplified by incubation with the appropriate B. 
fragilis strain (see section 2.11.1). Initial isolations were performed by students in an 
undergraduate practical class. 
In total, fifteen potentially new B. fragilis-specific bacteriophages were isolated (Table 5.1), 
twelve of which were isolated by propagation on NCTC9343 and three by propagation on 
638R. To determine the titre and host range of each phage, 10-fold serial dilutions were 
carried out, and 10 μl of each dilution was spotted onto soft agar overlays containing 
NCTC9343 or 638R (Figure 5.1). Spot plating was carried out in triplicate and average 
plaque counts were used to determine bacteriophage titres on each B. fragilis strain (Table 
5.1). Nine isolated bacteriophages were able to infect NCTC9343, one infected 638R and 
five infected both strains, including previously identified phage, ФED01. Four 
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bacteriophages, ФED01, ФED0 , ФED13 and ФED15 which infected both NCTC 343 and 
638R did not form clear plaques when spotted onto 638R. Instead, hazy zones were 
formed, suggesting these phage may have been entered a lysogenic lifecycle or the host 
cells were partially resistant to phage infection. Resistance of a bacterial strain to phage 
infection could occur if the receptor to which the phage binds had been lost or expression 
turned off. Those phage which infected both strains of B. fragilis, did so at different titres, 
for example the titre of ФED08 on NCTC 343 was 2x109 PFU/ml, but on 638R it was 8x105 
PFU/ml (Table 5.1).  This indicated host-mediated restriction of bacteriophage infection 
which is consistent with the different R-M systems identified in the genomes of these 
strains. ФED14 was unable to infect either B. fragilis strain after isolation, suggesting this 
phage was lost during the amplification and purification process.  
Table 5.1: Bacteriophage titres 
Bacteriophage 
Original strain of 
isolation 
Titre on NCTC9343 
(PFU/ml) 
Titre on 638R 
(PFU/ml) 
ΦED01 NCTC9343 3.6x1010 neat* 
ΦED02 NCTC9343 1.1x105 X 
ΦED03 NCTC9343 1.6x103 X 
ΦED04 NCTC9343 2x104 X 
ΦED05 NCTC9343 3x103 X 
ΦED06 NCTC9343 1x104 X 
ΦED07 NCTC9343 4x102 X 
ΦED08 NCTC9343 2x109 8x105 
ΦED0  NCTC9343 3x107 neat* 
ΦED10 NCTC9343 2.4x105 X 
ΦED11 638R X neat 
ΦED12 638R 8x102 X 
ΦED13 638R 4x104 104* 
ΦED14 NCTC9343 x X 
ΦED15 NCTC9343 3.6x109 neat* 
ΦED16 NCTC9343 5x106 X 
 x No infection 

















































































































































































































































































































Figure 5.1: Bacteriophage titres on NCTC9343 and 638R 
10μl of 10-fold dilutions of the indicated phage were spotted on soft agar overlay seeded 
lawns of NCTC9343 and 638R. Nine phages were able to infect NCTC9343, one infected 
638R and five infected both strains. Four phages, ФED01, ФED0 , ФED13 and ФED15 
appeared to infect 638R with only a partial zone of clearance, indicating either a lysogenic 
































































5.2.2. Restriction endonuclease digestion of bacteriophage DNA 
Restriction endonuclease mapping of phage DNA was carried out with the aim of identifying 
which of the isolated bacteriophages were related to ФED01 or which differ.  Phage DNA 
was extracted from CsCl purified lysates using formamide (see section 2.11.4). Purified DNA 
was digested individually with EcoRI, EcoRV, PstI, SmaI, BamHI, NcoI, XbaI and HindIII, with 
the exception of ФED02 and ФED13; DNA isolated from these phage was digested with all 
enzymes apart from XbaI (Figure 5.3 ФED02 and ФED13). The previously sequenced phage, 
ФED01, was only sensitive to cleavage by HindIII, and six DNA fragments were observed 
when the digest was analysed by agarose gel electrophoresis (Figure 5.2 ФED01). The 
genome sequence of ФED01 contained eight target sequences for HindIII, and also 
contained three target sequences recognised by SmaI, one recognised by NcoI and one 
recognised by XbaI, as determined by NEBcutter v2.0 (Vincze et al., 2003), however, 
cleavage by these enzymes was not observed suggesting DNA modification. Restriction 
endonuclease profiles revealed 6 other phages, ФED03, ФED04, ФED06, ФED07, ФED10 and 
ФED15 that were only digested by HindIII (Figure 5.2). As with ΦED01, multiple DNA 
fragments, between four and seven, were visible by gel electrophoresis following 
incubation with HindIII, indicating that multiple recognition sites were present within the 
genomes of these phages. All of these phage were isolated from NCTC9343, and with the 
exception of ФED01 and ФED15, only infected NCTC 343 (Table 5.1). ФED01 and ФED15 
appeared to infect 638R, but with a hazy zone of clearance when an undiluted sample was 
spotted onto a soft agar overlay containing 638R (Figure 5.1). This suggested these six 
bacteriophages may be identical to the previously sequenced phage, ФED01.  
Seven further bacteriophages, ФED02, ФED05, ФED08, ФED0 , ФED11, ФED13 and ФED16 
had restriction endonuclease cleavage profiles which differed from ФED01 (Figure 5.3). 
ФED02 was isolated from NCTC 343 and was not capable of infecting 638R; this DNA was 
cleaved by PstI, SmaI and BamHI (Figure 5.3 ФED02). ФED05 was isolated from NCTC 343 
and was cleaved by both HindIII, which produced six DNA fragments and NcoI, which 
produced two DNA fragments (Figure 5.3 ФED05). Cleavage of ФED05 DNA with HindIII 
produced a digestion pattern similar to that of ФED01, which also contains a target 
sequence recognised by NcoI, suggesting that this phage could be the same as ФED01 
however, it may contain modified DNA. ФED08 and ФED11 were isolated from NCTC9343 
and 638R respectively. DNA from these phage was resistant to digestion by all of the 
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endonucleases tested (Figure 5.3 ФED08 and ФED11). Since ФED11 was only able to infect 
638R and ФED08 was able to infect both NCTC 343 and 638R (Figure 5.1), the difference in 
host-range suggested they may be different. ФED0  was isolated from NCTC 343 and 
infected 638R with a hazy zone of lysis rather than clear plaques. DNA isolated from this 
phage was susceptible to cleavage by EcoRI, SmaI and HindIII (Figure 5.3 ФED0 ). Digestion 
of ФED0  by HindIII resulted in three DNA fragments, which differs from ФED01, in addition 
the genome of ФED01 does not contain any target sequenced for EcoRI, suggesting this 
bacteriophage may be different from ФED01. ФED13 was originally isolated from a plate 
containing 638R but was also able to infect NCTC9343. This phage DNA was cleaved by 
HindIII and SmaI to generate five and three DNA fragments, respectively (Figure 5.3 
ФED13). The genome of ФED01 contained three target sequences recognised by SmaI, 
suggesting that ФED13 may be the same bacteriophage but contain polymorphisms. Finally, 
ФED16 also appeared to have a different restriction endonuclease cleavage profile to the 
other bacteriophages. DNA isolated from ФED16 was susceptible to cleavage by HindIII, 
NcoI and SmaI. Six DNA fragments were visible following digestion with HindIII, two with 
SmaI and two with NcoI (Figure 5.3 ФED16). Since the genome of ФED01 contained target 
sequences which are recognised by HindIII, SmaI and NcoI, it is possible that ФED16 may be 
the same phage as ФED01.  
All of the isolated bacteriophages were susceptible to cleavage by HindIII, with the 
exception of ФED08, ФED11 and ФED02. DNA from seven of the phages was only cleaved by 
this enzyme, suggesting they may be the same as bacteriophage ФED01, however since the 
number of DNA fragments differed, some polymorphisms may be present. The remaining 
seven phages had unique restriction endonuclease cleavage profiles which differed from 
ФED01, however, DNA from ФED05, ФED13 and ФED16 was susceptible to cleavage by 
HindIII and at least one other restriction enzyme, the target sequence of which was also 
present in the genome of ФED01. This suggested that these bacteriophages may be the 
same as ФED01, but may contain DNA modifications. DNA isolated from ФED0  was also 
susceptible to cleavage by HindIII, but was also cleaved by EcoRI. The genome of ФED01 did 
not contain a target sequence recognised by this enzyme, suggesting this bacteriophage 
may be different. ФED02 DNA was cleaved by BamHI and PstI, the target sequences of 
which were not present within the ФED01 genome. DNA from ФED08 and ФED11 was 
resistant to cleavage from all restriction endonucleases tested, indicating they may also be 
different from ФED01. Restriction endonuclease cleavage profiles suggested that of the 
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fourteen isolated bacteriophages, four new phages; ФED02, ФED08, ФED0  and ФED11 
may have been identified. In addition, three phages, ФED05, ФED13 and ФED16 had 
cleavage profiles which differed from ФED01, therefore are potentially new bacteriophages. 
Sequencing of the bacteriophage genomes would confirm this and also determine if the 




























Figure 5.2: Restriction endonuclease cleavage profiles of bacteriophages similar to ФED01 
 
Agarose gels showing B. fragilis-specific bacteriophage DNA digested with a range of 
restriction enzymes for 1 hour at 37°C, with the exception of SmaI which was incubated at 
25°C. The first lane of each gel contains molecular size markers. Phage DNA was digested 
with the restriction enzyme indicated. DNA from the seven isolated bacteriophages was 










Figure 5.3: Bacteriophages with restriction endonuclease cleavage profiles different to 
ФED01 
Agarose gels showing B. fragilis-specific bacteriophage DNA digested with a range of 
restriction enzymes for 1 hour at 37°C, with the exception of SmaI which was incubated at 
25°C. The first lane of each gel contains molecular size markers. DNA was digested with the 
restriction enzyme indicated. DNA from the seven bacteriophages displayed a restriction 
endonuclease profile which differed from that of ФED01. DNA from two phages, ФED08 and 




5.2.3. Transduction of ermF cassette 
The ability of the isolated bacteriophages to transduce DNA between B. fragilis strains was 
tested by plating bacteriophage lysates onto soft agar overlays inoculated with a strain 
containing an erythromycin resistance gene and incubated anaerobically overnight before 
harvesting (see section 2.11.3). Dilutions of the bacteriophages (0.5μl neat, 1:5, 1:10 and 
1:100), made in phage buffer, were incubated with 100 μl B. fragilis NCTC9343 or 638R, 
grown to OD600 0.6 in BHI-S. Cells were incubated anaerobically for 15 minutes before the 
addition of 500μl BHI-S and incubation for a further 30 minutes.  Cells were pelleted and re-
suspended in 200μl BHI-S, and two 100 μl aliquots of each dilution were spread plated onto 
BHI-S erythromycin (10 μg/ml) plates and incubated for up to three days. Transduction 
experiments were repeated three times for each bacteriophage, but no erythromycin 
resistant colonies were identified. This indicated under these conditions, none of the 
identified bacteriophages were capable of transducing DNA containing the ermF gene. 
 
5.2.4. Transmission electron microscopy  
Transmission electron microscopy was performed to determine phage morphology and 
allow classification (Figure 5.4) (see section 2.9.4).  CsCl purified phage lysate was diluted 
1:100 in PBS, a drop was added to a carbon/formvar-coated grid, and stained with 2% 
uranyl acetate for 30 seconds. Negatively stained preparations of ФED13 (Figure 5.4a), 
ФED02 (Figure 5.4b), ФED15 (Figure 5.4c), ФED07 (Figure 5.4d), ФED04 (Figure 5.4e) and 
ФED08 (Figure 5.4f) clearly showed phage heads and tails of varying length. ФED04 
appeared to have the shortest tail, an average of    6nm, taken from ten phages, over four 
fields of view. The tail lengths of ФED02 and ФED15 were similar (  120-130nm), an average 
measured from 5 and 10 bacteriophage respectively. The tails of ФED13 appeared to be 
longer, however length was difficult to estimate as the tails were curled rather than straight 
(Figure 5.4a). ФED07 and ФED08 were always seen clumped together (Figure 5.4d) or in 
pairs (Figure 5.4f), therefore tail length was not determined. Tail striations were observed 

















Figure 5.4: Transmission electron microscopy of B. fragilis-specific bacteriophage 
 
Electron micrographs of bacteriophage negatively stained in 2% uranyl acetate (a) ФED13, 
(b) ФED02, (c) ФED15, (d) ФED07, (e) ФED04 and (f) ФED08. Tail length ranged from 95nm-







5.2.5. OMV interact with bacteriophage to decrease efficiency of infection 
Manning & Kuehn (2011) hypothesised that bacterial OMV may act as a defence 
mechanism in response to external stressors, including bacteriophage infection. The 
authors demonstrated that the infectivity of T4 bacteriophage reduced following incubation 
with E.coli OMV. The ability of B. fragilis OMV to decrease the efficiency of infection of 
ФED01 and ФED13 was determined. 105 ФED01 were co-incubated with 1μg NCTC 343 
OMV and ФED13 with both NCTC 343 OMV and 638R OMV, for 2 hours at 37°C.  Ten-fold 
serial dilutions were subsequently spotted onto soft agar overlays containing 100μl of the 
appropriate B. fragilis strain and plates were incubated overnight under anaerobic 
conditions. As controls, ФED01 and ФED13 were incubated with 1xPBS under the same 
conditions before dilutions were plated onto NCTC9343 and 638R (Figure 5.5).  The 
experiment was carried out in triplicate, plaques were counted and an average titre was 
calculated. Following incubation with PBS, the average titre of ФED01 on NCTC 343 was 
6x1011 PFU/ml; there was a ten-fold decrease in infection after pre-incubation of ФED01 
with NCTC9343 OMV which had a post-infection titre of 4x1010 PFU/ml (Figure 5.5a). ФED13 
was capable of infecting both NCTC 343 and 638R (Table 5.1, Figure 5.3 ФED13), therefore 
was incubated with NCTC 343 and 638R OMV, respectively. The average titre of ФED13, 
pre-incubated with PBS and spotted onto NCTC9343 was 6x105 PFU/ml. Following 
incubation with NCTC9343 OMV no plaques were visible at any dilution spotted onto 
NCTC 343 (Figure 5.5b). ФED13 infection of 638R did not produce clear plaques of lysis, 
instead hazy zones were visible within the lawn of cells (Figure 5.3 ФED13), possibly due to 
the phage undergoing a lysogenic lifecycle or host cell resistance. These zones were 
observed following pre-incubation of ФED13 with PBS to a dilution of 10-4, however no hazy 
zones were visible following pre-incubation of the phage with 638R OMV (Figure 5.5c). This 





Figure 5.5: B. fragilis OMV interact with bacteriophage. 
 
Ten-fold serial dilutions of bacteriophages pre-incubated with OMV spotted onto soft agar 
overlays containing NCTC 343 or 638R. (a) ФED01 incubated with PBS and NCTC 343 OMV 
spotted onto NCTC 343, (b) ФED13 incubated with PBS and NCTC 343 OMV spotted onto 
NCTC 343, (c) ФED13 incubated with PBS and 638R OMV spotted onto 638R.  
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5.2.6. Development of a recombineering system in B. fragilis 
Recombineering is a genetic engineering system that utilises bacteriophage encoded 
recombination proteins to generate recombinants.  As it is based upon homologous 
recombination, it allows precise sequence alteration with only short segments of DNA 
homology (~ 50bp), eliminating the need for restriction enzymes and DNA ligase used in 
traditional genetic engineering (Sharan et al., 2009). Usually, linear DNA with flanking 
regions encoding sequence homology to the target DNA is generated by PCR, and 
introduced to a strain containing the recombination system via electroporation (Yu et al., 
2000; Copeland et al., 2001).  
Recombineering in E.coli can be mediated either by the λ Red system, which involves three 
phage proteins, Exo, Beta and Gam, or the Rac-encoded RecET system, which contains two 
proteins, RecE and RecT (Court et al., 2002).  Exo and RecE are 5’→ 3’exonucleases which 
degrade linear double-stranded DNA (dsDNA) resulting in a 3’ single-stranded DNA (ssDNA) 
overhang. The exposed 3’ ends are bound by a ssDNA-annealing and strand invasion 
protein, Beta or RecT, which protect the target DNA and facilitate annealing to the 
homologous sequence (van Kessel et al., 2008). The λ Red protein, Gam, enhances the 
efficiency of λ Red-mediated recombination by binding to the RecB subunit of the host 
RecBCD enzyme, therefore inhibiting the degradation of incoming linear dsDNA (Murphy, 
1991; Copeland et al., 2001).  These systems have also been used for genetic manipulation 
of Salmonella and Shigella (Marinelli et al., 2012), however they have been less successful 
in some other bacterial species (van Kessel & Hatfull, 2007; Swingle et al., 2010). 
Genes with homology to bet or recT, encoding putative DNA recombination proteins have 
been identified in phages and prophages of several Gram-positive and Gram-negative 
bacteria. A number of these genes are located next to a putative exonuclease gene, for 
example within Bacillus subtillis- and Mycobacterium-specific bacteriophages and in a 
prophage of Pseudomonas syringae (Datta et al., 2008; van Kessel et al., 2008; Swingle et 
al., 2010).  The use of these proteins in recombineering was demonstrated by van Kessel & 
Hartfull (2007), in which RecE and RecT homologues encoded by mycobacteriophage Che9c 
were utilised to create a recombination system, facilitating the genetic manipulation of 
Mycobacterium spp., including M. smegmatis and M. tuberculosis. Genes which encode 
proteins with homology to RecE and RecT have also been identified within a horizontally 
acquired prophage of P. syringae and are currently being used to develop a recombineering 
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system in this organism. It has been demonstrated that these proteins promote 
homologous recombination of linear dsDNA and ssDNA with the bacterial chromosome, 
following introduction to the cell via electroporation (Swingle et al., 2010; Bao et al., 2012). 
Genetic manipulation of B. fragilis is problematic, mainly due to the extensive R-M systems 
which recognise and cleave foreign DNA.  Therefore the development of alternative 
strategies, such as recombineering, to simplify manipulation of this organism would be 
advantageous.  Analysis of the genome of B. fragilis-specific phage, ФED01, revealed two 
genes which encoded proteins with similarity to RecE and RecT (Figure 5.6a) (G.W. Blakely, 
personal communication). The first of these genes, phirecT (CDS 42965-43609), encoded a 
214aa protein, PhiRecT, with 95% amino acid sequence identity to a putative essential 
recombination protein of Bacteroides phage B40-8. PhiRecT belonged to the ssDNA 
annealing proteins ERF superfamily, of which RecT and λ Beta are also members. The 
second gene, phirecE (CDS 43610-44596), encoded a 328aa protein, PhiRecE, which 
contained a domain from the YqaJ family of phage-encoded exonucleases (Figure 5.6b). 
These genes were utilised with the aim of developing a recombineering system in B. fragilis. 
5.6.1.1. Construction of a PhiRecET expression vector 
To determine the ability of these proteins to mediate homologous recombination within B. 
fragilis, a plasmid containing phirecE and phirecT (pKJ03) was constructed. pKJ03 was 
created using the shuttle vector, pLYL01, which confers ampicillin resistance in E.coli and 
tetracycline resistance in B. fragilis. The bacteriophage genes were placed under the control 
of B. fragilis RpsF ribosomal protein promoter, PrpsF. Primers were designed to amplify 
PrpsF and phirecE-phirecT. The two amplicons were isolated, then fused and amplified via 
crossover PCR using the two outside primers. The PrpsF and phirecET outside primers 
contained KpnI and HindIII restriction sites, respectively. The crossover PCR product and 
pLYL01 were digested with HindIII and KpnI before the fragments were ligated using T4 
DNA ligase. E.coli strain S-17 was transformed with the plasmid and ampicillin resistant 
colonies were selected. Plasmid DNA was extracted from four colonies and analysed by PCR 
using the two outside primers to amplify the bacteriophage genes and subsequent 
restriction endonuclease analysis was carried out with HindIII and KpnI (Figure 5.6c).  
Amplicons of ~1.8kb were detected following PCR with DNA extracted from clones 2-4 
(Figure 5.6ci lanes 3-5). These fragments were similar in size to the digested insert DNA 
used in the ligation (1770 bp) (Figure 5.6ci lane 2). Following digestion of pKJ03 DNA, 
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extracted from clone 3, with KpnI and HindIII (Figure 5.5cii), two DNA fragments of 
approximately 8 kb and 1.8 kb were observed. This correlated with the size of pLYL01 (~8 
kb) and the size of the DNA insert encoding PrpsF, phirecE and phirecT (1.77 kb). The 
construct was verified by Sanger sequencing.  Transformation of B. fragilis NCTC9343 with 
pKJ03 was attempted via electroporation and conjugation (see section 2.6.5.) six times, 
however, no tetracycline resistant colonies were detected. B. fragilis NCTC9343 was 
transformed with pLYL01 as a control, on each occasion tetracycline resistant colonies were 
detected. As a result, the ability of PhiRecE and PhiRecT to mediate homologous 






Figure 5.6: phirecE and phirecT genes of B. fragilis-specific bacteriophage ФED01 
(a)  Artemis genome browser showing phirecE and phirecT encoded by ФED01 (b) PhiRecE is 
a 328aa exonuclease, PhiRecT is a 214 aa, putative essential recombination protein with 
homology to RecT. (c) E.coli strain S-17 was transformed with pKJ03, plasmid DNA extracted 
from ampicillin resistant clones was analysed by (ci) PCR amplification (cii) restriction digest 
and agarose gel electrophoresis to confirm the presence of phirecE-phirecT insert. The first 
lane of each gel contains DNA molecular weight markers. (ci) Lanes: 1, phirecE-phirecT 
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insert DNA; 2, PCR product of clone 1; 3, PCR product of clone 2; 4, PCR product of clone 3; 
5, PCR product of clone 4. (cii) restriction digest analysis Lanes: 1, uncut pLYL01 DNA; 2, 






















Advances in whole genome sequencing have revealed that bacteriophages play an 
important role in the evolution of bacteria. Lytic infection of a host by bacteriophages 
results in multiplication of the phage and lysis of the host cell, however, lysogenic infection 
results in the integration of the bacteriophage genome into the bacterial chromosome as a 
prophage (Canchaya et al., 2003a). Many of the sequenced bacterial genomes contain 
multiple prophages, which can contribute up to 10% of the total DNA in some organisms 
(Brüssow & Hendrix, 2002; Canchaya et al., 2003b). Bacteriophages can contribute to the 
pathogenicity of a bacterium since a number of bacterial virulence factors are phage 
encoded, for example the cholera toxin of Vibrio cholerae or the Shiga toxins of 
enterohemorrhagic E. coli (EHEC) (Wagner & Waldor, 2002). Bacteriophages are also 
important mediators of HGT between bacterial species but can also account for inter-strain 
genetic variability within the same species (Brüssow et al., 2004). One extreme example of 
this was the comparison of the genome of foodborne pathogen E.coli O157 to the genome 
of the reference strain E. coli K12. The genomes of O157and K12 share approximately 4.1 
Mb of highly conserved sequence, however O157 contains 1.3 Mb of DNA not found in the 
reference sequence. Bacteriophages have played a prominent role in diversity; the genome 
of O157 contains 18 prophages and prophage remnants which account for half of the DNA 
identified in this strain that is absent from K12 (Ohnishi et al., 2001; Brüssow & Hendrix, 
2002). Patrick et al (2010) demonstrated that the genomes of B. fragilis NCTC9343, 638R 
and YCH46 contained a number of phage-related regions. This observation was also made 
for the genomes of the four newly sequenced strains described in Chapter 3. This 
demonstrates that bacteriophages have played a role in the within-strain variation of this 
organism. 
Due to their ability to mediate the transfer of DNA between bacterial cells, bacteriophages 
have been utilised in the development of a number of molecular techniques. Transducing 
phages are a useful tool for genetic engineering and genomic analysis of their host bacteria 
and they have been identified for a number of bacterial species, including E. coli and 
Salmonella. Due to the difficulties of genetic manipulation of B. fragilis, the identification of 
a generalised transducing phage for this organism would be a useful tool.  
Fifteen potentially new B. fragilis-specific bacteriophages were isolated from sewage from 
the Edinburgh area. Phage titres and restriction endonuclease cleavage profiles indicated 
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that seven of these bacteriophages may be similar to a previously identified phage, ФED01. 
A further seven bacteriophages displayed unique restriction endonuclease profiles which 
differed to both ФED01, suggesting they were potentially new bacteriophages. However, 
further analysis of this by genome sequencing would be required to confirm this. 
Unfortunately, none of the identified bacteriophage were capable of transduction, meaning 
to date, a generalised transducing phage has not been identified for B. fragilis. 
In addition to transduction, bacteriophages have also been utilised to create other genetic 
tools, such as recombineering (see section 5.2.6). The genome of ФED01 contained two 
genes which encoded homologues of the RecE and RecT proteins of the RecET system. An 
expression vector containing these genes was constructed to determine the potential to 
develop a recombineering system for B. fragilis. Attempts to transform B. fragilis NCTC9343 
with this plasmid were unsuccessful, however, these proteins may have been toxic to host 
cells, especially since a potentially strong promoter was used for expression. The construct 
may have interfered with homologous recombination of replication forks within the cell.  It 
is possible that the bacteriophages isolated in this study may also contain genes encoding 
















6. General Discussion 
The human gastrointestinal tract is colonised by a large population of diverse bacteria, 
which is estimated to be >1014 organisms, representing >1000 different species (Liu et al., 
2008). Most of the interactions between these bacteria and the host are mutually beneficial 
rather than pathogenic. Commensal organisms inhabit a protected, nutrient-rich 
environment and in turn they play a role in the development of the host immune system 
and carry out essential functions within the host (Troy & Kasper, 2010). One function 
performed by the intestinal microbiota, including B. fragilis, is the degradation of complex 
plant polysaccharides, which are otherwise non-digestible by the host (Hooper & 
Macpherson, 2010). Degradation of these polysaccharides into short-chain fatty acids 
provides the host with ≥10% of their daily absorbed calories,  and in return the bacteria are 
provided with an abundant carbon source (Hooper et al., 2002). Commensal organisms, 
such as the Bacteroides, have evolved to harvest these nutrients as demonstrated by the 
presence of the large number of genes which encode carbohydrate-degrading enzymes (Xu 
& Gordon, 2003). For example, the genome of B. thetaiotaomicron encodes 64 enzymes 
known to degrade xylan, pectin or arabinose, which are common components of plant cell 
walls and are indigestible by the host (Sonnenburg et al., 2005). 
In addition to carbohydrate degradation, several members of the intestinal Bacteroidales, 
including B. thetaiotaomicron, B. uniformis and B. fragilis, encode a large number of 
polysaccharide biosynthesis loci, from which they can synthesise and express capsular 
polysaccharides (Coyne & Comstock, 2008).  Polysaccharides produced by B. fragilis are 
important in the development and activation of the host immune system. PSA, a 
zwitterionic polysaccharide produced by some strains of B. fragilis, induces the splenic 
development of CD4+ T cells via IL-10 stimulation in mice (Mazmanian et al., 2005; 
Mazmanian et al., 2008; Round & Mazmanian, 2010). This induces an immunotolerance 
effect, which protects mice from experimental colitis and promotes colonisation by B. 
fragilis (Round et al., 2011). PSA interacts with the host via OMV, which are internalised by 
dendritic cells. OMVs isolated from a PSA deletion strain do not stimulate anti-
inflammatory cytokine production (Shen et al., 2012).  In addition to interactions with the 
host immune system, B. fragilis capsular polysaccharides are important in colonisation of 
the GI-tract. Coyne et al (2008) demonstrated that the presence of a single polysaccharide 
was sufficient for a mutant strain to effectively compete with wild-type B. fragilis when co-
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inoculated into a gnotobiotic mouse. However, these findings were contradicted by 
evidence which suggested strains expressing a single polysaccharide were not competitive 
with wild-type B. fragilis for colonisation of the GI-tract (Liu et al., 2008). These authors 
demonstrated that mutant strains expressing only PSA, PSB or PSC were quickly 
outcompeted by wild-type B. fragilis. Mutants expressing only one polysaccharide also 
displayed growth attenuation, suggesting multiple capsular polysaccharides are not only 
required for effective colonisation of the GI-tract by B. fragilis but also growth of the 
organism.  
The genomes of three previously sequenced B. fragilis strains, NCTC9343, 638R and YCH46 
each encoded ten polysaccharide biosynthesis loci, only two of which were conserved 
between two strains (Patrick et al., 2010). The genomes of four further B. fragilis strains, 
RD48, BE1, GNAB92 and LS66 were sequenced and analysed during this study. BE1 and 
GNAB92 contained ten polysaccharide biosynthesis loci divergent from those previously 
identified in NCTC9343, 638R and YCH46, meaning, between five B. fragilis strains there is 
the potential to express 38 different polysaccharides. A further three possible divergent 
polysaccharide biosynthesis loci were identified within the genome of strain LS66. 
However, analysis of this strain was limited due to problems with genome assembly. The 
expression of such a large number of capsular polysaccharides has not been observed 
before. Coyne & Comstock (2008) demonstrated that the variation in polysaccharide 
expression is not conserved in members of the Bacteroidales which colonise the oral cavity, 
suggesting there is a selective pressure for polysaccharide diversity within the GI-tract. 
Bacteriophages are estimated to outnumber their bacterial hosts ten-fold (Brüssow & 
Hendrix, 2002), therefore, to survive in the GI-tract, commensal organisms have evolved  
strategies to avoid bacteriophage infection. Due to the variation in bacteriophage genomes 
and their high rates of evolution, bacteria need diverse anti-phage mechanisms to prevent 
processes such as bacteriophage adsorption or entry and expression of foreign DNA into 
the bacterial cell. Finally, if bacteriophages circumvent these barriers then abortive 
infection systems trigger bacterial cell ‘suicide’, preventing bacteriophage multiplication 
(Bikard & Marraffini, 2012). The first step in bacteriophage infection is adsorption to the 
host cell, in which phages recognise a specific-host cell component (Weinbauer, 2004). 
Bacterial capsules can present an effective physical barrier to bacteriophage adsorption, for 
example, E. coli strains expressing the K1 polysaccharide capsule are resistant to infection 
138 
 
by bacteriophage T7. Removal of the capsule allows adsorption and replication (Scholl et 
al., 2005). Some bacteriophages have evolved ways to penetrate the bacterial capsule, such 
as the expression of polysaccharide degrading enzymes (Sutherland et al., 2004), however, 
it has been demonstrated that these enzymes are very specific and only act on a small 
number of closely related polysaccharide structures (Hughes et al., 1998). Phase variation 
of capsular polysaccharides may be a mechanism to avoid the degradative enzymes 
encoded by bacteriophages.  Variation in the surface components of the bacterial cell can 
also block host-specific bacteriophage receptors, therefore preventing adsorption. Different 
bacterial surface components have been identified as receptors for bacteriophages, 
including LPS and capsular polysaccharides (Xu et al., 2013). LPS has been shown to act as 
receptor for phage which infect several Gram-negative bacteria, including E. coli, 
Salmonella, V. cholerae and Campylobacter jejuni (Lindberg & Hellerqvist, 1971; Zhang et 
al., 2009; Sørensen et al., 2011; Xu et al., 2013). Lytic bacteriophage VP4 which infects V. 
cholerae serogroup O1 uses the O-antigen as its receptor. Xu et al (2013) demonstrated 
that mutations in the O-antigen biosynthesis genes resulted in changes to the O-antigen 
and prevented adsorption of the phage. The capsular polysaccharides of C. jejuni have been 
identified as the binding receptor of multiple C. jejuni-specific bacteriophages and 
mutations in several of the capsular polysaccharide genes resulted in phage resistance 
(Coward et al., 2006). Sørensen et al (2012) demonstrated that the phase variable 
expression of a moiety present in the capsular polysaccharide of C. jejuni prevented the 
adsorption of bacteriophage F336. The variation in surface components of B. fragilis may 
similarly convey resistance to bacteriophage infection in the GI-tract by removing the host-
specific bacteriophage receptors.  
Following adsorption, bacteriophage DNA is injected into the bacterial cell. To prevent this, 
bacteria encode R-M systems which protect the cell from incoming foreign DNA. However, 
bacteriophages have evolved mechanisms to subvert these systems. Host cell DNA is 
methylated, therefore not recognised and cleaved by R-M systems, unlike unmethylated 
bacteriophage DNA. However, when phage DNA is methylated it is no longer recognised by 
the bacterial R-M systems, the new virions produced will be resistant to restriction and can 
easily infect cells containing the same R-M system. The bacteriophage DNA will remain 
methylated until the phage encounters a cell encoding a different R-M system, at which 
point the DNA once again becomes susceptible to restriction (Bikard & Marraffini, 2012). 
Some bacteriophages have acquired methylase encoding genes or can stimulate host 
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encoded methylases to confer protection to the bacteriophage DNA and so overcome host 
R-M systems (Kruger & Bickle, 1983; McGrath et al., 1999). Diversity in R-M systems may be 
a mechanism by which bacteria can counteract this phage resistance mechanism. Diverse R-
M systems increase the likelihood that methylated bacteriophage DNA will encounter a 
different R-M system and once again become susceptible to cleavage. Bacteriophages can 
also avoid restriction systems by changes to the DNA sequence which subsequently remove 
endonuclease restriction sites, usually via the accumulation of point mutations (Labrie et 
al., 2010). A reduction in the number of sites can enable phage to avoid cleavage, for 
example, the enzyme EcoRII can only cleave when it binds two target sequences, however, 
the large distance between EcoRII sites in the genomes of phage T3 and phage T7 results in 
resistance to cleavage by the endonuclease (Tock & Dryden, 2005). Restriction 
endonuclease sites can also be completely absent from bacteriophage genomes, for 
example, Staphylococcus phage K has no Sau3A sites within its genome (Labrie et al., 2010).  
Another bacteriophage anti-restriction system is the presence of unusual bases within the 
genome. Bacteriophage T4 is nearly devoid of cytosine residues, which are replaced by the 
unusual base hydroxymethylcytosine, T4 is therefore resistant to R-M systems that 
recognise sequences containing a cytosine (Stern & Sorek, 2011). Some bacteriophages 
encode proteins which target and inhibit host restriction endonuclease genes. Ocr 
(overcomes classical restriction activity) is one of the first proteins expressed by 
bacteriophage T7 following injection of its genome into the host cell. Ocr binds to the active 
site of type I R-M enzymes and inhibits their activity, therefore preventing restriction of the 
phage genome (Atanasiu et al., 2002). A similar protein encoded by the bacteriophage T3 
inhibits the activity of type I R-M systems and type III R-M systems (Labrie et al., 2010).   
B. fragilis strains NCTC9343, 638R and YCH46 encode a number of R-M systems which act 
as a barrier to bacteriophage infection. NCTC9343 encodes a type I R-M shufflon which can 
recognise eight different DNA specificities (Cerdeño-Tárraga et al., 2005). The ability to 
quickly switch between DNA specificities could provide an advantage to the organism 
during phage infection. Type I R-M systems are composed of three subunits: a restriction 
enzyme (HsdR), a methylase (HsdM) and a specificity determinant (HsdS), which determines 
the DNA sequence to bind (Murray, 2000). The B. fragilis NCTC9343 shufflon in the hsdS 
gene has eight recombination sites which could potentially lead to the formation of eight 
different hsdS genes, therefore eight different DNA specificities. Another type I R-M 
shufflon was identified in B. fragilis 638R (Patrick et al., 2010) and a similar shufflon was 
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identified in the genome of the newly sequenced strain GNAB92. In addition to the type I 
shufflons, the genomes of B. fragilis NCTC9343, 638R, YCH46 and strains sequenced in this 
study, GNAB92, BE1, RD48 and LS66 contain a number of other type I, type II and type III R-
M systems. The variation in restriction systems present in B. fragilis may enhance survival 
of the organism by preventing bacteriophage infection. Another mechanism by which 
bacteria resist bacteriophage infection is through abortive infection systems, which are 
toxic and lead to the death of the bacterial cell thus preventing bacteriophage proliferation 
and protecting the population from infection (Labrie et al., 2010). The Rex abortive 
infection system is found in E. coli strains which are susceptible to bacteriophage λ. 
Infection results in the activation of RexB, which produces an ion channel that reduces 
membrane potential. This leads to a reduction in cellular ATP and cell division is halted. In 
turn phage infection, which requires ATP, will also abort (Parma et al., 1992).  
Bacteria-encoded phage defence mechanisms display a high level of genetic variability, 
driven by the rapid evolution of bacteriophage genomes, which places a selective pressure 
upon bacteria to evolve strategies to evade infection and killing by bacteriophages (Stern & 
Sorek, 2011). The variation in polysaccharide biosynthesis loci and R-M systems observed in 
the three previously sequenced genomes of B. fragilis, and the four genomes sequenced 
and analysed in this study, may convey resistance to bacteriophage infection and therefore 
promote survival of the organism in the GI-tract.  
In addition to being a member of the gut microbiota, B. fragilis is an opportunistic pathogen 
and the most commonly isolated anaerobic organism from intra-abdominal abscesses 
(Wexler, 2007). The capsular polysaccharides of B. fragilis are a major virulence factor and 
at least one of these polysaccharides had been linked to abscess formation. Coyne et al 
(2000) demonstrated that PSB, purified from B. fragilis NCTC9343, alone induced abscess 
formation. The MC is also involved in complement resistance and the large capsule has 
been associated with resistance to phagocytic uptake and killing (Patrick et al., 2010). 
Variation in the cell surface components of B. fragilis may also enhance the survival of the 
organism when it escapes the GI-tract and causes infection, however, in comparison to 
other Bacteroidetes which also encode phase-variable polysaccharides, B. fragilis is more 
commonly isolated from opportunistic infections. This may be due in part to the presence 
of other horizontally acquired virulence factors.  
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Genome sequencing has revealed that a number of bacterial virulence factors are encoded 
by horizontally acquired mobile genetic elements such as prophages, plasmids and genomic 
islands (Pallen & Wren, 2007). For example, the anthrax toxin of Bacillus anthracis and the 
Type III secretion system of Shigella spp. are plasmid encoded (Hueck, 1998; Okinaka et al., 
1999), while the Type III secretion systems of enteropathogenic and enterohaemorrhagic E. 
coli are encoded by a pathogenicity island (Elliott et al., 1998). A number of virulence 
factors are encoded by bacteriophage genomes which have integrated into the host 
chromosome such as diphtheria toxin of Corynebacterium diphtheriae and cholera toxin of 
V. cholerae (Freeman, 1951; Wagner & Waldor, 2002). In addition to capsular 
polysaccharides, B. fragilis has a number of other virulence factors which may play a role in 
its success as an opportunistic pathogen, including the release of degradative enzymes such 
a fibrinogenolysin and enterotoxin production (Patrick et al., 2010). B. fragilis induces 
abscess formation, which is an important host mechanism to contain bacteria and limit the 
spread of infection. The main component involved in abscess formation is fibrinogen. B. 
fragilis strains NCTC9343, 638R and YCH46 which have been shown to bind human 
fibrinogen, encode a putative fibrinogen-binding protein and have fibrinogenolytic activity 
(Houston et al., 2010). The genomes of the four strains sequenced in this study also encode 
putative fibrinogen-binding proteins. Houston et al (2010) demonstrated that supernatant 
isolated from LS66 degraded human fibrinogen, which demonstrates a potential 
mechanism by which B. fragilis evades host abscess formation so leading to dissemination 
of infection. A subset of B. fragilis strains, termed enterotoxigenic B. fragilis, encode an 
exotoxin (BFT) which has been associated with an acute form of disease, characterised by 
diarrhoea and loss of appetite in children, adults and livestock (Franco et al., 1999). The 
enterotoxin gene has been identified in strains isolated in a number of different countries, 
including USA, Japan and Italy. bft was also detected in 18% of clinical isolates tested from 
the UK, Poland, France and Holland (Luczak et al., 2001). The bft gene is found in a 
pathogenicity locus which is contained within a conjugative transposon (Franco, 2004). The 
genome of NCTC9343 encodes a similar conjugative transposon but does not contain the 
pathogenicity locus. Of the four newly sequenced genomes, only one, GNAB92 encoded the 
bft pathogenicity locus, while RD48 contained the same conjugative transposon identified 
in NCTC9343. The location of bft within a conjugative element implies this virulence factor 
was horizontally acquired and may contribute to B. fragilis pathogenicity. However, the 
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identification of the gene in only a small proportion of clinical isolates suggests there may 
not be a significant selective advantage to ensure dissemination of the gene. 
B. fragilis encodes and expresses a unique homologue of the eukaryotic protein-modifier, 
ubiquitin. The ubb gene is located within an 11 kb, low GC content region in comparison to 
the backbone sequence and the closest DNA sequence homology is to a Grasshopper 
entomopox virus, suggesting acquisition of this gene was via inter-kingdom HGT. The ubb 
gene is predicted to encode a 76 amino acid protein, termed BfUbb, with 63% identity to 
human ubiquitin. This is the first example of ubiquitin being produced by a prokaryote. 
Ubiquitin plays a key role in a number of eukaryotic cellular processes, including protein 
degradation, endocytosis, DNA repair and regulation of the immune system. The role of 
BfUbb has yet to be determined, but ubb has evolved additional features which 
differentiate the encoded protein from human ubiquitin. BfUbb contains a signal sequence 
which results in the transport of the protein across the inner membrane to the periplasm of 
the cell; this in addition to the detection of BfUbb in concentrated supernatants suggests 
BfUbb may be packaged into OMV. Recently it has been shown that in addition to 
colonisation of the lumen of the GI-tract, B. fragilis also colonises the colonic crypts of 
mono-colonised mice (Round et al., 2011), and B. fragilis OMV are phagocytosed by 
dendritic cells (Shen et al., 2012). B. fragilis ubiquitin may be delivered to host cells by OMV 
and may interact with the host ubiquitylation pathway to aid the survival of the organism as 
a member of the resident microbiota or as an opportunistic pathogen.  
Commensal bacteria have been shown to interfere with the host pro-inflammatory 
response, of which ubiquitin in an integral component, to maintain homeostasis in the GI-
tract. Preserving the balance between regulation of the host immune response and 
inflammation is an essential function of the microbiota as overstimulation of anti-
inflammatory pathways can lead to increased colonisation by pathogens and chronic 
inflammation can cause autoimmune diseases such as IBD (Kubinak & Round, 2012).  
Commensals can have an anti-inflammatory effect on the host immune system through the 
inhibition of NF-κB activation. For example, B. thetaiotaomicron and Faecalibacterium 
prausnitzii both act upon the NF-κB signalling pathway to reduce NF-κB activation, 
therefore dampening the host inflammatory response (Kelly et al., 2004; Sokol et al., 2008). 
BfUbb may have an anti-inflammatory effect of the host immune system, possibly through 
the inhibition of NF-κB activation, to aid in maintenance of gastrointestinal homeostasis. In 
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contrast, BfUbb may have a pro-inflammatory effect on the host immune system by 
interfering with the ubiquitylation pathway to stimulate NF-κB activation and therefore aid 
B. fragilis pathogenesis. In addition, the causes of IBD are not yet fully understood, 
although, a number of cellular signalling pathways, such as NOD2 have been implicated, in 
which ubiquitin plays an important role (Abbott et al., 2004). Could BfUbb be a driver of 
autoimmune diseases by interfering with ubiquitin or ubiquitin-bound proteins within the 
host inflammatory pathways, therefore generating an autoimmune response? 
Furthermore, the mis-regulation of ubiquitin has been associated with a number of 
diseases such as cancer and neurodegenerative disorders. Could BfUbb be involved in the 
development of these diseases? 
The organisms of the human GI-tract establish long-term, mutualistic relationships with the 
host. To survive within this specific niche, bacteria must successfully compete with other 
members of the microbiota for nutrients and space and withstand attacks from 
bacteriophages. B. fragilis has evolved a number of features which have aided the organism 
in establishing itself as a predominant member of the gastrointestinal microbiota. These 
features include the synthesis of phase-variable polysaccharides which play a role in 
colonisation and prevention of bacteriophage adsorption and diverse and variable R-M 
systems which may convey resistance to bacteriophage infection. B. fragilis has also 
evolved to utilise ingested plant-derived polysaccharides, allowing the organism access to 
nutrients not available to some other members of the microbiota. The presence of a 
number of mobile genetic elements such as transposons, insertion sequences and phage-
related regions, within the genome of B. fragilis suggests this organism has undergone 
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This report summarizes the case of a 23 year-old otherwise healthy male that was injured in an
improvised explosive device (IED) blast in support of Operation Enduring Freedom (OEF). He sustained
bilateral open tibia and fibula fractures in the setting of being exposed to water contaminated with raw
sewage. Despite long-term carbapenem therapy, the patient’s wounds were repeatedly noted to have
purulent drainage during surgical debridement and cultures from these wounds were persistently
positive for Bacteroides fragilis. Apparent clinical failure persisted despite the addition of metronidazole
to his regimen and an eventual trial of tigecycline.
Susceptibility testing of the B. fragilis isolate was performed and resistance to penicillin, clindamy-
cin,metronidazole, cefoxitin, meropenem, imipenem, piperacillin/tazobactam, and tigecycline was
confirmed. The presence of a nimE gene on a potentially transferrable plasmid was also confirmed by
plasmid sequencing. The only antibiotics that displayed in vitro susceptibility were moxifloxacin and
linezolid. These antibiotics were initiated in combination with aggressive irrigation and serial surgical
debridement. Conversion to left-sided internal fixation became feasible and his left lower extremity was
salvaged without residual evidence of infection. The patient completed an eight week course of
combination moxifloxacin and linezolid therapy without adverse event.
This B. fragilis isolate displayed simultaneous high-level resistance to multiple antibiotics routinely
utilized in anaerobic infections. This was evidenced by clinical failure, in vitro susceptibility testing, and
demonstration of genes associated with resistance mechanisms. This case warrants review not only due
to the rarity of this event but also the potential implications regarding anaerobic infections in traumatic
wounds and the success of a novel treatment regimen utilizing combination therapy with moxifloxacin
and linezolid.
Published by Elsevier Ltd.1. Introduction
Bacteroides species are normally commensal in human colonic
microbiota; however, infections with these bacteria can be associ-
ated with significant morbidity and mortality. The most commonly
isolated Gram-negative anaerobic pathogen, Bacteroides fragilis, has
potent virulence factors and has been associated with a variety of: þ1 202 782 3765.
(J.E. Sherwood), susan.fraser@
.patrick@qub.ac.uk (S. Patrick).
ace, Burtonsville, MD 20866,
r Ltd.clinical syndromes including intra-abdominal sepsis and necro-
tizing skin and soft tissue infections. B. fragilis also has an under-
appreciated ability to develop several different mechanisms of
resistance to universally utilized antimicrobials due to mobile
genetic elements [1]. Susceptibility profiles can vary widely
between different geographical locations and medical institutions.
In the United States, multi-drug resistance is rare and anaerobic
susceptibility testing is usually only pursued for specific surveil-
lance purposes or due to extraordinary clinical circumstances.
In 2004, a national survey of the susceptibility patterns of
B. fragilis was conducted in the United States. 5225 clinical isolates
from 10 different medical centers were reviewed. Resistance to
carbapenems and beta-lactam plus beta-lactamase inhibitor
Table 1
Minimum inhibitory concentrations (MIC) in mg/ml of 12 antibiotic/antibiotic
combinations for a Bacteroides fragilis wound isolate.
Antibiotic MIC Interpretation
Penicillin > 256 Resistant
Ampicillin and sulbactam > 128/64 Resistant
Piperacillin and tazobactam > 64/4 Resistant
Clindamycin > 128 Resistant
Metronidazole > 64 Resistant
Cefoxitin > 64 Resistant
Imipenem > 32 Resistant
Meropenem > 32 Resistant
Tigecycline > 16 Resistant
Chloramphenicol > 32 Resistant
Moxifloxacin < 0.5 Susceptible
Linezolid < 2 Susceptible
Susceptibility testing was performed by E-test (which antibiotics) and by agar
dilution (which antibiotics).
J.E. Sherwood et al. / Anaerobe 17 (2011) 152e155 153combinations was found in less than 1% of the total isolates while
only one isolate in this report was resistant to metronidazole.
However, rates of resistance to carbapenems and beta-lactam plus
beta-lactamase inhibitor combinations have been increasing in
more recent reviews [2]. In 2005, Wareham et al. [3] reported the
isolation of a B. fragilis strain (WI1) that was simultaneously
resistant to carbapenems, beta-lactam plus beta-lactamase inhib-
itor combinations, and metronidazole in a patient who ultimately
died from complications related to anaerobic sepsis. Subsequent
genetic analysis of this isolate confirmed the presence of a carba-
penemase gene (cfiA), macrolide-lincosamide-streptograminin
resistance associated gene ermF, a plasmid-located tetracycline
resistance tetQ, and increased efflux pump gene expression among
several mechanisms of resistance [4]. 12 (6.9%) of 175 clinical
B. fragilis isolates in another review from the United Kingdomwere
positive for carbapenemase gene (cfiA) indicating that these
isolates could potentially convert to high-level resistance when
placed under selective pressure [5]. In blood stream B. fragilis
isolates from National Taiwan University Hospital rates of resis-
tance to ampicillin plus sulbactam, clindamycin, and carbapenems
have also been found to be increasing over time [6]. Given the
clinical importance of appropriate empiric antimicrobial selection
for the treatment of anaerobic infections, these reports of resistance
in B. fragilis isolates are particularly worrisome.
2. Case report
The patient in this review was a 23 year-old previously
healthy United States Army soldier who sustained multiple
injuries in an improvised explosive device (IED) blast in
Afghanistan during the summer of 2009. He was riding in an
armored patrol when the explosion occurred. The vehicle he was
in rolled over into a local stream believed to be contaminated by
raw sewage. There were known open sewer systems in the area
and the patient himself reported visible pollution. He was
submerged in water up to his neck for several minutes while
awaiting initial medical care. His injuries included a C5/C6
cervical fracture, a right femoral fracture, and bilateral open tibia
and fibula fractures. By the time he arrived at Landstuhl Regional
Medical Center (LRMC) in Germany two days after this initial
injury his lower extremity wounds were noted to have foul odor.
He underwent multiple surgeries while at LRMC to include right
femoral intramedullary nail placement, external fixation of his
bilateral tibia and fibula fractures, a left lower extremity fas-
ciotomy, and several wound irrigation and debridement proce-
dures. Meropenem 1 g intravenously every 8 h was initiated
empirically shortly after his admission to LRMC and antibiotic
beads containing vancomycin and tobramycin were placed intra-
operatively. Wound cultures grew both an extended spectrum
beta-lactamase (ESBL) Escherichia coli and B. fragilis.
After his arrival at Walter Reed Army Medical Center (WRAMC)
in the United States approximately one week after his initial injury,
the patient’s bilateral lower extremity wounds continued to
produce purulent drainage despite serial irrigation and debride-
ment and continuation of broad-spectrum antibiotic therapy with
meropenem. B. fragilis bacteremia was transiently detected on
admission to WRAMC although B. fragilis was not found on several
subsequent blood cultures. Metronidazole 500 mg intravenously
every 6 h was added to his antibiotic regimen, but despite this
intervention the patient’s right lower extremity could not be
salvaged and he required amputation below the right knee three
weeks into his WRAMC hospital course. In order to salvage his left
leg, internal fixation of his left tibia fracture was completed and
continuous wound irrigation with Dakin’s solution was initiated.
The predominant organism from intra-operative wound culturesremained B. fragilis. Due to refractory anaerobic wound infection
despite nearly four weeks of meropenem therapy, the patient was
transitioned to empiric tigecycline 1 gm intravenously every 12 h
and anaerobic susceptibility testing was pursued.
2.1. Microbiology
The patient’s initial wound cultures from his left lower
extremity were positive for an ESBL E. coli and B. fragilis. He had an
isolated blood culture one week later that was also positive for
B. fragilis, although several follow up blood cultures were negative
indicating that this bacteremia was transient. In addition, antibiotic
susceptibility testing of his blood stream isolate revealed a pheno-
typically different strain that was susceptible to carbapenems.
However, a total of eight wound cultures from serial irrigation and
debridement procedures from bilateral lower extremities were
positive for B. fragilis. This occurred while the patient was on
meropenem and metronidazole therapy.
The susceptibility testing performed by Quest Diagnostics by “E”
test and at the R.M. Alden Research Laboratory by the agar dilution
method [7] on one of the patient’s B. fragilis wound isolates from
WRAMC is summarized in Table 1.
A retrospective analysis of his very first wound B. fragilis isolate
by the R.M Alden Research Laboratory revealed identical high-level
multi-drug resistance (MDR). The isolate was also analyzed for
plasmid content and found to contain two plasmids: a 5.5 kb
plasmid identical to pHAG isolated from a multi-drug resistant
B. fragilis in London UK [4] and the Class III plasmid pBFB35 [8] and
also an 8.3 kb plasmid (designated pWAL610) with confirmed
similarity to the sequenced fragment of pBF388c, an 8.3 kb plasmid
present in ametronidazole resistant B. fragilis isolated in Kuwait [9].
The 8.3 kb pWAL610 was fully sequenced and annotated (Fig. 1).
The nitroimidazole resistance gene nimE is 100% identical to the
nimE gene in pBF388c. A transposase, 99% identical to tranposase
Bf6 of pBF388c, was identified and also located within an IS4 family
insertion sequence.
2.2. Clinical course
Based on ongoing clinical evidence of infection and available
susceptibility data tigecycline was discontinued after only a few
days of therapy in favor of combination therapy with both moxi-
floxacin and linezolid. Moxifloxacin 400 mg intravenously every
day and linezolid 600 mg intravenously twice daily were initiated
and transitioned to an oral route of administration when his
scheduled surgeries became less frequent. Both agents were
utilized simultaneously due to concerns regarding demonstration
Fig. 1. Artemis DNA plotter image of the 8.3 kb pWAL610 isolated and sequenced from
the patient’s B. fragilis isolate (WAL610). Circular tracks from outside to inside: 1, DNA
co-ordinates; 2, forward strand putative coding sequences; 3, reverse strand putative
coding sequences; 4, insertion sequence ISBf6; 5, inverted repeats.
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therapeutic options. Due to the depth of invasion and the presence
of hardware, this antibiotic regimen was continued for an 8 week
total duration without adverse effect and with complete resolution
of signs and symptoms of infection. The patient’s left lower
extremity was saved and upon discharge from the hospital he was
ambulating with the use of right lower extremity prosthesis.
3. Discussion
B. fragilis infections are generally endogenous, arising from the
patient’s own normal microbiota [10]. In this case, however, it
seems likely that the infectionwas environmentally acquiredwhich
is highly unusual. Although B. fragilis is an obligatory anaerobic
bacterium that cannot be cultivated in the presence of oxygen, it is
aero-tolerant and able to survive for a several hours under aerobic
conditions [11]. This case demonstrates how underlying problems
regarding the lack of infrastructure in Afghanistan have impacted
the medical support mission in Operation Enduring Freedom (OEF).
In the urban areas of Afghanistan specifically it is estimated that
only 12e23% of the population has access to a safe source of
drinking water. With the notable exception of one wastewater
treatment facility near the city of Kabul, wastewater collection and
treatment are virtually non-existent throughout the country. As
a result, open sewer systems are commonplace [12]. The confir-
mation of identical high-level resistance in the patient’s first clin-
ical isolate of B. fragilis suggests an environmental source of the
MDR isolate as opposed to treatment-induced resistance. It is
highly likely that the MDR B. fragilis arose from within the local
human population and that the water the patient was exposed to
was contaminated through this population’s utilization of an open
sewer system. The presence of a 5.5 plasmid identical in sequence
to a plasmid that is widespread across Europe and partial identity
to an 8.3 plasmid identified in isolates from Europe and Kuwait is
also intriguing.B. fragilis and taxonomically related Bacteroides species are
usually resistant to benzylpenicillin, other penicillins and, with the
exception of cephamycins such as cefoxitin, many cephalosporins.
Classically, resistance to penicillin in B. fragilis is associated with the
production of active site serine beta-lactamases distantly related to
Ambler’s Class A. These beta-lactamases are susceptible to the
inhibitory effects of compounds such as clavulanic acid, sulbactam
and tazobactam. Resistance genes, for example cepA, may be
plasmid or chromosomally located, and on mobile or mobilisable
genetic elements. Similarly, the cfxA gene which encodes a cepha-
losporinase that degrades cephalosporins, penicillins and cefoxitin
is located on a mobilisable transposon, Tn4555. Some B. fragilis
strains produce a zinc requiring metallo-beta-lactamase of
Ambler’s Class B, associated with resistance to cephamycins and
carbapenems. These enzymes are resistant to the beta-lactam
inhibitors and are associated with the chromosomally encoded
gene cfiA (ccrA). Furthermore, macrolide (e.g. erythromycin), lin-
cosamide (e.g. clindamycin) and streptogramin (e.g. pristinamycin,
virginiamycin) resistance is transferrable within and between
Bacteroides spp. via conjugative plasmid transfer and also chro-
mosomally located self-transmissible conjugative elements [13].A
wide range of metronidazole resistance mechanisms have been
described (e.g. Patel et al., 2009; Steffens et al., 2010) in addition to
the nim (A-F) encoding genes [14e16]. Unlike the MDR B. fragilis
WI1 isolated in London in 2004, the isolate presented in this review
possesses a nim gene (nimE) located on a potentially mobile
plasmid. TheWI1 isolate demonstrated resistance tometronidazole
without expression of a nim gene, an ability attributed to this
isolate’s enhanced efflux pump mechanisms. Similarly, efflux
mechanisms and modifications of topoisomerase genes can
contribute to fluoroquinolone resistance [4]. Of course, theWAL610
isolate did not demonstrate resistance to fluoroquinolones in vitro
and a combination of both moxifloxacin and linezolid was the final
successful treatment regimen.
Linezolid is traditionally thought of as a therapeutic option for
resistant Gram-positive organisms such as methicillin-resistant
Staphylococcus aureus and vancomycin-resistant Enterococcus.
However, it may also have efficacy in treatment of resistant
anaerobic infections. In one review evaluating the minimal inhi-
bition concentrations (MIC’s) for linezolid among 265 different
anaerobes, the MIC range for the B. fragilis group was found to
consistently range between 2 and 4 mg/l. The authors discovered
no linezolid-resistant strains, suggesting that linezolid may be
a potential candidate for the treatment of anaerobic infections [17].
Although most Gram-negative bacteria are resistant to linezolid as
a result of endogenous efflux activity, another review examining
MIC’s for linezolid among Bacteroides species reported MIC’s
between 4 and 8 mg/L [18]. Of note, the WI1 case patient was also
treated with linezolid therapy with apparent microbiological cure
although the patient did not survive [3].
The reports over the past several years regarding drug-resistant
B. fragilis isolates in clinical settings is concerning, especially when
an isolate such as WAL610 reveals the ability to simultaneously
express multiple different mechanisms of resistance. WAL610
closely resembles the MDR WI1 in this regard, although the
mechanism of metronidazole resistance appears to be different.
Further genetic analysis of the MDR B. fragilis WAL610 is underway
to determine the mechanisms that generate resistance to the other
antibiotics. While MDR B. fragilis have not previously been reported
in United States, the very existence of isolates such as WAL610 and
WI1 raises serious concerns regarding the eventual spread of
resistance mechanisms and selection of empiric antibiotic therapy
in anaerobic infections. The Clinical Laboratory Standards Institute
(CLSI) does not recommend routine susceptibility testing for clini-
cally encountered anaerobes although testing is recommended to
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serious or life-threatening infections” and “persistence of infection
despite adequate treatment with an appropriate therapeutic
regimen” [7]. The diagnosis of a multi-drug resistant isolate in this
case was delayed in part due to the time it took to arrange adequate
anaerobic susceptibility testing through appropriate reference
laboratories.4. Conclusion
MDR B. fragilis is a truly rare clinical pathogen in the United
States, although Bacteroides species certainly exhibit chromoso-
mally mediated and plasmid-encoded resistance mechanisms and
readily acquire resistance genes via mobile and mobilisable genetic
elements. There are reports of increasing rates of resistance to beta-
lactam and beta-lactamase inhibitor combinations and carbape-
nems throughout the world. While there has been much attention
placed on MDR pathogens associated with traumatic war wounds
from Iraq and Afghanistan such as Acinetobacter baumannii and the
ESBL producing enterobactereciae, MDR B. fragilis should also be
considered in patients with consistent exposure history especially
when empiric antibiotics are failing. Furthermore, the oxazolidi-
none antibiotic linezolid represents a novel and potentially useful
therapeutic option for resistant anaerobic infections.Disclosures
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In the complete genome sequences of Bacteroides fragilis NCTC9343 and 638R, we have
discovered a gene, ubb, the product of which has 63 % identity to human ubiquitin and cross-
reacts with antibodies raised against bovine ubiquitin. The sequence of ubb is closest in identity
(76 %) to the ubiquitin gene from a migratory grasshopper entomopoxvirus, suggesting
acquisition by inter-kingdom horizontal gene transfer. We have screened clinical isolates of B.
fragilis from diverse geographical regions and found that ubb is present in some, but not all,
strains. The gene is transcribed and the mRNA is translated in B. fragilis, but deletion of ubb did
not have a detrimental effect on growth. BfUbb has a predicted signal sequence; both full-length
and processed forms were detected in whole-cell extracts, while the processed form was found in
concentrated culture supernatants. Purified recombinant BfUbb inhibited in vitro ubiquitination
and was able to covalently bind the human E1 activating enzyme, suggesting it could act as a
suicide substrate in vivo. B. fragilis is one of the predominant members of the normal human
gastrointestinal microbiota with estimates of up to .1011 cells per g faeces by culture. These data
indicate that the gastro-intestinal tract of some individuals could contain a significant amount of
aberrant ubiquitin with the potential to inappropriately activate the host immune system and/or
interfere with eukaryotic ubiquitin activity. This discovery could have profound implications in
relation to our understanding of human diseases such as inflammatory bowel and autoimmune
diseases.
INTRODUCTION
The highly conserved protein-modifier ubiquitin has, to
date, only been found in eukaryotes, where tagging of
proteins with ubiquitin (ubiquitination) is intrinsic to
control of diverse processes central to cell function. The
first role identified for ubiquitin was the regulation of
intracellular proteolysis via the 26S proteosome, in which
ubiquitin becomes covalently bound to a substrate that is
subsequently targeted for degradation (Hochstrasser,
2009). The first step of ubiquitination in eukaryotes is
the covalent attachment of ubiquitin to the cognate
activating enzyme E1, initially by adenylation of the C
terminus of ubiquitin followed by formation of a thioester
bond with the active site cysteine of E1. The covalently
attached ubiquitin is subsequently transferred to the active
site cysteine of the ubiquitin-conjugating enzyme E2,
followed by formation of an isopeptide bond with the
final substrate mediated by the ubiquitin ligase enzyme E3
(Komander, 2009).
It is now recognized that post-translational regulation by
ubiquitination also plays an important role in modification
of protein function, including cell cycle progression,
membrane protein endocytosis, intracellular trafficking,
ribosome biogenesis, signal transduction, DNA repair,
stress responses, chromatin-mediated regulation of tran-
scription and antigen presentation.
Ubiquitin is also a major factor involved in development
and function of both the innate and adaptive immuneAbbreviations: GI, gastrointestinal; OMV, outer membrane vesicle.
Microbiology (2011), 157, 3071–3078 DOI 10.1099/mic.0.049940-0
049940 G 2011 SGM Printed in Great Britain 3071
systems. Mis-regulation of the ubiquitin pathway is
therefore implicated in a wide range of diseases, including
cancer, cardiac disease, neurodegenerative disorders and
type 2 diabetes (Schwartz & Ciechanover, 2009; Rodrı́guez
et al., 2009; Komatsu & Ichimura, 2010; Vereecke et al.,
2009). Immune surveillance for invading pathogens is also
controlled by ubiquitin. Extracellular pathogens are
recognized by Toll-like receptors that activate a cascade
leading to phosphorylation of IkBa, the inhibitor of NF-
kB. Ubiquitination and subsequent proteolytic degradation
of IkBa releases NF-kB for entry into the nucleus where it
activates transcription of pro-inflammatory associated
genes (Karin & Ben-Neriah, 2000). Similarly, regulatory
events triggered by nucleotide oligomerization domain-like
receptor recognition of intracellular pathogens involve
ubiquitination (Shaw et al., 2008). In addition, Salmonella
enterica internalized by macrophages is recognized by a
cytosolic mechanism that stimulates direct polyubiquitina-
tion of bacterial surface proteins with subsequent recruit-
ment of the proteosome, followed by destruction of the
invading prokaryote and presentation of derived peptides
to class I major histocompatibility complex molecules
(Perrin et al., 2004).
While the evolutionary origin of eukaryotic ubiquitin is
hypothesized to be rooted within a common prokaryotic
ancestor, structural homologues of ubiquitin identified in
bacteria do not have sequence similarity, apart from two
terminal glycine residues; examples include the MoaD and
ThiS proteins in Escherichia coli involved in thiamine and
molybdopterin biosynthesis, respectively. These proteins
are not involved in proteolysis but do utilize chemistry
similar to ubiquitin conjugation, i.e. formation of a
thioester bond between the C-terminal glycine and a
cysteine catalytic residue in a complementary activating
enzyme (Hochstrasser, 2009).
The primary mechanisms for regulation of protein half-life
and translation quality control in bacteria do not involve
homologues of eukaryotic ubiquitin. In E. coli the N-
terminal rule pathway dictates the stability of a polypeptide
via an adaptor protein, ClpS, which targets degradation by
the ClpAP protease (Erbse et al., 2006). Prematurely
terminated translation products are marked at the C
terminus with an 11 amino acid SsrA tag that directs the
polypeptide for degradation by either ClpXP or ClpAP
(Gottesman et al., 1998). The analogous N-terminal rule
pathway in eukaryotes uses the specificity of a class of
ubiquitin E3 ligases, the N-recognins, to direct proteolysis
by the proteosome (Tasaki et al., 2005). A protein-tagging
system that functions in a similar manner to the ubquitin–
proteosome pathway has been identified in Mycobacterium
tuberculosis; however, the Pup protein that becomes
covalently attached to proteins destined for digestion does
not share sequence homology with eukaryotic ubiquitin
(Pearce et al., 2008).
We now report evidence of horizontal gene transfer from a
eukaryotic source into a bacterium of the normal human
resident microbiota which results in expression of a
secreted protein with 63 % identity to human ubiquitin.
The Bacteroidetes are predominant members of the gastro-
intestinal (GI) tract microbiota. By culture, B. fragilis
represents ~10–15 % of the members of the Bacteroides
present in faeces, with estimates between 1011 and 1012 cells
g21 (Patrick, 2002). B. fragilis is also the most frequently
isolated obligately anaerobic Gram-negative bacterium from
life-threatening human infections, such as intra-abdominal,
vaginal and brain abscesses (Patrick, 2002; Patrick &
Duerden, 2006), and is a major cause of anaerobic
bacteraemia, with a potential mortality rate of up to
~30 % (Cheng et al., 2009). Such infections generally arise
from faecal contamination of normally uncolonized body
sites, for example, peritonitis following perforation of the
bowel (Patrick & Duerden, 2006). The discovery that
ubiquitin-positive B. fragilis is present in the GI tract,
however, could have profound implications for our under-
standing of several human diseases in which ubiquitin
malfunction is implicated, and indeed also in relation to the
development of autoimmune disease.
METHODS
Bacterial strains and growth conditions. The isolates used in this
study were B. fragilis NCTC9343, NCTC9344 and NCTC10584;
Bacteroides ovatus Queen’s University Belfast culture collection; and
clinical isolates obtained from Craigavon Area Hospital Northern
Ireland (designated ‘LS’), the Royal Victoria Hospital Northern Ireland
(designated ‘JC’), the Free University of Amsterdam kindly supplied by
J. van Doorn (designated ‘BE’), the University of Edinburgh Scotland
kindly supplied by I. Poxton (designated ‘GNAB’); and a rifampicin-
resistant mutant of an isolate from Chigaco, USA, kindly supplied by C.
J. Smith (638R). Identification was confirmed with the API 20A system
or PCR and sequencing. All Bacteroides strains were grown in an
anaerobic atmosphere containing 10 % CO2, 10 % H2 and 80 % N2 in
either supplemented brain heart infusion broth or defined medium
(DM) (Van Tassell & Wilkins, 1978).
Molecular and immunological techniques. ubb from genomic
DNA was amplified by PCR from Bacteroides strains using Pfu poly-
merase (NEB) using ubb-specific oligonucleotide primers designed
using the NCTC9343 DNA sequence. RNA was isolated from cultures
grown in DM (samples taken at OD600 0.4, 0.8 and 1.6) using the
Qiagen RNeasy kit and quantified using a Hitachi U-2000
spectrophotometer. RT-PCR analysis of RNA samples used the
Qiagen Omniscript RT kit with 20 ng RNA template. The absence of
DNA contamination in RNA samples was confirmed by omitting the
reverse transcription step and performing the PCR amplification.
DNA was analysed by electrophoresis through 1 % agarose gels
followed by staining with ethidium bromide and visualization by UV
light. The ubb deletion mutant was generated in NCTC9343 by
replacing ubb with an erythromycin resistance cassette using our
previously described method (Patrick et al., 2009).
The ubb gene was cloned as a 66His-tagged N-terminal fusion in
pTRC99a. Recombinant (r)BfUbb was purified to homogeneity by
overexpression in E. coli DH5a, followed by affinity purification using
Qiagen Ni-NTA agarose resin and gel filtration through a Superose 12
10/300 GL column (GE Healthcare). Polyclonal antiserum was
produced by inoculation of a New Zealand white rabbit with
rBfUbb conjugated to keyhole limpet haemocyanin (KLH) carrier
protein using an Imject Immunogen EDC kit with mcKLH (Thermo
S. Patrick and others
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Scientific). The conjugated antigen was suspended in PBS containing
QuilA (0.125 mg ml21) adjuvant (Brenntag). rBfUbb (0.2 mg) was
inoculated at approximately 4 week intervals over a 6 month period
under UK Government Home Office Personal and Project Licences
and with local ethical approval. Rabbit anti-bovine ubiquitin was
obtained from Sigma-Aldrich. Whole cells for immunoblots were
electrophoresed through 12 % polyacrylamide gels, transferred to a
PVDF membrane and incubated with the appropriate primary and
secondary antibodies before detection using the ECL+ chemilumin-
escent system (GE Healthcare). Supernatants from cultures grown in
DM were prepared by centrifugation, filtration through a 0.45 mm
membrane and concentrated by centrifugation through a membrane
with a 100 kDa cut-off (Amicon Ultra; Millipore). Concentrated
supernatant samples for immunoblotting were separated by electro-
phoresis through 16 % SDS Tris-Tricine polyacrylamide gels.
Immunoblots were incubated with the appropriate primary antibody
followed by anti-rabbit alkaline phosphate antibody conjugate and
reacted with Sigma Fast BCIP/NBT(Sigma). Bacterial genome
sequences were viewed with Artemis and the Artemis Comparison
Tool (Carver et al., 2008).
In vitro ubiquitination. In vitro ubiquitination reactions were carried
out in 25 mM HEPES and 0.5 mM DTT at 37 uC for 180 min and used
the fraction II HeLa conjugation kit (Boston Biochemicals) with a
biotinylated lysozyme substrate (Boston Biochemicals). Reactions
contained 4 mg Fraction II HeLa ml21, 2.5 mg ubiquitin ml21,
4 mM ubiquitin aldehyde, 5 mM MG-132 and an ATP regeneration
system. Reactions containing 280 mg BfUbb ml21 were pre-incubated
at 37 uC for 15 min prior to the addition of ubiquitin. Protein samples
were separated by electrophoresis through 12 % polyacrylamide gels
followed by transfer to a PVDF membrane and detection of
biotinylated lysozyme using an avidin–HRP conjugate (Boston
Biochemicals). Binding of BfUbb to human E1 was carried out in
reactions containing 390 mg BfUbb ml21 and either 55 mg or 27.5 mg
E1 ml21 (Boston Biochemicals) in 50 mM HEPES pH 8.0 at 37 uC for
60 min. Samples were analysed on a non-reducing 12 % polyacryla-
mide gel followed by transfer to a PVDF membrane and detection with
polyclonal anti-eukaryotic ubiquitin antibodies (Chemicon) and the
ECL+ chemiluminescent system (GE Healthcare).
RESULTS
A horizontally acquired gene encoding ubiquitin
in B. fragilis
The annotation of the B. fragilis NCTC9343 genome
indicates that it encodes a number of polypeptides with
similarities to human proteins (Cerdeño-Tárraga et al.,
2005). The most striking homology, however, is found with
a putative protein encoded by BF3883 that has 63 %
identity (48 of 76 amino acids) to human ubiquitin, such
as Uba52 or UbcEP2 (Fig. 1). While many of the amino
acids important for interactions with the E1 activating
enzyme are conserved in B. fragilis ubiquitin (BfUbb), it
has at least two unusual features. Firstly, it contains a signal
sequence and secondly, it does not possess the two terminal
glycine residues required for covalent interactions with the
E1 and E2 enzymes of the ubiquitin pathway (Fig. 1).
Despite the implication of its name, ubiquitin has to date
only been found in eukaryotes. BF3883 is contained within
an 11 kb sequence exhibiting a low GC content, with the
closest DNA homology to the gene being 76 % identity (151/
199 bp; E55610229) to a ubiquitin-encoding sequence,
MSV144, from a migratory grasshopper entomopoxvirus
(GenBank accession no. AF063866.1). This suggests that
BF3883 was acquired by inter-kingdom horizontal gene
transfer. Hereafter, we refer to BF3883 as ubb.
The genome sequences of two other B. fragilis strains, 638R
(isolated in the USA) and YCH46 (isolated in Japan), have
also been determined (Patrick et al., 2010; Kuwahara et al.,
2004). Strain 638R contains a similar low GC region that
includes a putative ubiquitin-encoding gene (BF638R3923)
which has 100 % sequence identity to ubb. In contrast, the
YCH46 genome only has three genes from the equivalent
low GC region and does not contain ubb, suggesting that
the ubiquitin gene has been deleted. To determine the
prevalence of ubb in other B. fragilis strains, we screened a
number of isolates derived from different source materials
and different geographical locations. Analysis by PCR
demonstrated that ubb was present in clinical isolates from
patients in Edinburgh, Belfast and Amsterdam (Fig. 2).
Sequence comparison of the ubb amplicons with the
NCTC9343 sequence showed 100 % conservation within
the coding region (data not shown). While there was no
obvious correlation with the presence or absence of the
ubiquitin gene and the source of the sample, this
demonstrates that the ubb gene is present in B. fragilis
strains resident in the GI tract of individuals from diverse
populations. Homologues of ubb were not found in other
Bacteroides species, by either PCR or genome sequence
analysis.
BfUbb MRFIKQVLLTITLCNIMLFALPSTVNAMQVFIKNRYGWTITLEVSPTDTVENVKQKIQDK
:                           :.:.:.  : :::::: :.::.:::: :::::
Ubc52 M---------------------------QIFVKTLTGKTITLEVEPSDTIENVKAKIQDK
10        20        30
* * * * *
BfUbb EGFPPDKIRLIYGGKQMEDGRTLADYNVQKDSTILICIRDVDC
::.:::. :::..:::.::::::.:::.::.::. . .:
Ubc52 EGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG
40        50        60        70 
Fig. 1. A homologue of ubiquitin present in the
bacterium B. fragilis. Alignment of the pre-
dicted polypeptide encoded by the ubb gene
in B. fragilis with human ubiquitin Ubc52. The
first 28 residues of BfUbb represent the
putative signal sequence. Identical and similar
amino acids are indicated, with residues
important for interactions with E1 activating
enzyme shown in bold and with asterisks. The
two C-terminal glycine residues of Ubc52
involved in covalent attachment to the E1-
activating enzyme are underlined.
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To determine whether BfUbb has a central role in the
metabolism of B. fragilis NCTC9343, as YCH46 which lacks
ubb has a slower growth rate and attains lower cell density
in stationary phase (Patrick et al., 2010), we generated a
strain in which ubb was deleted. Using our previously
described method, ubb was replaced with an erythromycin
resistance cassette (Patrick et al., 2009). The resulting
Dubb : : ermF strain did not show any cell morphology
defects and had the same growth rates compared with the
parental strain in BHI-S medium and glucose defined
medium (DM). This indicates that BfUbb is not essential
for B. fragilis growth in laboratory medium, although it
may be advantageous for survival within the host.
Expression of BfUbb in B. fragilis
Since it is possible that ubb had been acquired from a
eukaryotic source, the gene may be an evolutionary relic
and may or may not be integrated adjacent to a promoter.
We confirmed active transcription of ubb in B. fragilis by
detection of mRNA using RT-PCR (Fig. 3a). Total RNA
was isolated from cultures grown in DM during early
exponential growth and upon entry into stationary phase.
RT-PCR products were detected from RNA templates
derived from both growth phases, suggesting that ubb is
transcribed by the housekeeping RNA polymerase of B.
fragilis.
We cloned and expressed the predicted processed form
of BfUbb as a 66His-tagged fusion in E. coli and used
this protein to generate rabbit polyclonal antiserum.
Immunoblotting of cell extracts from cultures grown in
glucose DM revealed BfUbb as a major protein band of
~9 kDa, plus a second band of ~12 kDa (Fig. 3b). This
pattern is consistent with cleavage of the signal peptide
having generated the abundant form of BfUbb and the
~12 kDa band, representing the holo-protein prior to ex-
port and processing. In addition, some lower-molecular-
mass bands, interpreted as degradation products were
observed. Interestingly, anti-bovine ubiquitin antibodies
cross-reacted with purified recombinant 66His-BfUbb, but
did not detect BfUbb in whole-cell extracts of B. fragilis. The
presence of a signal sequence and its apparent cleavage is
consistent with BfUbb being transported to the periplasm of
B. fragilis. To interact with the eukaryotic host, however,
BfUbb would need to be secreted by the bacterium. B. fragilis
is known to produce outer membrane vesicles (OMVs) that
bleb from the cell surface (Patrick et al., 1996). To determine
whether BfUbb was potentially present in OMVs, we con-
centrated supernatants by filtration through membranes
with a 100 kDa cut-off. Immunoblotting of these concen-
trated supernatants showed the presence of a smeared band
of BfUbb that migrated close to the position of the purified
66His-BfUbb (Fig. 3c; note these samples were separated
on a higher percentage gel than that used in Fig. 3b). This
band was not detected in concentrated supernatants from
the Dubb strain (data not shown). Smeared bands are often
characteristic of glycosylated proteins. Two triplet amino
acid sequences (DTV and DST; Fig. 1) corresponding to the
consensus recognition site for B. fragilis O-glycosylation
(Fletcher et al., 2011) are present in BfUbb. The potential
glycosylation of BfUbb is being investigated.
In vitro activity of BfUbb
Since ubb is not present in all strains of B. fragilis, and





































































Fig. 2. Agarose gel showing detection of the ubb gene by PCR in isolates of B. fragilis from different geographical locations.
Origins of B. fragilis samples are: PtA, peritoneal abscess; A, abscess; NpA, neoplasm abscess; PaA, perianal abscess; AbA,
abdominal abscess; UN, unknown origin. The position of the ubb amplicon is shown adjacent to the image, with DNA molecular
size markers in the first and last lanes. Note the absence of ubb in B. ovatus and some B. fragilis isolates.
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apparent effect on growth of the bacterium, we hypo-
thesized that BfUbb might be a candidate protein for
interaction with the host. To examine the effect of BfUbb
on the ubiquitination pathway, we reconstituted the
reaction using HeLa cell extracts (Fraction II) and a
biotinylated lysozyme substrate. Pre-incubation of purified
66His-BfUbb with the HeLa extract, prior to addition of a
10-fold excess of eukaryotic ubiquitin, inhibited sub-
sequent covalent attachment of ubiquitin to the substrate
(Fig. 4a). This suggested that 66His-BfUbb was binding
to the activating and conjugating enzymes of the ubiqui-
tin pathway and inhibiting their catalytic functions. The
first step of ubiquitination is the covalent attachment of
ubiquitin to the E1 activating enzyme by formation of a
thioester bond with the active site cysteine. The ubiquitin
homologues encoded by all B. fragilis strains tested do not
contain a C-terminal glycine but do have a C-terminal
cysteine (Fig. 1). We hypothesized that BfUbb might form
a disulphide bridge with human E1 that would lead to its
inactivation. Under non-reducing conditions a covalent
complex could be detected between 66His-BfUbb and
human E1 by immunoblotting with anti-bovine ubiquitin
antibodies (Fig. 4b). This complex was not detected under
reducing conditions (data not shown). These data
indicated that the two proteins are capable of forming a
covalent intermediate in the absence of both ATP and a
terminal glycine residue, and suggest that BfUbb could act
as a suicide substrate leading to inactivation of E1 and
blocking of the ubiquitination cascade.
DISCUSSION
The presence of ubb only in selected strains of B. fragilis,
the similarity of BfUbb to human ubiquitin and its
antigenic cross-reactivity, as well as the potential for
BfUbb to interfere with the eukaryotic ubiquitination
pathway could have profound implications for a range of
human diseases. By culturing faeces, Bacteroides species
numbers range from 109 to 1014 cells g21, of which B.
fragilis estimates range from 4 to 14 % (reviewed by
Patrick, 2002). This provides a potentially large reservoir
of an aberrant form of ubiquitin in some humans. The
resident GI tract microbiota has a well-proven role in the
normal development of the immune system. In addition,
inflammatory bowel disease is recognized as being caused
by a deficient or abnormal mucosal immune response in
individuals who are genetically susceptible, clearly related
to the presence of intestinal microbes (Marks et al., 2010;
Xavier & Podolsky, 2007). In microscopic studies of the
spatial organization of the adherent mucosal microbiota, B.
fragilis was consistently associated with the mucosal surface
of patients with inflammatory bowel disease. It was the
predominant member of the adherent mucosal biofilm,
accounting for .60 % of the biofilm mass (Swidsinski et al.,
2005). It will be intriguing to determine whether, given the
intimate association of B. fragilis with the human GI tract,
BfUbb plays a role in the development of these diseases.
Furthermore, we postulate that BfUbb could be a driver of
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Fig. 3. Detecting expression of BfUbb. (a) Agarose gel showing transcription of ubb detected by RT-PCR. Lanes: 1, PCR using
genomic DNA; 2–4, PCR using RNA from cultures at OD600 0.4, 0.8 and 1.6 (indicates absence of DNA contamination); 5–7,
RT-PCR using RNA from cultures at OD600 0.4, 0.8 and 1.6. The position of ubb is indicated with an arrow. (b) Immunoblot
using rabbit anti-BfUbb polyclonal antiserum. Lanes: 1, purified 6His-BfUbb; 2, whole-cell extract of B. fragilis NCTC9343; 3,
whole-cell extract of B. fragilis Dubb. The lowest band in lane 2 represents a degradation product of BfUbb. (c) Immunoblot of
concentrated supernatant from a culture of NCTC9343 grown in DM (lane 1), compared with purified 6His-BfUbb (lane 3).
Molecular mass markers are shown in lane 2.
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autoimmune reaction to either or both ubiquitin or
proteins to which ubiqutin is bound.
The genome of B. fragilis does not encode the molecular
components required to make a proteosome equivalent to
the eukaryotic 26S proteosome; nor does it appear to
contain the activating and conjugating enzymes of the
ubiquitination pathway. The ubb gene has evolved from the
eukaryotic equivalent to encode a protein containing a
bacterial signal sequence predicted to specify export to the
periplasm; also, the C-terminal glycine residues that are
required for successful ubiquitination of target proteins in
eukaryotes are absent. This suggests that BfUbb has been
subverted by the bacterium to fulfil a unique role. So what
is the function of BfUbb? The high degree of homology
between BfUbb and human ubiquitin, with conservation of
residues important for interaction with the E1-activating
and E2-conjugating enzymes, implies that these interac-
tions are important. Although we have shown that BfUbb
can inhibit ubiquitination in vitro, it is possible that the C-
terminal cysteine residue could form a thiol-ester bond
with other amino acids on selected targets that lead to
modified protein function. The isopeptide bond formed
between eukaryotic ubiquitin and lysine residues is not the
only way that conjugates can be generated; for example, the
viral E3 ligase MIR1 can catalyse the formation of thiol-
ester bonds between ubiquitin and cysteine residues on
major histocompatibility complex I class proteins found on
the surface of cytotoxic T lymphocytes (Cadwell & Coscoy,
2005).
The periplasmic localization of BfUbb would provide a
means for mobilizing the protein into the environment. B.
fragilis produces a large number of OMVs (Patrick et al.,
1996) that are free to diffuse throughout the gut lumen.
The detection of BfUbb in supernatants that had been
concentrated through a membrane with a 100 kDa cut-off
suggests that the protein is associated with extra-cellular
macromolecular complexes. OMVs are ‘secretory vehicles’
that can deliver bacterial components to host cells and
tissues as well as other bacteria (Kuehn & Kesty, 2005;
Bomberger et al., 2009). The OMVs of B. fragilis agglutinate
erythrocytes, via sodium periodate sensitive agglutinins, and
are also known to contain degradative enzymes (Patrick
et al., 1996). The presence of unusual sphingolipids in the
B. fragilis outer membrane may allow fusion between
OMVs and eukaryotic cytoplasmic membranes that contain
sphingolipids. Alternatively, the vesicles may enter epithelial
cells by endocytosis. Ubiquitin plays a central role in the
regulation of the pro-inflammatory response. Following
exposure to a bacterial pathogen, a Toll-like receptor-
initiated signalling cascade ultimately results in the phos-
phorylation of IkB that is subsequently ubiquitinated and
degraded by the proteosome. Destruction of IkB releases
NF-kB to enable its nuclear localization and initiation of
transcription (Bhoj & Chen, 2009). If BfUbb were to enter
the cytoplasm of an epithelial cell and act as a suicide
substrate for ubiquitination, it could potentially inhibit
activation of NF-kB, thus downregulating the inflammatory
response.
BfUbb could also aid the success of B. fragilis as an
opportunistic pathogen. Many pathogenic bacteria have
evolved the ability to avoid or suppress the host immune
response by interfering with the ubiquitin-proteosome
pathway, although none of these mechanisms involve
ubiquitin homologues (Boyer & Lemichez, 2004). For
example, Yersinia pestis uses YopJ to prevent activation of
the innate immune response, Salmonella enterica serovar
Typhimurium produces a ubiquitin ligase and a deubiqui-
tinating protease that are secreted into infected macrophages,
Lysozyme
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Fig. 4. In vitro activity of BfUbb. (a) Immunoblot of in vitro ubiquitination of lysozyme using HeLa cell extract in the absence
(lanes 1 and 2) or presence (lanes 3 and 4) of BfUbb. Samples were taken at the start of the reaction (0) and at 180 min (180).
Lane 2 shows the increase in molecular mass of the lysozyme substrate following covalent attachment of ubiquitin (+Ub). This
covalent modification is inhibited by the addition of BfUbb (lane 4). (b) Covalent complexes between human E1 and BfUbb,
under non-reducing conditions, were detected by immunoblotting using anti-bovine ubiquitin polyclonal serum. Two reactions
using different concentrations of E1 are shown, with time points at 0 and 60 min. Note there was some antibody cross-reactivity
with E1 at the higher concentration.
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while intracellular Chlamydia trachomatis secretes two
proteases that have deubiquitinating activities (Zhang et al.,
2006; Rytkönen et al., 2007; Le Negrate et al., 2008).
This discovery of a novel ubiquitin homologue in a
bacterium, which is a key member of the normal human
resident microbiota, could fundamentally alter our under-
standing of diseases that currently have an unknown
aetiology. While we postulate a possible role in inflam-
matory bowel and autoimmune diseases, mis-regulation of
ubiquitin is implicated in a wide range of diseases
including cancer, neurodegenerative disorders and type 2
diabetes. The extent to which BfUbb may or may not be
involved in any of these diseases remains to be determined,
and will require careful consideration of BfUbb-positive B.
fragilis colonization, the control of BfUbb expression and
underlying human genetic predispositions.
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